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Abstract 
Phenotypic change is a hallmark of adaptation of Pseudomonas aeruginosa to the lung 
during chronic infection in patients with cystic fibrosis (CF). Well-characterised 
phenotypic variants include mucoid and small colony variants (SCVs), the appearance of 
which is associated with disease severity. In this thesis, P. aeruginosa SCVs isolated from 
the murine lung following the establishment of chronic infection are characterised at the 
phenotypic and genetic level. The isolated SCVs are shown to closely resemble those 
isolated from CF patients and conversion to the SCV phenotype is accompanied by 
transcriptional changes that include upregulation of key virulence determinants and the 
oxidative stress regulon, suggesting that selection of the SCVs in the lung is driven by the 
host immune response to chronic infection. Using a combination of single-molecule real-
time (PacBio) and Illumina sequencing we identified the genetic switch for conversion to 
the SCV phenotype as a large genomic inversion through recombination between 
homologous regions of two rRNA operons. The observations that a highly similar 
inversion is observed in a recently sequenced P. aeruginosa SCV isolate from a patient 
with cystic fibrosis and that genomic inversion in S. aureus can also drive conversion to an 
SCV phenotype, suggests this may be a common mechanism through which diverse 
bacteria adapt to the environment of chronically inflamed host tissue. 
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1.1 Cystic Fibrosis 
Cystic Fibrosis (CF) was first described in 1936 by Fanconi and further characterized by 
Andersen in 19381 and is the most prevalent, fatal single gene defect in the Caucasian 
population.  Individuals of Northern European origin have the highest incidence of CF with 
about 1 in 2500 newborn children affected and a carrier frequency of 1 in 252.  Within the 
United Kingdom (UK), over 9,700 individuals have cystic fibrosis.  The CF 
transmembrane conductance regulator (CFTR) gene, mapped on chromosome 7 encodes 
the gene responsible for CF which functions as a cAMP-regulated chloride ion channel3.   
CFTR is expressed in higher quantities in the tissues clinically affected by CF such as the 
sinuses, lungs, pancreas, liver, gastro-intestinal tract and reproductive tract making it a 
complex multi-system disease.  The major cause of morbidity and mortality in this patient 
group is pulmonary infection and inflammation, which leads to progressive pulmonary 
failure.  The most common pathogen in adult patients with CF is Pseudomonas aeruginosa 
(P. aeruginosa) which chronically infects most adult patients leading to irreversible 
respiratory demise4. 
 
The lungs of neonates with CF are pathologically normal, however infection and 
inflammation occurs early in life4.  The initiating event for bacterial colonization remains 
poorly understood, however in early childhood infection with Haemophilus influenzae and 
Staphylococcus aureus is common5.  Early infection leads to a florid inflammatory 
response with neutrophil recruitment and activation.  Subsequently P. aeruginosa  rapidly 
becomes the predominant organism and due to its ability to form complex drug resistant 
biofilms making this opportunistic pathogen almost impossible to eradicate6 (see Figure 1-
1).  P. aeruginosa can be cultured from the sputum of approximately 80% of adults with 
CF over the age of 18.  The definition of chronic P. aeruginosa infection is when 50% or 
more sputum samples test positive in a 12 month period for P. aeruginosa7. 
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Figure 1-10-1 Bacterial burden in CF patients by age 
Data gathered from the UK Cystic fibrosis registry annual data report 2014.  The trend for P. 
aeruginosa infection is intermittent infection in approximately 25% of children under 15 years of 
age.  (Taken from CF registry annual report 20148) 
 
Later in the course of infection, further pathogenic bacteria including multi-resistant 
Stenotrophomonas maltophilia9,10, Burkholderia cepacia11–13, MRSA14,15 and 
Mycobacterium abscessus16 become increasingly problematic with failure of treatment and 
worsening outcomes8. 
 
 
1.2 Pseudomonas aeruginosa 
 P. aeruginosa is a Gram-negative, usually obligate aerobicfacultative anaerobic bacillus of 
the class Gammaproteobacteria.  It is a ubiquitous environmental bacterium and 
opportunistic pathogen which normally inhabits the soil and aquatic environments, but is 
able to establish itself in vulnerable patients.  It displays high levels of intrinsic resistance 
to many antibiotics and disinfectants, which makes it extremely difficult to eradicate.  
Serious P. aeruginosa infections are often nosocomial and the majority are associated with 
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significantly compromised host defences such as in neutropenia, severe burns or cystic 
fibrosis (Table 1-1).  
 
Table 1-1 Common P. aeruginosa  infections and risk factors17  
Infection Major risk factors 
Soft tissue 
Urinary tract 
Bacteraemia 
Diabetic foot 
Respiratory/pneumonia 
 
Otitis externa 
Keratitis  
 
Otitis media folliculitis 
Burns, wounds, ulcers, post surgery 
Use of urinary catheter 
Immunocompromised in particular 
Diabetes, impaired microvascular circulation 
Elderly, COPD, bronchiectasis, cystic 
fibrosis, mechanical ventilation 
Tissue injury, water in ear canal 
Extended contact lens wear, contaminated 
contact lens solution 
Poorly cleaned hot tubs 
 
 
 
1.3 Pseudomonas aeruginosa pathogenesis and major virulence 
factors 
Previous studies have revealed that P. aeruginosa  isolated from acute infections differ 
significantly in phenotype from those isolated from chronic infections18.   P. aeruginosa  is 
endowed with a large genome containing over 5,570 predicted open reading frames 
(ORF’s) and 6.3 million base pairs19.   The P. aeruginosa genome is highly adaptable 
allowing it to rapidly colonise relatively hostile environments.  As many as one in ten 
genes in the genome are involved in regulatory functions20,21 and encode known or putative 
transcriptional regulators22.  Studies of clinical and environmental strains have revealed 
that up to 90% of the genome is conserved between strains and very few single nucleotide 
polymorphisms (SNPs) seem to distinguish different strains, suggesting some phenotypic 
differences are likely to be due to changes in gene expression rather than genome 
sequence23.  
 
Isolates from acute infections express a wealth of virulence factors as outlined in Table 1-2 
below whereas many isolates from chronic infections lack or produce low levels of some 
inflammatory features including pili and the type 3 secretion system (T3SS)24.   Figure 1-2 
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outlines the interaction between the P. aeruginosa virulence factors and the host cells 
which allow cell adhesion, invasion and metabolism. 
 
 
Table 1-2 Summary of P. aeruginosa  virulence factors25 
Pathogenic function Cell-associated factors Extracellular factors 
Adhesion 
 
Type IV pili 
Carbohydrate-binding proteins 
(lectins) 
Glycocalix 
Alginate slime (biofilm) 
 
Adhesion facilitation  Neuraminidase 
 
Motility/Chemotaxis Flagella (swimming), pili 
(twitching) 
 
Invasion 
 
 Elastase (LasB and LasA) 
Alkaline protease 
Haemolysins 
Cytotoxin (leukocidin) 
Pyocyanin pigment 
Siderophores 
 
Toxinogenesis 
 
Lipopolysaccharide (endotoxin) 
LecA and LecB lectins 
Exotoxin A 
Type III effector cytotoxins – ExoS, 
ExoU, ExoT, ExoY 
Enterotoxin 
Antiphagocytic surface 
properties 
 
Slime layers 
Glycocalix 
Lipopolysaccharide 
 
Defense against serum 
bactericidal reaction 
 
Slime layers 
Glycocalix 
 
Protease enzymes 
Defense against 
immune responses 
Slime layers 
Glycocalix 
Protease enzymes 
 
 
Isolates from chronic patients more readily form biofilms and overexpress alginate, 
resulting in a mucoid phenotype26.  Such altered virulence subsequently results in reduced 
immunostimulation and inevitably reduces clearance from the CF lung6.    
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Figure 1-20-2 Virulence factors produced by Pseudomonas aeruginosa17 
Main virulence factors produced by Pseudomonas aeruginosa and how these allow cell adhesion, 
invasion and metabolism. Taken from Gellatly with permission 201317. 
1.3.1 Flagella and type 4 pili 
Type 4 pili (T4P) are long protein fibres which provide the ability to adhere to chemically 
diverse surfaces including glass, metals and mammalian cells, promoting bacterial cell 
aggregation and virulence27. T4P are unique in mediating flagellum-independent, twitching 
motility28,29.  Together with flagella, pili also facilitate swarming motility.  They also 
provide a pivotal role in biofilm development, providing initial attachment to a surface 
therefore making them a major virulence factor in early infection.  Often, T4P are 
downregulated in chronic infections30.  
 
Flagella are highly complex bacterial organelles with over 50 genes involved in their 
synthesis and function31.  They are required for swimming motility and are well conserved 
between bacterial species and facilitate the acquisition of essential nutrients playing a role 
in the virulence of pathogenic organisms32.  P. aeruginosa  lacking functional flagella (Fla- 
mutants) have been shown to be less invasive than motile strains in a mouse burn infection 
model, with the addition of antiflagellum antibody also having a protective effect31,33. 
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1.3.2 Quorum Sensing and Rhamnolipid Biosynthesis 
Many bacteria use quorum sensing (QS) to monitor cell density and to coordinate their 
behavior34 via small membrane-diffusible molecules called autoinducers (outlined in Fig 1-
3).  P. aeruginosa   produces three autoinducers, two of which are acyl homoserine 
lactones (AHLs): 3-oxo-dodecanoyl homoserine lactone and butyryl homoserine lactone35.  
Recently it has been reported that P. aeruginosa  produced a third intracellular signalling 
molecule, 2-hepatyl-3-hydroxy-4-quinolone designated the Pseudomonas quinolone 
signal36,37 (PQS).  To orchestrate the synchronous production of virulence factors and 
biofilm formation, P. aeruginosa  depends on two major LuxI/R quorum-sensing 
systems36,38,  the Las and Rhl systems which act as global regulators of gene expression.  
Both regulatory proteins LasR and RhlR show high specificity and bind only their cognate 
signal molecule.  Rather than working in parallel, the two systems form a hierarchy, with 
the Las system controlling the Rhl system.  A small regulatory RNA-binding protein, 
RsmA negatively regulates the production of AHLs at the post-transcriptional level35,39.   A 
non-coding RNA,second protein RsmZ (also known as RsmB), antagonises the action of 
RsmA40,41, with overexpression of RsmZ resulting in loss of swarming behaviour42. 
 
The Rhl system controls the production of rhamnolipids which act as virulence factors and 
surface wetting agents, allowing easier flagellar motility over semi-solid surfaces42.  The 
genes rhlA, rhlB and rhlC code for the enzymes that produce rhamnolipids.  The genes 
which encode the rhamnosyls-transferase enzymes RhlA and RhlB are on the same operon 
and are strongly upregulated by the Rhl quorum-sensing signalling system43.  A function of 
great importance is the fact that rhamnolipids cause release of LPS from the outer 
membrane resulting in increased surface hydrophobicity44.  Within a biofilm community, 
rhamnolipids have an important role in maintaining non-colonised pores that are an 
essential part of the biofilm architecture45. 
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Figure 1-30-3 Quorum sensing regulators and their control  
 
las and rhl are the two quorum sensing systems in Pseudomonas, which control expression of 
numerous genes. The Pseudomonas quinolone signal (PQS)  provides a link between the las and rhl 
quorum sensing systems, strongly inducing rhl39,46,47. Taken with permission from Strateva 201125).  
Virulence factors which are regulated via this system include elastase, protease, exotoxin 
A, pyocyanin and siderophores37,48–50, therefore strategies interfering with this cell-to-cell 
signalling system are potentially an innovative approach to combatting bacterial disease51. 
 
 
1.3.3 Biofilm Formation 
Biofilms are microbial communities encased in an extracellular polymeric substances 
(EPS) which represents a protective mode of growth enabling microorganisms to survive in 
hostile environments facilitating the dispersion of seeding cells to colonise new niches28,52.  
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It involves a coordinated and regulated transition from free-swimming planktonic bacteria 
to complex and highly differentiated communities of surface attached organisms (Fig 1-4).  
The formation of biofilms is intricately linked to QS53.   Bacterial biofilms are implicated 
in chronic infections because they show increased tolerance to antibiotics and many 
disinfectant chemicals as well as the ability to resist phagocytosis and other components of 
the body’s immune defence system34. Alginate is a well characterised component of P. 
aeruginosa  biofilms although evidence suggests biofilm formation can also occur 
independently of alginate28,54.  Early studies which examined the role of alginate in the 
initiation or maturation of biofilms focused on the mucoid phenotype from the CF lung, the 
basis of which is the overproduction of alginate.  It was previously suggested that mucoid 
variants would most likely be responsible for biofilm formation in the CF lung and that the 
copious extracellular polysaccharide produced by these strains would play a protective 
role.  A study by Wozniak in 200354 however suggested that in fact alginate is not a major 
constituent of the extracellular matrix of PA01 biofilms with the structural properties and 
antibiotic-resistance profiles of wild-type and algD mutant biofilms found to be 
indistinguishable54.   
 
Non-mucoid strains utilize primarily the Pel and Psl polysaccharide to form the 
extracellular matrix of the biofilm55,56.  Regulation of Pel and Psl expression is complex, 
with multiple and intricate levels control.  RpoS acts as a positive transcriptional regulator 
of psl gene expression35.  Both the Gac-Rsm signal transduction pathway and QS have 
been suggested to positively regulate pel and psl57.     
 
The shift between motile and sessile states is under complex regulatory control, including 
the GacA/GacS two-component system which controls the translational repressor RsmA 
which directly affects biofilm formation via pel, psl and the second messenger cyclic-di-
GMP (c-di-GMP )35,58.  Additional studies have also identified and characterised YfiBNR 
as an important regulatory system involved in P. aeruginosa  biofilm formation and in vivo 
persistence59,60.  Activation of YfiN results in c-di-GMP production and consequent 
activation of several downstream targets affecting cell motility, exopolysaccharide 
production and induction of the Pel and Psl exopolysaccharides in particular. 
Biofilms are highly heterogeneous environments with gradients of oxygen, nutrients and 
iron which may contribute to the slow growth of some bacteria in the biofilm and the 
upregulation of the stress response alternative sigma factor, RpoS, observed on 
transcriptional profiling61,62.   Growth, protein synthesis and metabolic activity is high at 
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the surface of the biofilm however slow, impaired or no growth is observed in the centre of 
the biofilm which is one explanation for the reduced susceptibility of biofilms to 
antibiotics63,64.  The centre of the biofilm is extremely limited in oxygen saturations which 
has been well documented and in fact these anaerobic conditions protect the P. aeruginosa 
strains growing in biofilms from killing by antibiotics65.    Monotherapy with antibiotics is 
thus relatively ineffective at eradicating biofilm infections66. 
 
 
 
 
Figure 1-40-4.  Process of biofilm formation 
The process begins with (a) planktonic cells which adhere to a substratum, followed by (b) 
microcolony formation, (c) proliferation, maturation and mature biofilm formation and finally (d) 
detachment and reversion to planktonic growth. 
 
1.3.4 Type 3 Secretion System 
Type 3 secretion systems (T3SS) are produced by many pathogenic Gram-negative 
bacteria as a means of injecting toxins directly into the cytoplasm of eukaryotic cells.  
Cells of the innate immune system are thought to be the central target for T3SS 
intoxication allowing bacteria to evade clearance mechanisms, prevent phagocytosis and 
establish initial infection67.  The injection of cytotoxins also leads to modulation of the 
actin cytoskeleton dynamics within the host cell, inhibiting mammalian DNA synthesis68.   
The role of T3SS in the unique setting of P. aeruginosa  infection is controversial as 
studies have shown that isolates cultured from CF patients tend to secrete less T3SS 
effectors with increased duration of infection69.  The T3SS of P. aeruginosa consists of 
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several proteins forming a macromolecular complex spanning the inner membrane, the 
periplasmic space, peptidoglycan layer, the outer membrane, the extracellular space and 
the host cell membrane (Figure 1-5). 
 
 
 
Figure 1-50-5 Type III secretion apparatus of P. aeruginosa 
The main components making up the regulon:  the needle complex and proteins involved in 
translocation, secretion, chaperone and effector functions.  The four main effectors are shown, 
ExoS, ExoT, ExoU and ExoY.  Taken with permission from Galle et al 70. 
 
Thirty-six genes encoded in five different operons are involved in the biogenesis and 
regulation of the T3SS71.  The complex regulon can be divided into five parts:  proteins 
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constituting the needle complex, translocation of secreted proteins into host cells, proteins 
regulating the secretion process, chaperone proteins and effector proteins72.  The needle-
like appendage of the T3SS permits the translocation of proteins from the bacterium to the 
host through a pore formed in the cell membrane.  Four effectors have been identified, 
ExoS, ExoT, ExoY and ExoU (Fig 1-5)73–76 however most strains only posses three of the 
Exo effectors..   
 
Type III secretion in P. aeruginosa  is regulated at two levels: transcription of T3SS genes, 
via the transcription factor ExsA70 and initiation of secretion itself.  Transcription is 
induced upon activation of the secretion process allowing T3SS components to be 
produced at high levels when required76.  Early studies revealed that ExsA is essential for 
full virulence in animal models of acute pneumonia in which alveolar instillation of ExoS 
producing P. aeruginosa  strains led to severe alveolar damage when compared with 
mutant strains77. 
 
The T3SS has been shown to be a major reason for the cytotoxicity of the bacterium for a 
wide range of host cells.  Comparison of the relative contributions of ExoS, ExoT and 
ExoU toxins to mortality, bacterial persistence and dissemination in a mouse model 
indicated that secretion of ExoU had the greatest impact74.  In a mouse model of acute 
pneumonia it was found that secretion of ExoU was associated with a 40-fold decrease in 
the LD50 and in addition a significantly altered lung pathology78.  Recent work has 
revealed that the increased virulence associated with ExoU secretion is the result of its 
phospholipase A2 activity, leading to cell death79.  Additionally, the T3SS apparatus is 
itself a major cytotoxic factor independently of exotoxin translocation.  It is associated 
with increasing inflammation and neutrophil recruitment into the airways72 and therefore 
inhibiting the internalisation of P. aeruginosa  into macrophages80.  P. aeruginosa  mutants 
with defective T3SS have been shown to be less virulent than their wild-type 
counterparts75,81,82.  
 
It has recently been shown that, via a functional T3SS, P. aeruginosa  triggers the 
activation of an intracellular cytosolic sensor, NLRC4 (Nods-Like Receptor family, CARD 
domain containing 4)83.   The NLCR4 detects the basal body rod component of the T3SS 
apparatus from a variety of bacteria including Salmonella typhimurium, Burkholderia 
cepacia, Eschericia coli, Shigella flexneri and P. aeruginosa 83–85.  Studies have shown 
that NLRC4-coupled inflammasome (a multimeric protein complex of innate immunity 
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involved in IL-18 and IL-1B secretion)83 activation by T3SS leads to IL-8 secretion which 
increases neutrophil recruitment to the lung and subsequently lung injury71. 
 
 
1.3.5 Other virulence factors 
The main role of proteases in P. aeruginosa  virulence is thought to involve tissue 
penetration86,87.  P. aeruginosa  produces several extracellular proteases including LasA 
elastase (encoded by the lasA gene), LasB elastase (encoded by the lasB gene), alkaline 
protease (encoded by the aprA gene) and protease IV, all of which have been shown to 
play a major role during acute infection88.  The participation of alkaline protease in 
systemic infections and tissue invasion is not entirely clear, however, it is known to play a 
substantial role in corneal infection89.  LasA and LasB are regulated by the las quorum-
sensing system and secreted via the type 2 secretion system36.  They have elastolytic 
activity, degrading surfactant proteins and destroying elastin containing human lung tissue, 
resulting in pulmonary haemorrhages seen particularly in invasive P. aeruginosa  
infection88. Three other soluble proteins involved in invasion are also produced: a 
cytotoxin (previously named leukocidin) and two hemolysins which exert their major 
cytotoxic effects on lymphocytes, neutrophils and other eukaryotic cells90. 
 
Lipopolysaccharide (LPS) constitutes a physical barrier protecting the bacterium from host 
defences, mediating direct interactions with host cell receptors and antibiotic molecules91–
93.  It also acts as an endotoxin itself which initiates inflammation, host tissue damage and 
much of the pathology associated with bacteremia91.  P. aeruginosa  simultaneously 
produces two distinct LPS species,  an O-specific antigen (OSA) and the common 
polysaccharide antigen (CPA)94.  The CPA is composed of α-1-2, α1-3-linked D-rhamnose 
sugars and has been shown to be vital for attachment of the bacteria to respiratory 
epithelial cells94.  Several studies have suggested that LPS contributes substantially to P. 
aeruginosa  virulence including the toxic nature of LPS itself95, development of serum 
resistance to LPS96 and the fact that antibodies to LPS have been shown to be highly 
protective in animal models97–99.  Studies on chronic infection in CF  have also revealed 
that mean serum antibody titres to LPS correlate with duration of P. aeruginosa  
colonization and with disease severity as reflected by weight and vital capacity100.  
 
P. aeruginosa has a strong iron requirement and is able to excrete large amounts of two 
chemically unrelated siderophores, mainly pyoverdine (PVD) and to a lesser extent 
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pyochelin into its environment.  They both function as powerful iron chelators allowing it 
to fulfill its nutritional requirements within the host which aims to limit iron availability to 
prevent bacterial growth48,49,101. In addition, P. aeruginosa also produces molecules which 
are directly and highly toxic to host cells. Pyocyanin, for example, is a toxic phenazine 
metabolite produced by P. aeruginosa  which accelerates neutrophil apoptosis in vitro and 
is associated with reduced bacterial clearance from the lungs102. Pyocyanin is the most 
abundant phenazine and is present in significant quantities in the sputum of patients with 
cystic fibrosis and bronchiectasis whose lungs are colonised by P. aeruginosa 103.  The 
neutrophil-killing abilities of different P. aeruginosa  strains correlate with their 
production of pyocyanin suggesting that phenazine-induced neutrophil apoptosis may be 
clinically relevant in the mechanism of P. aeruginosa  persistence.104,105   Pyocyanin is also 
responsible for causing oxidative damage to the host and mitochondrial electron transport 
disruption105.  There is overwhelming in vitro and in vivo experimental data to support the 
argument the pyocyanin has important roles during P. aeruginosa -mediated 
pathogenesis104–106.  P. aeruginosa  also produces hydrogen cyanide which acts as a potent 
respiratory inhibitor due to its reactivity with cytochrome c oxidases and other 
metalloenzymes leading to the inhibition of aerobic respiration107,108.  There is 
accumulating evidence for a role of cyanide in pathogenicity as a mediating factor in the 
paralytic killing of Caenorhabditis elegans109. 
 
1.4 Pseudomonas aeruginosa and Airway Infection 
The lung is exposed to a constant bombardment of harmful inhaled agents and 
microorganisms.  Several layers of defence in the healthy lung help prevent infection from 
inhaled or aspirated microorganisms.  A combination of mechanical filtering, the innate 
mucosal immunity and circulating immune cells all participate in the clearance of 
microorganisms from the lung, usually at the cost of some degree of inflammation.  A loss 
of any of these barriers frequently results in lung infection.  Figure 1-6 below outlines the 
steps in initial colonisation of the lung followed by the establishment of acute and chronic 
infection. 
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Figure 1-6 Stages of Pseudomonas lung infection 
Lung infection is initiated by a break in the first line defences of the host, leading to colonisation.  
Acute infection results from high production of extracellular virulence factors and often multi-
organ failure leading to death.  Chronic infection is secondary to the more indolent persistence of 
bacteria in the lung and chronic inflammation as a result of biofilm formation. Taken with 
permission from Strateva et al, 201125 
 
P. aeruginosa is one of the most common pathogens causing respiratory infections of 
hospitalized patients.  In CF patients, airway infection with P. aeruginosa leads to a broad 
spectrum of lung injury and pathological response.   Acute lung injury, in comparison, 
which can lead to nosocomial necrotizing pneumonia is associated with a high incidence of 
morbidity and mortality110.  Infection leads to destruction of the epithelium and bacterial 
invasion of the pulmonary vasculature with subsequent bacteraemia due to increased 
production of extracellular virulence factors (figure 1-6).  Ventilator associated pneumonia 
generally demonstrates a mortality as high as 30%110.    
 
At the other extreme is the chronic and persistent airway infection seen in both cystic 
fibrosis and other chronic lung conditions where lung defence is damaged, including 
bronchiectasis.   If not eradicated during the acute infection phase, P. aeruginosa can adapt 
to the lung environment to grow as a biofilm resulting in chronic infection (figure 1-6).  
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Typically, the bacteria isolated from an established chronic infection are less inflammatory 
and cytotoxic than the strains isolated years earlier from the same patient during the initial 
phase of infection111.  Chronic P. aeruginosa lung infection in the form of structured 
biofilms is still highly problematic as it is generally not eradicable.  CF patients often 
develop a P. aeruginosa lung infection by adolescence and can live with persistent 
infection for 20 years or more.  
 
In CF, the thickened respiratory secretions, as a result of the CFTR mutation, prevents 
clearance of bacteria and impairs the immune response resulting in perpetual 
immunological stimulation110.  As a consequence of persistent inflammation and impaired 
bacterial clearing, patients develop worsening suppurative lung disease.  Small airways 
become obstructed with viscous mucus, organisms and inflammatory cells.  An endless 
cycle of infection, inflammation and progressive endobronchial destruction and loss is 
established, leading to widespread fibrosis and bronchiectasis.  Respiratory failure may 
finally develop with hypoxaemia and hypercapnia which is responsible for over 80% of 
CF-related deaths5. 
 
Outside CF, chronic infection with P. aeruginosa  is also commonly seen in the setting of  
bronchiectasis and chronic obstructive pulmonary disease (COPD)112,113.  The P. 
aeruginosa  isolates from these conditions also share features to those seen in CF including 
the mucoid phenotype with increased mutation rates, increased antibiotic resistance and 
increased biofilm formation114. 
 
1.4.1 Immune Responses in Cystic Fibrosis 
Absence of the CFTR function leads to chronic lung disease which is characterised by 
inflammation and persistent infection.  There is significant controversy as to whether 
patients with CF have an intrinsic impairment in their immune response, which predisposes 
to pulmonary P. aeruginosa  infection, with particular focus on neutrophil dysfunction115–
117.   The exact mechanisms are complex and only partially understood.   Clinical data 
indicates that patients with CF have a normal immune response at sites other than the 
lung118.  Alterations in the cellular components of the innate and adaptive immune system 
are likely to contribute to the impaired immune defence in CF lung disease. 
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Figure 1-7. The suggested hypothesis to explain the predilection of Pseudomonas aeruginosa 
for the cystic fibrosis airway. 
 (1) Impaired mucociliary clearance (MCC) due to dehydrated airway surface liquid (ASL) and 
mucus.  (2) The malfunction of antimicrobial peptides due to raised ASL salt content (3) An 
increased availability of bacterial receptors and the production of neuraminidase. (4) Defective 
internalization of bacteria by CF epithelial cells.  (5) Low levels of defence molecules such as NO 
and glutathione. Image taken with permission from Davies et al, 20026. 
 
There are three general components comprising the innate and adaptive immune defences 
in the respiratory tract  (Figure 1-7): (1) the mucociliary escalator; (2) humoral component 
of surfactant proteins, defensins and other antimicrobial compounds; and (3) cellular 
component including epithelial cells, monocytes, macrophages, neutrophils, dendritic cells 
and lymphocytes. 
1.4.2 Neutrophilic inflammation and lung injury 
CF lung disease is dominated by neutrophilic airways inflammation, with high levels of 
neutrophils being recovered from airway fluid samples including sputum and 
broncoalveolar lavage (BAL). In addition, high levels of IL-8 are consistently found and is 
known to act as a major neutrophil chemoattractant117,119.   IL-8 induced recruitment of 
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additional neutrophils to the airways results in release of neutrophil elastase120,121 and the 
additional induction of IL-8 gene expression by bronchial epithelial cells, which 
establishes a chronic cycle of respiratory inflammation leading to poorer disease 
outcome121–123.  Neutrophils induce lung damage via various mechanisms including release 
of matrix metalloproteinases (MMPs) which have the ability to degrade phagocytosed 
proteins.  Neutrophil elastase is able to degrade a number of structural proteins including 
elastin, collagen, fibronectin and proteoglycan and also augments mucus secretion adding 
to airway obstruction120,121.    
1.4.3 B cell and T cell Responses 
The role of B cell responses against pulmonary P. aeruginosa infection remains unclear.  
P. aeruginosa  specific IgA and IgG are produced by CF patients in response infection and 
have been found to increase progressively as patients develop chronic infection124,125.  
Mice unable to produce secretory IgA in lung secretions were found to have a three-fold 
increase in mortality in response to acute P. aeruginosa  infection126.  Infection with P. 
aeruginosa is known to evoke a T cell response.  In a murine model of acute P. aeruginosa  
infection, T cell immunity was found to develop and be important in host defence whereas 
humoral immunity was found to be dispensable127.   
1.5 Current Management of Cystic Fibrosis  
Life expectancy in cystic fibrosis has improved dramatically in the last 4 decades, 
unfortunately, however, the majority of patients still die of respiratory failure with a mean 
predicted survival of 28 years8.  The primary aim of therapy is to slow the progression of 
lung disease with meticulous daily management together with prompt, aggressive 
treatment of exacerbations to preserve lung function2.  Figure 1-8 below highlights the 
improvement and reduction in chronic P. aeruginosa infection between 2008 and 2014. 
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Figure 1-8.  Proportion of patients with chronic Pseudomonas aeruginosa and Staphylococcus 
aureus infection over time 
Data gathered from the UK Cystic fibrosis registry outlining the age at acquisition of Pseudomonas 
aeruginosa infection and subsequently lifelong persistence. Taken from CF registry annual report.  
20148 
 
 
1.5.1 Antibiotic therapy 
Antibiotic therapy for patients with CF is primarily directed at preventing, eradicating or 
controlling respiratory infections.  Prompt use of antibiotics in these situations has been 
one of the major reasons for decreased morbidity and mortality over the last few decades.  
Detailed and up to date guidelines can be found at the Cystic Fibrosis Trust8 website and 
also the European Cystic Fibrosis Society Standards of Care: Best Practice guidelines2.  
Briefly, treatment of P. aeruginosa infection begins with first isolates which are treated 
with a combination of oral ciprofloxacin and nebulised colistin for a period of 3 months.  If 
the initial treatment of P. aeruginosa infection fails, or if patients become chronically 
infected, a combination of intravenous (IV) antibiotics is used.  Although IV antibiotics 
have played a central role in the management of pulmonary infection in CF for 4 decades, 
there have only been two studies comparing their action against placebo128,129.  The general 
principles of treatment of exacerbations depend on the clinician and the patient involved as 
well as the organism isolated from the sputum culture.  The sensitivity pattern from the 
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organisms isolated from sputum and the clinical response shown by the patient is often 
discordant when there is infection with P. aeruginosa.  First line treatment of P. 
aeruginosa comprise a β-lactam e.g. ceftazidime, meropenem, or an anti-pseudomonal 
penicillin (piperacillin-tazobactam or ticeracillin-clavulanic acid) combined with colistin or 
tobramycin.  Nebulised colistin and tobramycin are widely used as long term treatments for 
patients chronically infected with P. aeruginosa  and many clinicians will stop nebulised 
antibiotics whilst the patient is receiving IV antibiotics8. 
 
A number of different morphotypes of P. aeruginosa may be present in cultures from CF 
patients, which may complicate the useful interpretation of antibiotic sensitivity patterns.  
There is a concern that the use of a single antibiotic may be associated with increased 
levels of antibiotic resistance, hence the use of tailored combination therapy with 
antibiotics of differing mechanisms of action used130–132. 
 
Azithromycin is a macrolide antibiotic often used on a long-term basis in patients with 
chronic lung infections including CF, COPD and bronchiectasis.  Azithromycin has well 
described anti-inflammatory properties with several studies showing that azithromycin 
alters macrophage phenotypes and inhibits inflammatory cytokine production133–136.  A 
recent Cochrane review of the evidence revealed that addition of azithromycin to therapy 
doubled the rate of being free of exacerbations over 6 months compared to placebo.  The 
need for oral antibiotics was also significantly reduced with azithromycin137.   
1.5.2 Channel Potentiators 
The most common mutation responsible for the CF phenotype is the Phe508del mutation 
encoding the CFTR protein with approximately 45% of patients with cystic fibrosis 
homozygous for this allele5.  The Phe508del mutation results in significantly reduced 
protein levels at the epithelial membrane and for those channels which do reach the 
membrane, the mutation also disrupts channel opening5,138.  Together, these effects lead to 
minimal CFTR chloride transport activity.  One approach to treating CF is to target the 
dysfunction of the CFTR channel in two specific steps:  increase the amount of functional 
mutated CFTR and potentiation to increase channel opening139. 
 
Ivacaftor (Kalydeco) is an investigational CFTR potentiator and has been shown in 
numerous clinical studies to potentiate CFTR channel gating and enhance chloride 
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transport mainly in the G551D CFTR gating mutation, however may have a similar effect 
on all CFTR forms140–142. 
 
Lumacaftor is an investigational CFTR corrector that has shown in vitro to correct 
Phe508del CFTR misprocessing and ultimately increase the amount of cell-surface 
protein143.  The combination of ivacaftor and lumacaftor in patients with CF who are 
homozygous for the Phe508del CFTR mutation has been shown in several studies to be 
associated with an increase in chloride transport than has either agent alone143–146. 
1.5.3 Mucolytics 
Lower airway mucus accumulation is a key factor in CF lung disease by favouring chronic 
airway infection with P. aeruginosa and other Gram-negative organisms.  There is 
characteristic airway inflammation which leads to bronchiectasis, progressive pulmonary 
function decline and eventually respiratory failure (see figure 1-9). 
 
 
Figure 1-9 Cycle of mucus retention and recurrent infections.  
Image taken from Tenke et al with permission147. 
 
Mucolytic agents break down the complex gel structure of mucus and therefore decrease 
its viscosity and elasticity.  The only mucus degrading agent with proven efficacy in CF is 
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dornase alfa (DNase or Pulmozyme)148,149.   As early as 1959, DNA was identified as being 
present in significantly higher quantities in sputum from CF patients compared to those 
with bronchiectasis resulting in increased sputum viscosity150.  The source of DNA was 
identified as primarily leukocytes infiltrating the sputum as a result of infection with 
elevated DNA concentrations also being found in bronchoalveolar lavage fluid from 
infants with CF111,151,152.  Dornase alpha specifically cleaves the extracellular DNA into 
shorter lengths which transforms the CF sputum into a flowing liquid148.  Other mucolytics 
such as N-acetylcysteine have not been proven to be effective in CF patients153. 
1.5.4 Airway clearance techniques 
In addition to the above therapies and nebulised saline solutions, chest physiotherapy uses 
airway clearance techniques to help clear excess mucus from the lungs.  Once the lungs 
become productive of purulent sputum, airway clearance treatment is usually required on a 
daily basis and may be required up to three-four times during an exacerbation154. 
1.6 Phenotypic Variation in Chronic Infection 
Phenotypic variation is a hallmark of adaptation to the host during chronic bacterial 
infection. Several studies have followed progression of Pseudomonas infection in patients 
with CF suggesting that a number of genotypic and phenotypic changes occur over time.  
The long term persistence of P. aeruginosa in the cystic fibrosis (CF) lung is characterized 
by the selection of a variety of genotypes and phenotypes that typically descend from one 
infecting P. aeruginosa clone via adaptive changes.  P. aeruginosa isolates from a single 
patient may differ significantly in their specific morphotypes including mucoid, rough, 
smooth, dwarf, colourless, small colony variants and variants with visible autolysis or 
autoaggregative behaviour.  These morphotypes may all differ significantly in their 
behaviours and antibiotic susceptibility patterns155–157.  The changes seen in bacteria 
isolated from chronic infections typically include loss of flagellum and pili 158(required for 
adherence and type III secretion system function159), mutations in mucA, mucB or mucD 
resulting in transformation to the mucoid phenotype160,161.   
 
A phenotypic variant common to diverse bacteria is the small colony variant (SCV) which 
is characterised by reduced growth, increased adherent biofilm production162, antibiotic 
resistance, hyperpiliation and atypical colony morphology.  SCVs have been described for 
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a wide range of bacterial genera and species including Staphylococcus aureus, 
Staphylococcus epidermidis163, Streptococcus sp164,165,  Enterococcus166, Listeria167, 
Burkholderia12, Salmonella168, Vibrio169, Shigella, Brucella170, Lactobacillus, Serratia, 
Neisseria171 species and yeast172.  S. aureus SCVs have been most extensively studied and 
their presence in persistent and recurrent infections is associated with a poor clinical and 
bacteriologic response to standard antimicrobial therapy in patients with abscess, chronic 
osteomyelitis, implantable prosthetic devices and bronchopulmonary infections173–176.  
Recently SCVs from Enterococcus faecium have been isolated from several patients.  One 
case was thought to be due to epithelial cell invasion and subsequent intracellular 
persistence in the bladder in a patient with recurrent urinary tract infections177.  A second 
case of  an Enterococcus SCV was from a confirmed native heart valve endocarditis, likely 
due to SCV subpopulations with decreased sensitivity or resistance to the antibiotics 
given178.  Chronic prosthetic joint infections are a major cause of morbidity and mortality 
following orthopedic surgery.  There are many case studies focusing on the SCVs role in 
prosthetic infections, but also similar studies looking at gram-negative SCVs, including 
Escherichia coli179.  In the case of P. aeruginosa, SCVs are commonly associated with 
chronic infection of the lung in patients with cystic fibrosis.  
 
1.6.1 SCVs in Chronic infection of the CF lung 
The opportunistic pathogen P. aeruginosa is responsible for chronic infections in the 
airways of cystic fibrosis (CF) patients leading to progressive decline in pulmonary 
function and inevitably respiratory failure.  Over 2-years of follow up, P. aeruginosa  
SCVs were isolated from 38% of patients with CF infected with P. aeruginosa 180,181.  
Compared with patients without SCVs, the presence of SCVs was associated with poorer 
lung function as well as increased daily inhaled antibiotic usage180.   P. aeruginosa  SCVs 
demonstrate features favouring chronic and persistent infection in the deeper airways 
including increased biofilm formation11,155 which enables them to resist physical stress and 
antibiotic therapy and enables increased adherence to respiratory cells155.   SCVs are able 
to grow preferentially in nutrient deplete conditions, which would favour the persistence in 
the CF lung and the ability to outgrow the wild-type phenotypes182. 
 
The exact mechanism behind the phenotypic switch to SCV has yet to be fully elucidated 
and research has shown that a number of different mutations can confer the SCV 
phenotype47,60,182,183.    A recent study showed that a large scale chromosomal inversion 
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enabled conversion between a normal colony S. aureus (NCV) and a SCV isolated from 
the same patient, found presumably allowing it to switch its phenotype to adapt to the 
environment during chronic infection184.  S aureus SCVs have been well studied in CF and 
are detected in about a quarter of patients173,185.  The presence of S. aureus SCVs is 
independently associated with substantially worse outcomes and worse lung function185,186.  
Given the virulent properties of SCVs and their altered antibiotic susceptibility profiles, it 
is important to confirm their presence in the microbiology laboratory.  Unfortunately, the 
mixed cultures obtained from sputum samples frequently makes the detection of SCVs 
very difficult.  Figure 1-10 below demonstrates the marked difference in colony size 
between a normal colony variant and an SCV.  Several studies have also suggested that the 
ability of granulocytes to uptake S. aureus SCVs is decreased.  It can therefore be 
hypothesized that the specific environmental conditions present in the host suffering from 
CF (highly viscous mucous, hyperosmolarity, oxidative stress) may select for SCVs186.  
 
 
 
 
Figure 1-10 MRSA colony surrounded by SCVs 
Image showing the difference in colony size and lack of heamolysis between the normal MRSA 
colony (large) and the SCV187. 
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When P. aeruginosa moves from the environment to the CF airway, there are extensive 
nutritional and physiological changes for the bacterium to adapt to enabling it to survive in 
hostile environments.  The immune system, constant antibiotic pressure, other respiratory 
microorganisms and osmotic stress resulting from the high viscosity of the mucus are 
important factors which influence adaptation.   
 
When P. aeruginosa  is faced with stressful conditions such as oxidative stress or antibiotic 
pressure, a fundamental transition in gene expression profile occurs188–191.  During aerobic 
respiration, some electrons escape from the electron transport chain and generate reactive 
oxygen species (ROS).  ROS have the ability to damage cellular structures, lipids, proteins 
and DNA resulting in loss of cell viability.  As a consequence, cells have evolved complex 
enzyme systems such as superoxide dismutase (SOD) and catalase to eliminate the 
damaging mitochondria generated superoxides188,192.  P. aeruginosa  encounters several 
sources of oxidative and nitrosative stress during infection in the CF airway which can lead 
to increased bacterial  mutation rates and select for variants that are able to survive in this 
environment193.  A frequent phenotypic adaptation of P. aeruginosa  in patients with CF is 
the conversion to the mucoid phenotype which results in overproduction of alginate and 
protection from the host immune response194–196.  The most common mutations responsible 
for the mucoid conversion are found in the mucA gene.  MucA normally limits the 
expression of the algD operon (which encodes the enzyme required for alginate synthesis) 
by sequestering the alternative RNA polymerase σ-factor σ22.  This inevitably leads to 
altered expression of numerous stress response and virulence associated genes197.  During 
long-term colonisation of CF lungs, P. aeruginosa  undergoes specific adaptation to the 
host environment and following prolonged persistence it develops small colony variants 
(SCVs) which display high intracellular c-di-GMP levels59,60,182,198,199, enhanced biofilm 
formation, repression of flagellar genes, high fimbrial expression, resistance to 
phagocytosis and enhanced antibiotic resistance.  The appearance of SCVs in the CF lung 
correlates with poor patient clinical outcome12,156,185,200,201. 
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1.7 Antibiotic Resistance in Pseudomonas aeruginosa 
‘Antimicrobial resistance (AMR) within a wide range of infectious agents is a growing 
public health threat of broad concern to countries and multiple sectors. Increasingly, 
governments around the world are beginning to pay attention to a problem so serious that 
it threatens the achievements of modern medicine. A post-antibiotic era—in which common 
infections and minor injuries can kill—far from being an apocalyptic fantasy, is instead a 
very real possibility for the 21st century.202’ 
Bacterial infections remain a major health problem both within the UK and worldwide. In 
particular, the ability of bacteria to develop resistance against antibiotics is limiting the use 
of these drugs to treat bacterial infections.  Resistance has spread around the world.  
MRSA has spread between continents203 as have resistant strains of TB, malaria, HIV and 
pneumococci. Resistance to antibiotics is common and widespread across the globe. In 
Scotland, the Gram-negative pathogen P. aeruginosa  shows resistance to mainline 
therapies such as Piperacillin-Tazobactam at 9.8% and cephalosporins of 8%204. Across 
Europe, the ECDC estimates that the human burden of the 6 most common drug-resistant 
bacteria alone is at least 25,000 deaths annually with an economic burden of greater than 
€900 million per year205. Moreover, the emergence of novel resistance mechanisms, such 
as the extended spectrum β-lactamases, highlights the rapid evolution of antibiotic 
resistance. There is thus an urgent need for therapies with modes of action distinct from 
conventional antibiotics. 
 
1.7.1 Resistance Mechanisms in Pseudomonas aeruginosa 
P. aeruginosa presents a serious therapeutic challenge for treatment of infections and 
selection of appropriate antibiotics is essential to optimizing clinical outcomes.  
Unfortunately P. aeruginosa  has the ability to rapidly develop resistance to multiple 
classes of antibiotics even during the course of treatment, increasing morbidity and 
mortality significantly206.   Patients with CF and bronchiectasis are exposed to prolonged 
and frequent courses of antibiotics throughout their lives which inevitably leads to intense 
selection pressure which drives antibiotic resistance207,208.  Table 1-3 below outlines the 
major mechanisms by which bacteria develop antibiotic resistance.  All known 
mechanisms of antibiotic resistance, namely intrinsic, acquired and adaptive, can be 
displayed by P. aeruginosa.  Intrinsic resistance is imparted by low outer membrane (OM) 
permeability, expression of multi-drug efflux pumps and the occurrence of chromosomally 
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encoded antibiotic degrading enzymes (β-lactamases)209–211.  Acquired resistance results 
from the transfer of genetic material encoding resistance genes, the accumulation of 
mutations in antibiotic targets and mutations in genes or regulators affecting intrinsic 
resistance mechanisms.  Finally, adaptive resistance occurs when changing environmental 
conditions lead to increased resistance including P. aeruginosa growth in a biofilm. 
 
Table 1-3.  Mechanisms of bacterial antibiotic resistance.   
Mechanism Resistance class Example(s) 
Efflux pumps 
 
 
Outer membrane 
impermeability 
β-lactamases 
Targeted mutation 
 
Horizontal transfer 
 
Membrane changes 
Intrinsic 
 
 
Intrinsic 
 
Intrinsic 
Acquired 
 
Acquired 
 
Adaptive 
MexAB-OprM, MexCD-OprJ, MexEF-OprN, 
MexXY-OprM (cephalosporins, carbapenems, 
aminoglycosides, quinolones, ureidopenicillins) 
OprF, OprD, OprB (carbapenems, aminoglycosides, 
quinolones) 
AmpC (penicillins) 
DNA gyrase, DNA topoisomerase (quinolones) 
MexZ (quinolones, cefapimes, aminoglycosides) 
Metallo- β-lactamases, ESBLs (penicillins, 
cephalosporins, carbapenems) 
Lipid A modification (aminoglycosides, 
polymyxins) 
AmpC upregulation (penicillins) 
 
 
The outer membrane of gram-negative bacteria constitutes a semipermeable barrier that 
reduces the penetration of many classes of antibiotics.  Specifically, the outer membrane in 
P. aeruginosa  is only 8% as permeable to small molecules as the outer membrane of 
Escherichia coli212.  To cross the P. aeruginosa  outer membrane some antibiotics use 
porin channels such as the carbapenem-specific porin OprD213,214.  Studies have proven 
that imipenem resistance in P. aeruginosa  is associated with the loss of the porin OprD in 
combination with the activity of the chromosomally encoded β-lactamase AmpC, while 
overexpression of multidrug efflux pumps confers resistance to meropenem213,214.   
Reduced outer membrane permeability of vital antibiotics can arise from changes to the 
structure and composition of the PA outer membrane such as changes to the O-antigen, 
reduction in cell envelope Ca2+ and Mg2+ content or the covalent addition of 4-amino-L-
arabinose to phosphate groups within the lipid A and core oligosaccharide moieties of 
LPS215. 
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Efflux pumps are ubiquitous among Gram-negative and Gram-positive bacteria, 
transporting antibiotics and other toxins out of the bacterial cell53,187,206,212. 
 
1.7.2 Biofilms and Antibiotic Resistance 
The ability of P. aeruginosa and many other bacteria to attach to wet surfaces and to each 
other, with subsequent differentiation into highly structured biofilms is considered a major 
virulence trait and enables chronic infection of the host60,216,217.  The environmental stimuli 
that drive switching to the biofilm phenotype are poorly understood, however studies have 
shown that genetic diversity may arise by means of a mechanism involving the recA gene 
function216.  It has been recognised for many years that ‘dwarf’ colonies can be isolated 
from the chronically infected CF lung and correlated with poor lung function199,218.  P. 
aeruginosa  biofilms can be up to 1000 times more resistant to antibiotics than bacteria in 
the planktonic (free living) state209,216, are more inconspicuous to the immune system and 
provide physical protection from immune cells. 
 
The development of antibiotic resistance in biofilm communities is not fully understood.  
Owing to the compact nature of biofilm structures, slow growth, nutrient limitation, 
activation of the general stress response and the protection conferred by the biofilm matrix 
polymers, natural and artificial chemical agents are unable to adequately attack and destroy 
infectious biofilm populations219.  Growth, protein synthesis and metabolic activity are 
stratified in biofilms, with high levels at the surface and low levels in the centre.  Very 
slow in situ growth rates in biofilms have been measured in the sputum of CF patients, 
with an average doubling time of 2-3 hours and the presence of a significant number of 
cells in stationary growth phase191,209.  Use of β-lactam monotherapy in this setting is not 
effective at eradicating biofilm infections as these antibiotics are only effective against 
dividing P. aeruginosa cells. 
 
The mutation frequency of biofilm-forming bacteria is significantly increased compared 
with planktonically growing isogenic bacteria with increased horizontal gene transfer in 
biofilms220.  Biofilm-growing bacteria develop multidrug resistance against β-lactam 
antibiotics, fluoroquinolones and aminoglycosides by means of traditional mechanisms 
including enzymatic acquired resistance and recurrent mutations221.  Bacterial cells present 
in biofilms may simultaneously produce enzymes which degrade antibiotics, have 
antibiotic targets of low affinity and overexpress efflux pumps with a broad range of 
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substrates.  A high percentage of hypermutable P. aeruginosa isolates associated with 
antibiotic resistance have been isolated from CF patients157,220,222,223. 
 
The physical diffusion barrier in biofilms plays a pivotal role in biofilm resistance in P. 
aeruginosa via overproduction of β-lactamases in the matrix.  These extracellular β-
lactamases have the ability to inactivate the antibiotic as it penetrates, thereby protecting 
the deeper lying cells191,224.  Sub-MIC concentrations of β-lactam antibiotics have been 
found to be responsible for the induction of increased alginate synthesis225 in P. aeruginosa  
biofilms226.  One of the only antimicrobial agents which is effective against the non-
dividing dormant cells of the P. aeruginosa biofilm is colistin, whereas the metabolically 
active cells remain sensitive to ciprofloxacin.  Combination therapy is often used and has 
shown to be effective in eradication of P. aeruginosa 227.   
1.7.3 Persister Cells 
All microbes are capable of producing a small subpopulation of dormant persister cells that 
are highly tolerant to killing by antibiotics.  As the concentration of an antibiotic falls to 
sub-therapeutic levels, surviving persisters are able to re-establish the population resulting 
in relapsing chronic infection66.  There are many studies outlining the presence of bacterial 
persisters and Candida albicans subpopulations that can remain viable at high 
concentrations of an antifungal agent.228  Such subpopulations are not mutants, but rather 
phenotypic variants that can survive antimicrobial treatment.  Drug tolerance appears to be 
a transient and reversible physiological state and when the antimicrobial agent is 
removed229 these persisting microbial cells resume growth and become sensitive to 
antimicrobial agents230.    
1.7.4  Epigenetic Modification and Resistance 
It is well established that many species of bacteria, including P. aeruginosa , E.coli and S. 
enterica exhibit resistance when they are exposed to successive steps of increasing 
concentrations of antibiotics231.  One important finding in these studies is that there is often 
reversion back to the sensitive phenotype once the antibiotic pressure has been removed.  
This would be incompatible with a genetic mutation being the sole reason for this adaptive 
phenotype as the resistant phenotype would not be easily reversible.  It has been suggested 
that a combination of epigenetic processes such as methylation and stochastic gene 
expression, may be driving the emergence of adaptive resistance232–235. 
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1.8 Transcriptional Analysis and Next Generation Sequencing 
in mechanisms of resistance and adaptation 
1.8.1 Transcriptome Analysis 
Microbial transcriptome and metatranscriptome analysis is important for understanding 
host-pathogen immune interactions, predicting resistance to specific antibiotics, 
quantifying gene expression changes and tracking disease progression236.   
  
Although many different kinds of microbes evolve resistance, resistant bacteria are 
currently the greatest cause for concern.  It is no coincidence that the nations with the 
strictest policies on antibiotic prescription (Scandinavia and Netherlands) have the lowest 
rates of resistance237.  The molecular basis of antibiotic resistance is in many cases well 
understood and modern techniques have defined the stable genetic changes involved. 
However, the pathways by which bacteria evolve these resistance mechanisms remain 
unclear. Additionally, the significance of mutations in elements controlling gene 
expression will not be immediately apparent from genome sequencing alone, since change 
in expression of a global transcriptional regulator will produce dramatic changes in the 
overall bacterial gene expression profile238,239. These changes can underpin antibiotic 
resistance: for example, a number of recent studies have shown significant changes in 
global bacterial gene expression in response to antibiotic exposure. These have suggested 
generic bacterial defences that counter the end result of antibiotic treatment which is 
oxidative stress induced by reactive oxygen intermediates240–243.  Bacteria counter this 
oxidative stress by upregulating specific genes such as the so-called stringent response244 
and through the induction of hydrogen sulfide245.   
 
Data from one of the initial transcriptome studies of the response of P. aeruginosa  to iron 
indicated that 137 genes were upregulated secondary to iron depletion246.  A further more 
systematic study was performed which addressed how the transcriptome changes when 
iron-starved P. aeruginosa cells were fed with iron.  Most genes were found to be 
downregulated including genes involved in transport of small molecules and transcriptional 
regulators however it was noted that genes involved in virulence were upregulated, some 
of which may help the cells to overcome the host innate immune system247.  There have 
also been several studies which look at how P. aeruginosa responds to varying levels of 
copper.  Tietzel et al248 identified a set of genes which form a core response of P. 
   
 
 
46 
aeruginosa  to copper.  Copper starvation under aerobic conditions led to downregulation 
of 132 genes, while only 10 genes were upregulated.  In a further study the global response 
to sulphate starvation was addressed in a non-mucoid CF isolate and PAO1.  Unlike PAO1, 
the CF isolate was shown to utilize mucin as a sulphur source.  Several genes involved in 
the type III secretion system and exoenzyme S were also induced suggesting that cells 
recognize mucin as a sulphur source and also a host component61.  Transcriptional 
profiling of osmotically stressed P. aeruginosa  has also been studied249 which led to the 
identification of a steady state osmotic shock regulon comprising 66 genes.  
 
1.8.2 Environmental adaptation 
In previous studies on global P. aeruginosa  transcriptional profiles of biofilms, it has been 
shown that planktonic culture in exponential and stationary phase of growth and biofilm 
cultures show distinct patterns of gene expression indicating that biofilms are not just 
surface attached films in a stationary phase52.  In a recent study by Dotsch et al250, the 
differential gene expression was compared in mature P. aeruginosa  biofilms as opposed to 
planktonic cells by the use of RNA sequencing technology, giving both qualitative and 
quantitative information on the transcriptome.  The comparative analysis of gene 
expression in planktonic and biofilm cultures revealed simultaneously regulated genes in 
the stationary phase of planktonic cultures and in biofilms as well as a set of genes that 
were specifically regulated in biofilms.  The latter included a large proportion of genes 
previously described to be biofilm regulated such as genes involved in type III secretion, 
adaptation to microaerophilic growth and the production of extracellular matrix 
components250.  Quorum sensing has been implicated as an important step in the formation 
of ordered antibiotic-resistant biofilm communities.  There have been several studies 
looking at quorum sensing mutants which has helped to identify a core set of 77 genes of 
the QS regulon that are positively regulated34.  
 
The versatility of P. aeruginosa in adapting to a wide range of environments including that 
of the human body is attributed to a large genomic repertoire consisting of a diverse set of 
genes encoding metabolic functions suited for proliferation in a wide range of 
environments.  P. aeruginosa also has an impressive armament of virulence factors, 
explaining why this species is the most common human pathogen amongst the members of 
the genus Pseudomonas.  Interestingly, virulence genes are highly conserved among 
different P. aeruginosa strains and are part of the core genome, leading to speculations that 
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some form of pathogenic interaction occurs in natural environments providing the 
evolutionary pressure for their maintenance.  Rapid adaptation of bacteria to changing 
environments is accompanied by reprogramming of their regulatory networks to activate 
the expression of genes essential for their survival in the new environment while repressing 
those that are unnecessary or potentially deleterious.  In a recent study by Wurtzel et al, 
RNA-sequencing was used to look at differential gene expression of P. aeruginosa grown 
at 28 and 37°C.  The results revealed genes which were preferentially expressed at the 
body temperature, suggesting they play a role during infection.  These temperature induced 
genes included the type III secretion system (T3SS) genes and effectors, as well as the 
genes responsible for phenazines biosynthesis251.  
 
Significantly, disruption of any of these pathways mentioned dramatically increased the 
susceptibility of the bacteria to a variety of antibiotics. Thus, drug targeting of these and 
related systems could offer novel therapeutic targets to treat antibiotic resistant bacteria.   
Although studies have been made of bacteria in different culture conditions, no studies 
have analysed changes in bacterial transcription that occur in vivo in response to antibiotic 
challenge. This is particularly important since growth of bacteria in vivo represents a 
totally different environment than the rich culture media used in laboratory studies245.  
 
1.9 Next Generation Sequencing technology 
The next generation sequencing (NGS) technologies are revolutionary tools which have 
made remarkable achievements in genetics possible since the beginning of the twenty-first 
century.  They produce great sequencing depth making them applicable to quantitative 
studies such as transcriptomic measurements. 
 
In 1977, Frederick Sanger developed DNA sequencing technology based on the chain 
termination method, also known as Sanger sequencing252,253.  The NGS technologies differ 
from the Sanger method in aspects of massively parallel analysis, high throughput and 
reduction in cost254. Recent advances in sequencing technology and bioinformatic 
interpretation have resulted in the availability of instruments that can be operated in a 
clinical environment.  These technologies have many potential applications for the control 
of infectious disease outbreaks.  In the recent 2014 Ebola outbreak in West Africa a new 
highly portable genome sequencer was used in the field (the MinION from Oxford 
Nanopore Technologies, Oxford) to track the evolution of the Ebola virus over the course 
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of the epidemic255.  Previously, outbreaks have been difficult to identify in part due to 
limitations in molecular typing technology.  Whole genome sequencing, in combination 
with phylogenetic analysis however are invaluable tools for epidemic investigation as they 
are able to identify exact transmission events and exclude cases mistakenly implicate by 
traditional methods256–258. 
Table 1-4 Comparison of NGS platforms. Table taken from Finseth et al with permission257 
Platform Chemistry Read 
Length 
(bp) 
Run Time Advantage Disadvantage 
454 GS Junior 
(Roche) 
Pyrosequencin
g 
500 8 hours Long read 
length 
High error rate in 
homopolymer 
454 GS FLX+ 
(Roche) 
Pyrosequencin
g 
700 23 hours Long Read 
Length 
High error rate in 
homopolymer 
HiSeq (Illumina) Reversible 
Terminator 
2*100 2 days (rapid 
mode) 
High 
throughput/cos
t 
Short reads, Long 
run time 
SOLiD (Life) Ligation 85 8 days Low error rate Short reads, Long 
run time 
Ion Proton 
(Life) 
Proton 
Detection 
200 2 hours Short run 
times 
Short reads 
PacBio RS Real-time 
sequencing 
3000 (up to 
15,000) 
20 min No PCR, 
Longest read 
length 
Can analyse 
methylation 
data 
High Error Rate, 
high cost 
  
Table 1-4 above outlines the main next generation sequencing platforms available and their 
main advantages and disadvantages. 
Illumina have dominated the sequencing industry over the last few years and set the 
standards for high throughput massively parallel sequencing with the HiSeq 2000.  Prior to 
the sequencing, the DNA samples are randomly fragmented during the library preparation 
step.  The library is then amplified using PCR which has the potential to introduce 
amplification bias against AT or GC rich regions259.   Illumina utilises sequencing by 
synthesis (SBS) technology using four fluorescently-labelled nucleotides to sequence tens 
of millions of clusters on a flow cell surface.  During each sequencing cycle, a single 
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labelled deoxynucleoside triphosphate (dNTP) is added to the nucleic acid chain, which 
then acts as a terminator for polymerisation.  The fluorescent dye is imaged to identify the 
base.  The end result is highly accurate base by base sequencing that eliminates sequence-
context specific errors and robust base calling across the genome259.  
 
Pacific Biosciences have developed a method for real time sequencing of single DNA 
molecules with a rate of several bases per second and read lengths into the kilobase range.  
This single-molecule, real-time (SMRT) technology utilises sequential base additions 
which are catalysed by each polymerase and detected with terminal phosphate linked 
fluorescent-labelled nucleotides. 
 
Figure 1-11  Principles of single-molecule, real –time (SMRT) DNA sequencing260 
(A) Single DNA polymerase molecules and bound DNA template immobilized to the bottom of the 
array.  (B) Molecular structure of the phospholipid linked nucleotides.  The arrow indicates the α-β 
phosphodiester bond cleavage mediated by the DNA polymerase.  (C)  Step 1: DNA 
template/primer/polymerase complex is surrounded by diffusing phospholinked nucleotides which 
probe the active site.  Step 2: Labelled nucleotide makes a cognate binding interaction with the 
template base in the DNA.  Fluorescence is emitted continuously, giving rise to a detectable pulse 
in the fluorescence intensity time trace.  Intensity of fluorescence indicates which base is 
incorporated.  Step 3: The polymerase incorporates the nucleotide into the growing nucleic acid 
chain by cleaving the α-β phosphodiester bond, thereby subsequently releasing the pyrophosphate-
linker-fluorophore. Step 4: The polymerase translocates to next template position. Step 5: The 
process repeats. Image taken from Korlach et al with permission260. 
   
 
 
50 
The principles of SMRT DNA sequencing are outlined in figure 1-11 above.  The 
technology uses a DNA polymerase to drive the reaction and images single molecules, 
which means there is no degradation of signal over time.  The sequencing reaction ends 
when the template and polymerase dissociate260,261.  The average read length from PacBio 
RS is about 3000bp but some may be 20,000 bp or longer.  The SMRT approach has 
several advantages, specifically in relation to the long read length.  With other 
technologies, the short read length and amplification bias can lead to fragmented 
assemblies whenever a repeat or poorly amplified area is encountered.  P. aeruginosa 
genomes in particular are GC rich which results in poor amplification, repetitive regions 
and therefore poor quality sequencing.  By combining the long reads of SMRT sequencing 
runs with the more accurate (in terms of nucleotide resolution) short reads of Illumina, the 
reads will span many more repeats and missing bases, closing many gaps and resulting in a 
highly accurate complete genome262.  The long read lengths also have the ability to reveal 
complex structural variations present in the DNA such as large scale chromosomal 
rearrangements. 
 
Methylation changes can also be detected from SMRT sequencing data due to the change 
in DNA polymerase kinetics as it moves along the template molecule263.  From analysis of 
bioinformatics data the gene responsible for any given base modification can be matched 
to a sequence motif in which the modification lies, thus functional information emerges 
directly from the SMRT approach263,264. 
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1.10 Aims 
The evolution of phenotypic variants during infection enables microorganisms to evade 
immune defences, tolerate antibiotic treatment and persist in the host during chronic 
infection.  Phenotypic change is a hallmark of adaptation of P. aeruginosa to the lung 
during chronic infection in patients with cystic fibrosis.  Well characterised phenotypic 
variants include mucoid and small colony variants, the appearance of which is associated 
with disease severity. In the case of small colony variants, which form a highly adherent 
biofilm and show increased and antibiotic tolerance to some antibiotics, it has been 
suggested that the environmental pressures that select for SCVs may include antibiotics 
and a highly active host immune system.  Here we show that P. aeruginosa small colony 
variants can be reproducibly isolated from the murine lung following the establishment of 
chronic infection in the absence of antibiotic pressure.   This thesis also looks at 
optimisation of methods for bacterial RNA extraction from CF sputum samples for 
downstream transcriptomic analysis. 
 
The three specific aims of this work were: 
 
1. To phenotypically characterise and compare the SCV and original mucoid strain 
2. To compare the transcriptome between the two isolates to establish changes in 
gene expression which may be accountable for the change in phenotype 
3. To compare the whole genome sequence using a combination of techniques to 
establish a genetic mechanism behind the phenotypic switch 
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Chapter 2 Materials and Methods 
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2.1  Chemicals, growth media, buffers and strains 
2.1.1  Chemicals 
All chemicals used in this thesis were of analytical grade and purchased from Sigma-
Aldrich, Fischer Scientific or Melford unless otherwise stated. 
2.1.2  Growth media 
Media used in this thesis was a combination of externally sourced agar plates, media 
prepared in the University of Glasgow and media prepared by myself in the laboratory. 
 
Table 2-1  Self prepared media recipe (components per litre).   
Lysogeny broth (LB) and minimal media were prepared in dH2O using the recipes outlined.  They 
were adjusted to pH 7.5 and sterilised by autoclaving.  For preparation of the solid media, 15 g L-1 
agar was added to the media prior to autoclaving. 
 
Lysogeny broth (LB) 
Per litre 
Minimal media 
Per litre 
10 g Tryptone 
5 g yeast 
10 g NaCl 
 
6.8 g Na2HPO4 
3 g KHPO4 
0.5 g NaCl 
1 g NH4Cl 
2 ml glycerol 
1 mM MgSO4 
100 μM CaCl2 
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Table 2-2  Externally sourced media 
Media Source 
Columbia blood agar (COB) 
 
Chromogenic Pseudomonas 
agar 
 
Chocolate Bacitracin 
 
CLED Agar 
 
Mueller Hinton agar (MHA) 
 
Tryptone soya broth (TSB) 
 
Sputasol 
Thermo Scientific (Oxoid Microbiology Products) 
 
bioMérieux, UK 
 
Thermo Scientific (Oxoid Microbiology Products) 
 
Thermo Scientific (Oxoid Microbiology Products) 
 
Thermo Scientific (Oxoid Microbiology Products) 
 
Thermo Scientific (Oxoid Microbiology Products) 
 
Thermo Scientific (Oxoid Microbiology Products) 
 
 
Brain heart infusion (BHI) broth was made in the media department of the GBRC.   
 
2.1.3  Buffers 
Buffers were made using dH2O, filter sterilised, autoclaved where necessary and stored at 
room temperature. 
1x PBS solution was prepared as shown in Table 2.3 
Table 2-3. Buffer recipe 
Component   Quantity Concentration 
NaCl 
KCl 
Na2HPO4 
KH2PO4 
8 g 
0.2 g 
1.44 g 
0.24 g 
137 mM 
2.7 mM 
10 mM 
2 mM 
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The mixture was made up to 800 ml in dH2O and then adjusted to pH 7.4 with HCl before 
being made to a final volume of 1 litre.  The buffer was then autoclaved and stored at room 
temperature.   
     
2.1.4  Strains 
The strains used in this study are described in Table 2-4 below. 
Table 2-4. Strains used in this study 
Strain of 
Pseudomonas 
Genotype or relevant characteristics Reference or source  
PA01 Clinical isolate Stover et al.19 
NH57388A 
(NHMuc) 
Clinical mucoid isolate N. Hoffman, University of 
Copenhagen 
SCV20265 Clinical small colony variant, human CF 
lung sample 
Hanover Medical School181 
SCVJan Small colony variant from murine model Murine model developed by 
Dr Hannah Bayes 
SCVFeb Small colony variant from murine model Murine model developed by 
Dr Hannah Bayes 
MUC 
 
Mucoid isolate from mouse model 
infected with NHMuc 
As above 
 
GRI Ventilator associated pneumonia clinical 
isolate 
Glasgow Royal Infirmary 
microbiology laboratory 
YH5 Paediatric cystic fibrosis isolate Glasgow Royal Infirmary 
microbiology laboratory 
 
2.2  Maintenance and growth of bacteria 
2.2.1  Storage of bacterial strains 
5 ml overnight cultures of bacterial strains were inoculated from a single colony on solid 
agar plates and grown overnight (~16 hours) in LB medium at 37°C with 220 rpm shaking.  
0.5 ml of this culture was then added to a cryo-vial containing 1ml sterile glycerol (40%) 
and peptone (2%).  The stocks were frozen at 80°C until required. 
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2.2.2  Bacterial colony morphology. 
Colony morphology was obtained by plating strains onto COB Agar and LB agar.  Plates 
were incubated at 37°C and 30°C to ensure no difference in morphology.  
 
2.3  Murine agar bead infection model (Dr Hannah Bayes, 
University of Glasgow).  
All mice were used between 12 and 16 weeks of age and of a C57BL/6 lineage. All 
procedures were carried out in accordance with UK Home Office regulations. The 
infection model was adapted from the protocol described by van Heeckeren et al. 265  P. 
aeruginosa-laden agar beads were prepared the day before inoculation, stored overnight at 
4 °C, and a different bead preparation used for each experiment. P. aeruginosa -laden 
beads were stored on ice throughout the murine surgery. Following inoculation of P. 
aeruginosa -laden beads, the administrated inoculum was confirmed by homogenization 
and quantitative bacteriology on a further two aliquots of beads.  
For inoculation of P. aeruginosa -laden beads, mice were anaesthetized using isofluorane 
via nose cone and the trachea exposed and cannulated (22G intravenous cannulae; BD 
Biosciences) under aseptic conditions. An average inoculum of 1x106 CFU/50 µl per 
mouse was delivered. Animals were monitored closely post-operatively using a disease 
severity scoring system. An animal reaching a moribund end-point was culled. Daily 
weights were used as a further measure of disease progression and those with weight loss 
of greater than 20% of baseline weight were culled. Surviving animals were culled at 14-
days post-procedure. 
2.3.1 Pulmonary bacterial quantification and identification 
Bronchoaveolar lavage (BAL) was performed aseptically with 1 ml sterile phosphate 
buffered saline (PBS) via transtracheal intubation. Lungs were removed aseptically and 
homogenized in 1ml PBS. BAL and homogenized lung tissue was plated on LBagar plates 
for morphology identification and serial dilution for quantification. Pulmonary bacterial 
burden was calculated from BAL plus right diaphragmatic lung homogenates. SCVs from 
murine samples were initially identified via typical morphology and via conventional 
laboratory methods including Gram stain, oxidase reaction and API 20NE (bioMérieux). 
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2.4  Culture of Clinical CF Sputum Samples 
50 sputum samples were collected from CF patients in the adult CF cohort in the West of 
Scotland, attending out-patient clinic and undergoing an infective exacerbation to examine 
for presence of small colony variants of P. aeruginosa. 
To the sputum sample, an equal volume of reconstituted Sputasol was added to the sample 
in the sterile universal.  The mixture was vortexed until liquefaction was complete.  The 
sample was then inoculated onto Colombia blood agar, chocolate bacitracin and CLED 
agar.  The COB and chocolate bacitracin plates were then incubated in a CO2 cabinet for 48 
hours and the CLED incubated in an aerobic cabinet for 48 hours, both at 35°C.  
The plates were analysed for the presence of SCVs and compared with the clinical report 
from the sample. 
2.5  Phenotype and Virulence Characterisation 
2.5.1  Growth curves. 
Overnight culture of a tested strain was diluted 1:1000 in 10 ml of fresh LB broth and 
grown at 37°C with gentle shaking in a shaking incubator (IKA KS 4000i Control, 180 
rpm).  OD600 was measured at hourly intervals using a spectrophotometer (Eppendorf Bio 
Photometer).  The experiment was performed with three biological replicates of each 
strain. 
 
2.5.2  Reversion assay 
Small colony variant isolates were inoculated into 5 ml BHI broth and incubated at 37°C, 
200 rpm overnight.  A 10 µl loop of the liquid overnight culture was then plated onto a 
Columbia blood agar plate and further incubated at 37°C overnight.  Plates were examined 
at 24 and 48 hours to look for evidence of reversion back to the mucoid phenotype.  One 
colony from the 48 hour culture was further inoculated into 5 ml BHI broth and incubated 
as before.  This was repeated 14 times to examine whether reversion to mucoid phenotype 
would occur.  The same assay was performed with the following variables: 
 
1. LB instead of BHI 
2. Minimal media instead of BHI 
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3. A range of incubation temperatures used; 21°C, 30°C, 42°C for cultures grown in LB, 
minimal media and BHI. 
 
2.5.3  LPS extraction and analysis 
A 5 ml overnight culture of each strain was set up in LB broth and incubated at 37°C in a 
shaking incubator at 200 rpm.  5ml of the cultures were then diluted 1:10 with LB and 
subsequently a 1.5 ml suspension made of the bacteria to obtain an OD600 of 0.5.   
The suspensions were centrifuged at 10,600 x g for 10 minutes and the supernatant 
removed and discarded.  Extraction of LPS using the hot aqueous-phenol extraction 
method was performed as previously described266.  LPS samples were then visualised by 
running samples on an SDS PAGE gel followed by staining using the SilverQuest Silver 
Staining kit (Life Technologies) as per the manufacturer’s protocol. 
 
2.5.4  Electron microscopy  
For scanning electron microscopy the bacterial strains were grown on a coverslip in a petri-
dish with LB broth at 37 °C for 36 hours.  These were then washed in PBS, processed and 
stained using a paraformaldehyde-glutaraldehyde cocktail with alcian blue dye as 
previously described267.  Both scanning electron microscopy (SEM) and transmission 
electron microscopy (SEM) were performed within the University of Glasgow. 
 
2.5.5  Antibiotic susceptibility testing  
2.5.5.1 E-test 
The MIC for various antibiotics was determined using E-test strips (AB bioMérieux).  A 
sterile cotton swab was immersed in 0.5 McFarland of tested bacterial culture before 
streaking on sterile Mueller-Hinton (MH) agar.  In addition, the MICs were read at 24h and 
48 h to take into account the slow growth of the SCVs.   
 
2.5.5.2 Vitek II 
Additional susceptibility testing was performed using the Vitek II as per the 
manufacturer’s protocol.  To ensure no contamination of the Vitek II antimicrobial 
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susceptibility card, purity was checked by plating on COB agar.  Overnight cultures were 
grown on COB agar. 
 
2.5.5.3 Microtitre Broth MIC 
Antibiotic stocks were prepared by dissolving and diluting as per the manufacturer’s 
instructions to 2X the maximum concentration required.  Solutions were frozen until 
required. 
 
Test strains were grown in LB broth until they reached an OD of 0.6 (104 to 105 CFU/ml).   
100 μl of LB was dispensed into the wells of a 96 well microtitre plate.  100 μl of the 
appropriate 2X antibiotic solution was then added to the wells in column 1 of the 96 well 
plate.  Using the multipipettor, antibiotic was mixed with the broth in column 1 and then 
100 μl added to column 2. This procedure was repeated from columns 1 to 10.  100 μl was 
then discarded from column 10 rather than adding to column 11. Bacteria were then diluted 
to the appropriate inoculum size and poured into a sterile petri-dish.  Using the 
multipipettor, 5 μl of bacteria were dispensed into wells in columns 11 to 1 in that order.  
Column 12 remains empty as a blank control.  The bacterial cultures were then streaked 
onto LB agar to check purity. The plates were incubated at 37 °C for 18 and 36 hours.  
Following incubation they were read using an ELISA reader and MIC was taken as the 
lowest concentration of drug that reduces growth by more than 90%. 
2.5.5.4 Microtitre Biofilm PEG Assay 
Antibiotic test solutions were prepared in advance as above.  Peg biofilms were produced 
as per the manufacturer’s protocol for the Innovotech MBECTM Assay for high-throughput 
antimicrobial susceptibility testing of biofilms. The antibiotic challenge plate was set up as 
per the protocol using tobramycin, ceftazidime and ciprofloxacin. To determine the 
minimum inhibitory concentration (MIC), the challenge plate was then placed in a fresh 
96-well microtitre plate and incubated at 37 °C for 18 and 36 hours.  An automated plate 
reader was used to measure the OD650 and determine the MIC. 
2.5.6  Motility assays 
Swimming, swarming and twitching motility were assessed according to previous 
studies158, except that the plates were incubated at 30°C for 48-72 hours and in the 
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twitching motility assay Coomassie blue was used instead of crystal violet to stain for 
evidence of motility.  
 
2.5.7  Biofilm microtitre plate assay 
Quantitative determination of biofilm production was performed with the use of a 
microtitre plate assay with crystal violet.  Briefly, for each isolate, the overnight bacterial 
culture was adjusted with LB broth to match a turbidity of 0.5 McFarland standard.  The 
suspension was subsequently incubated overnight at 37 °C.  The solution was diluted 1:100 
in LB and 200 µl aliquots were inoculated into three wells each of a 96-well sterile 
microtitre plate.  The plates were incubated overnight at 37 °C in air, washed and stained 
with 0.1% crystal violet.  The wells were then washed again and dried in air.  They were 
then decolourised with acetone.  The optical density was measured at 600 nm (Eppendorf 
Bio Photometer).  This was repeated with a 48 and 72 h incubation time period for the 
SCV to allow for the slower growth phase. 
 
2.5.8  Type III secretion assay 
Secreted protein profiles for SCVJan and NH were analysed by SDS-PAGE and 
immunoblot analysis after specific induction of type III proteins following addition of the 
chelator EGTA to the TSB media.  Overnight cultures of the strains were grown in 5 ml 
LB broth (37°C, 200 rpm).  The OD600 of the overnight culture was measured and used to 
calculate the volume required to add to the pre-warmed inducing media to give an OD600 of 
0.05.  This was then incubated at 37°C, 200 rpm and disturbed as little as possible.  The 
OD was measured until 0.8 reached, centrifuged at 3750 rpm 4°C for 10 minutes.  The 
supernatant was decanted into a fresh falcon tube and pellet discarded.  Precipitation was 
carried out as previously described268 following addition of 1 ml of 99% trichloroacetic 
acid (TCA).  Samples were stored overnight at 4°C then centrifuged at 3750 rpm, 4°C for 
60 minutes.  The supernatant was aspirated carefully and then the falcon tube drained 
upside to dry the pellet thoroughly.  The pellet was then resuspended in 100 µl of 1.5 M 
Tris-HCL pH 8.8. 
 
Specific antibodies for ExoS and ExoT were used and analysed using SDS-PAGE and 
Western blot hybridisation.  Assay and analysis was performed as previously 
described76,269. 
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2.5.9  Galleria mellonella killing assays.   
Larvae were stored on wood chips at 4 °C.  Overnight cultures of bacterial strains NH and 
SCVJan were grown in LB broth, diluted 1:100 in the same medium and grown to an 
optical density of OD600 of 0.3 to 0.4 as previously described159,270.  Cultures were 
centrifuged and pellets were washed twice and resuspended in 10 mM PBS to an OD600 of 
0.1.  Serial 10-fold dilutions were made in PBS.  Five-microliter aliquots of the serial 
dilutions were injected using a Hamilton syringe into G. mellonella larvae, via the 
hindmost left proleg as previously described271.  Ten larvae were injected per dilution for 
each Pseudomonas strain tested.  Larvae were incubated in 10 cm plates at 37 °C and the 
number of dead larvae scored 1 to 4 days after infection.  For each strain, data from 3 
independent experiments were combined.  A larvae was considered dead when it displayed 
no movement in response to touch.  A negative control was used in each experiment to 
monitor the killing due to physical injury or infection by pathogenic contaminants.  Time 
to death was monitored every 24 h post infection.  In any instance where more than one 
control larvae died in any given experiment, the data from infected larvae were not used.   
 
2.5.10 LDH Release/Cytotoxicity Assay. 
To investigate the effect of the P. aeruginosa strains on macrophages, J774A.1 cells were 
infected with NH and SCVJan.  Bacteria were grown for 17 h to stationary phase in LB 
broth at 37 °C.  Immediately prior to infection, the bacteria were diluted to exponential 
growth phase with culture medium lacking phenol red and the concentration determined by 
measuring the OD600.  Cells were grown, washed and infected as previously documented73.  
Cells were infected with test organisms and incubated for 4 h and 10 h.   Lactate 
dehydrogenase release was determined using the Cytotox 96 cytotoxicity assay kit 
(Promega USA) as described in the manufacturer’s protocol. 
 
2.5.11 Catalase Activity Assay 
Overnight cultures of the strains NH and SCVJan were grown in LB broth.  5 µl of each 
overnight culture was then transferred to a fresh 5 ml LB and grown to an OD of 0.6 in a 
shaking incubator at 37°C.  Catalase standard curves were prepared as per the 
manufacturer’s protocol using the OxiSelectTM Colorimetric Catalase Activity Assay Kit 
(Cell Biolabs, Inc).  10 μl of each sample was added to the initial well of a 96-well 
microtitre plate during the preparation of samples.  This was performed in triplicate for 
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each sample. Plate absorbances were read at 520 nm and results calculated as per the 
manufacturer’s protocol. 
2.5.12 Pyoverdine Measurement.   
The concentration of pyoverdine produced by the NH and SCVJan after overnight culture 
in LB broth was estimated spectrophotometrically from the absorbance at 405 nm as 
previously described272. 
 
2.6  Molecular Techniques 
2.6.1  DNA Isolation 
Two different methods to obtain purified bacterial genomic DNA from bacteria grown in 
broth cultures were tested.  The Promega Wizard DNA Extraction Kit was compared with 
the QIAGEN DNeasy Blood and Tissue Kit as per manufacturer’s protocol. 
 
DNA was subsequently prepared for sequencing on Illumina HiSeq using QIAGEN 
DNeasy Blood and Tissue Kit as per manufacturer’s protocol.   Sequencing and initial 
bioinformatics were performed in the Centre for Genomic Research, University of 
Liverpool.  
 
2.6.2  PFGE and Southern Blot Hybridization.   
PFGE using genomic DNA was carried out as previously described273, using CHEF DRII 
apparatus (Bio-Rad Laboratories) with an electric field strength of ~6 V/cm and a pulse 
time of 20 s for 18 h.  To differentiate the restriction profile of the genomes of NH and 
SCVJan, Xba1, Spe1 and Avr2 enzymes were used for DNA digestion.  Southern blotting 
hybridization was carried out as described previously274.   
 
2.6.3  RNA isolation. 
2.6.3.1 RNA isolation from cystic fibrosis sputum samples  
The initial goal of this thesis was to isolate RNA from P. aeruginosa from infected CF 
sputum samples for downstream transcriptome analysis.  Given the dense, purulent nature 
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of these clinical samples and high percentage of human neutrophils and other pathogens 
this was a lengthy process in trying to optimise isolation protocols. 
 
Sputum samples were obtained from a cystic fibrosis patient known to be colonised with P. 
aeruginosa.   This was immediately placed on ice following collection into a sterile 
universal.   On reaching the laboratory the sample was split into three aliquots of 
approximately 1 ml.  Following a literature search of potential methods, it was decided to 
compare and optimise three different methods of extraction, isolation and purification.  The 
initial essential step involves immediate protection and stabilisation of the RNA in the 
samples.  In tube 1, 1ml of Trizol (ThermoFischer) was added to the sputum sample.  Tube 
2, 1 ml of RNA protect (Qiagen).  Tube 3, 1 ml of RNAlater (Qiagen) was added.  Samples 
were vortexed and stored at -80 °C.   
 
Tube 2 was processed using RNeasy Protect Saliva Kit (Qiagen), according to the 
manufacturer’s protocol.  14 μl of RNase free water was added to the final preparation.  
Purified RNA was quantified using a NanoDrop spectrophotometer. 
 
Tube 1 was processed as previously described275.  3 volumes of Zirconia beads were added 
to the Trizol-sputum mixture.  This was homogenized immediately for 10 min at L5 setting 
on the vortex.  266 μl of chloroform was added to the mixture, shaken vigorously for 15 s, 
incubated for 10 min at room temperature and then centrifuged at 12,000 g for 15 min at 4 
°C.  The aqueous layer was transferred into an RNase free tube.  RNA was then purified 
using RNA Clean and Concentrator (Zymo) as per the manufacturer’s protocol.  In column 
DNA digestion was performed using in column DNase.  14 μl of RNAse free water was 
added to the final preparation.  RNA was quantified using a NanoDrop spectrophotometer. 
 
To confirm the presence of RNA from P. aeruginosa in the RNA extracted from the CF 
sputum sample, RT quantitative (Q) PCR was performed.  cDNA was synthesized from 
total RNA by reverse transcriptase (RT) using AffinityScript (Agilent) as per the 
manufacturer’s protocol.  GyrB primers were used to detect presence of Pseudomonal 
DNA. 
 
Ribosomal RNA depletion was carried out using Epicentre Ribo-Zero Magnetic Gold Kit 
(Epidemiology) as per the manufacturer’s protocol.  RNA was further quantified using a 
NanoDrop spectrophotometer and Agilent Picoanalyser.  
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In an attempt to further purify the microbial RNA, MEGAClear Transcription Clean up kit 
(ThermoFisher Scientific) was used as per manufacturer’s protocol.  
 
 
 
2.6.3.2 RNA Isolation from bacterial cultures 
Following the optimisation of RNA isolation from clinical sputum samples, it was evident 
that the Trizol/Zirconia bead extraction method was superior. 
 
RNA isolation was subsequently carried out on broth samples using the Trizol/Zirconia 
bead extraction followed by Zymo RNA Clean and Concentrator as initial results revealed 
a higher yield of RNA.   
 
RNA isolation from the samples was performed in triplicate.  Bacterial suspensions were 
grown to early stationary phase to an OD600 of 1.8 in LB broth at 37 °C in a shaking 
incubator.  2 ml of each suspension was pelleted at 12 000 g for 10 min.   RNA was 
extracted from samples using a bead beating/chloroform extraction method as previously 
described275.  The samples were digested with DNAse I for 1 h, in column as per the 
manufacturers protocol.  Bacterial RNA was enriched using MICROBEnrich (Life 
Technologies) as per protocol.   
 
Ribosomal RNA was depleted using Ribo-Zero Magnetic Gold Kit (Epidemiology) 
(Epicentre) as per manufacturer’s protocol.  The precipitated sample was resuspended in 
20 μl of RNAse free water.  The concentration of RNA was initially determined using a 
NanoDrop spectrophotometer followed by an Agilent Bioanalyser.  cDNA was generated 
by using the methods from the Superscript Double-Stranded cDNA Synthesis Kit 
(Invitrogen) per manufacturer’s instructions. 
 
2.6.4  Quantitative real time PCR (qPCR) 
cDNA was synthesised from total RNA by reverse transcription (RT) using AffinityScript 
(Agilent) as per manufacturer’s protocol.  Validation of differential gene expression was 
carried out using KAPA SYBR FAST Universal qRT-PCR master mix (KAPA 
Biosystems).  Total RNA was extracted as above and was quantified using a NanoDrop 
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spectrophotometer.  qRT-PCR was performed using a single reaction mixture; cDNA 
synthesis followed by qRT-PCR.  Individual reactions were performed in triplicate to 
account for technical variation.  qRT-PCR reactions were carried out using the ECO Real-
Time PCR System (Illumina) according to the manufacturers specifications and data 
analysed as previous276. 
 
  Forward primer: CCTGGTGGGTTTCCGTTCCT 
 
  Reverse primer: GATGTAGCTGGCCAGACCGT 
Figure 2-1.  GyrB primers used for qPCR. 
 
2.6.5  Library Preparation and Illumina Sequencing   
Ribosomal RNA deplete RNA was sent to Liverpool University Genomics Institute for 
cDNA library preparation and sequencing using the Illumina Hi-seq. cDNA libraries were 
prepared using the Paired End Sequencing Sample Preparation Guide (Illumina). 
Sequencing was performed using Illumina HiSeq at the Centre for Genomic Research, 
University of Liverpool. 
 
 
2.6.6  SMART Library Preparation and Sequencing 
SMRTbell™ template libraries were prepared according to the instructions from Pacific 
Biosciences, Menlo Park, CA, USA.  Briefly, for preparation of 10 kb libraries ~10µg 
genomic DNA isolated from SCVJan, SCVFeb and NH was sheared using g-tubes™ from 
Covaris, Woburn, MA, USA according to the manufacturer´s instructions. 5-10 µg sheared 
genomic DNA was end-repaired and ligated overnight to hairpin adapters applying 
components from the DNA/Polymerase Binding Kit P4 from Pacific Biosciences, Menlo 
Park, CA, USA. Reactions were carried out according to the manufacturer´s instructions. 
SMRTbell™ template was Exonuclease treated for removal of incompletely formed 
reaction products. Conditions for annealing of sequencing primers and binding of 
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polymerase to purified SMRTbell™ template were assessed with the Calculator in RS 
Remote, PacificBiosciences, Menlo Park, CA, USA. SMRT sequencing was carried out on 
the PacBio RSII (PacificBiosciences, Menlo Park, CA, USA) taking one 180 min movie 
for each SMRT cell. In total 6, 6 and 5 SMRT cells were run respectively. 
 
 
2.6.7  Genome assembly and annotation 
2.6.7.1 Illumina reads 
Initial read trimming and QC was performed in the Liverpool centre for genomics. 
Sequencing reads were mapped to the corresponding reference genome (annotated NH 
strain).  Transcriptome analysis was done in triplicate comparison within CLC Workbench.  
For each, the RPKM was calculated as previously described277.  Differentially expressed 
genes were called by performing   χ2 test on the RPKM values and applying Bonferroni 
correction for multiple testing.  Genes with adjusted p-values smaller or equal to 0.05 in 
both replicates were determined to be differentially expressed. 
 
2.6.7.2 PacBio reads 
Data from each SMRT Cell was assembled independently using the 
“RS_HGAP_Assembly.3“ protocol included in SMRTPortal version 2.3.0 using default 
parameters. Each assembly revealed the fully resolved chromosome in one single contig. 
Each chromosome was circularized independently, particularly artificial redundancies at 
the ends of the contigs were removed and all chromosomes were additionally adjusted to 
dnaA as the first gene. Validity of each assembly was checked using the 
“RS_Bridgemapper.1” protocol. For the purpose of this study it has been confirmed for 
each of the (repetitive) rRNA operons that enough uniquely mapping long read exist 
spanning the whole repeat structure. Finally, each genome was error-corrected by a 
mapping of Illumina reads (paired end reads, 100 bp) onto finished genomes using BWA278 
with subsequent variant calling using VarScan279. A consensus concordance of QV60 
could be confirmed for all of the three genomes. Finally, all genomes were annotated using 
Prokka 1.8280. All genome sequences were deposited in NCBI GenBank under Accession 
Numbers CP013477, CP013478 and CP013479. Illumina short read data has been 
deposited at EBI SRA under Accession Numbers ERS1005137, ERS1005138 and 
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ERS1005139. The shortened 16S rRNA gene for strains SCVJan and SCVFeb were 
confirmed by PacBio assembly as well as BWA mapping of Illumina reads against the 
final chromosome showing uniquely mapped reads only at that genome position. 
Reads were also analysed for methylation changes in the genomes that may account for the 
change in phenotypes.  This was performed using automated PacBio software. 
 
 
2.6.8  Accessibility of biological resources  
Strains of this study have been deposited at DSMZ under DSM 100776 - 100778. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
68 
 
 
 
Chapter 3 Phenotypic characterisation of isolated small 
colony variants 
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3.1  Introduction 
The infection process in the CF airways is associated with extensive genetic adaptation and 
microevolution of the infecting bacteria.  Previous studies have suggested the accumulation 
of mutations results in strains with phenotypes many of which are not observed among 
environmental isolates3,126.  Phenotypes associated with poor outcome in the CF population 
include presence of mucoid and SCV strains.  In the clinical laboratory mucoid strains 
generally receive most attention due to their size and ability to spread on agar plates, with 
subsequent overcrowding often hindering the identification of SCVs and other pathogenic 
bacteria which may be present.  The change in phenotype allows the SCV strain to evade 
the host immune system and persist within the human host.  The consequences of 
persistent bacterial infection include increased morbidity and mortality as well as potential 
spread to other individuals.  During these persistent infections, a sub-population of bacteria 
(including the SCV form and persister cells281–283) are able to persist in a non-replicating 
and metabolically altered state, with increased protection against oxidative stress188,284. 
The SCV phenotype represents a unique pan-bacterial strategy associated with persistent 
infection.  The most common phenotypic traits associated with the SCV includes enhanced 
biofilm formation and surface attachment199,285, a slower growth rate, small colony size 
(stemming from autoaggregation)59,60, infectious persistence and increased virulence286,287.  
SCVs are also usually non-motile, with flagellar motility absent in most SCVs to date47,155.  
Hyperpiliation has been reported for some strains although the distribution of this 
phenotype is unknown. 
 
It has been shown in several studies that during the course of lung infections, selection 
pressure from the CF host mucosal environment and/or the extensive antibiotic pressure 
routinely applied in the infected host, leads to emergence of the SCVs and subsequent 
worsening outcomes and mortality180,287.  
 
One important aspect in the persistence associated with the SCV phenotype is their ability 
to form highly adherent biofilm.  Once formed, biofilms are extremely difficult to eradicate 
as they show increased tolerance to both biocides and antibiotics as compared to 
planktonic microorganisms.  Several studies have shown that bacteria within biofilms have 
greater than one thousandhundred-fold increase in tolerance to antibiotics when compared 
to the same bacteria in planktonic state53,191,219. 
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The work in this chapter describes the phenotypic characteristics of SCVs that evolved 
during the course of a chronic infection of the murine lung, in the absence of antibiotic 
selection.  Comparison of the phenotypic characteristics of the isolated SCVs with the 
parent mucoid strain used to initiate infection, indicate clear mechanisms of adaptation to 
the chronically infected lung and increased virulence of the SCVs.  
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3.2  Results 
3.2.1  Isolation of SCVs from a murine model of chronic P. aeruginosa 
lung infection 
P. aeruginosa SCVs are commonly isolated from patients with cystic fibrosis and have 
been isolated in vitro as well as from experimental infection models following 
aminoglycoside treatment156,183,218.  A number of recent studies have suggested that there is 
a strong correlation between presence of SCV in the CF lung with increased 
mortality155,193, poor lung function and decreased FEV1180. Therefore the identification and 
further investigation into the SCV phenotype is clinically important. 
To determine if SCVs could be isolated from a model of chronic P. aeruginosa lung 
infection in the absence of antibiotic selection we utilized a murine model to mimic 
chronic pulmonary infection in CF patients265 (Figure 3-1). In this model, animals were 
inoculated with P. aeruginosa strain NH57388A (NH) a mucoid clinical isolate, embedded 
in agar beads. NH has a known mutation in the gene encoding the anti-sigma factor MucA, 
that results in alginate overproduction288,289.  
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Figure 3-13-1.  Recovery of small colony variants from a model of chronic P. aeruginosa lung 
infection  
The mucoid clinical CF strain NH was inoculated into the mouse trachea, as described, to initiate 
chronic infection. After 14 days bacteria isolated from lung homogenate showed either the 
phenotype of the inoculated mucoid strain or a distinct small colony phenotype. 
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Fourteen-days post-inoculation with NH, mean chronic pulmonary infection rates were 
43.3% (SD 21.3%; range 11.1-71.4%; results from 6 experiments with 7-10 surviving 
animals/group) with a median pulmonary bacterial burden of 1355 CFU/animal (IQR 182 – 
3633). Recovered bacteria from lung homogenate samples obtained from animals 
remaining persistently infected following treatment with NH embedded beads displayed 
two distinct colony morphologies: typical large mucoid colonies identical in morphology 
to the inoculating strain and SCVs. The mucoid colonies were evident after 24 hours of 
growth on agar plates at 37°C with SCVs visible only after 48 hours of growth on agar-
plates. 
 
Overall SCVs were isolated from 17 out of 22 animals (77.3%) with chronic NH infection 
at 2 weeks post-inoculation and were seen in the presence of mucoid colonies in the 
majority of persistently infected animals (16 of the 17 animals). In animals developing 
SCVs these were most frequently isolated from lung homogenates (15 out of 17 animals; 
88.2%) compared with bronchoaveolar lavage fluid (BALF) (9 out of 17 animals; 52.9%) 
(χ2=20.9, p=0.0001). In addition, SCVs developed rapidly in vivo, with SCVs isolated 
from 75% of infected animals at 48 hours post-inoculation (N=4 animals). To determine if 
recovery of SCVs was a direct consequence of interaction with the host, NH-laden agar 
beads were incubated on agar plates at intervals from 24 hours to 2 weeks after bead 
formation, with this procedure performed on 3 separately produced batches of NH-laden 
beads. No SCVs were isolated from the beads at any time-point post-formation suggesting 
in vivo factor(s) act to induce SCV emergence in the infected lung. 
 
 
3.2.2   Prevalence of SCV in the clinical setting 
 
To establish the prevalence of P. aeruginosa SCVs in the CF cohort in Glasgow, 50 
sputum samples from patients undergoing an infective exacerbation were cultured in 
parallel with their routine clinical culture in the microbiology laboratory in the QEUH, 
Glasgow.  Following culture, plates were examined for evidence of SCV presence and 
compared with the clinical laboratory report to establish whether SCV presence is routinely 
reported. 
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P. aeruginosa SCVs were isolated from 7 out of 50 specimens.  However, examination of 
the corresponding clinical reports showed that the presence of SCVs was not documented 
for any of the clinical specimens.  This highlights the problems associated with CF 
microbiology as the plates are overgrown with mucoid strains of P. aeruginosa which 
reduces the ability to detect any other potential pathogen.  Figure 3-2 shows an example of 
the plates from the clinical specimens and the difficulty in isolating single colonies. 
 
a)            b) 
 
c)             d) 
Figure 3-23-2. Culture plates from clinical CF sputum samples  
a) Heavy growth of Serratia sp,  b) Heavy growth of mixed P. aeruginosa including SCV, c) 
Heavy growth of P. aeruginosa with S. aureus mixed in and d) Mixed P. aeruginosa including 
mucoid and SCV.  Sputum processed using sputasol and plated onto Columbia Blood (COB) agar.   
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The cultures in Figure 3-2 are typical of sputum samples from chronically infected 
patients.  The bacterial burden tends to be persistently high and the upper airways are 
always colonised with both Pseudomonas and coliforms due to the overuse of antibiotics in 
this cohort of patients.  
3.2.3   Phenotypic characterisation  
Both the mucoid parent strain, NH and SCVs isolated from the murine lung homogenate 
show colony morphologies that are common to isolates from the lungs of patients with CF, 
with colonies of recovered SCVs growing to approximately 2 mm after 48 hours (Figure 3-
4a,b). Further phenotypic characterisation of one of these recovered SCVs (SCVJan) 
showed that like SCVs recovered from CF patients,  SCVJan displays slow growth in 
liquid media with both an extended lag phase and a slower generation time compared with 
the parental strain (Figure 3-8). In addition it is highly adept at forming adherent biofilms 
on an abiotic surface (Figure 3-3, 3-4c). Transmission electron microscopy (TEM) analysis 
of NH and SCV biofilms, show that in contrast to the mucoid parent strain, SCVJan 
biofilms display a high density of highly adherent bacteria embedded in a dense network of 
extracellular material (Figure 3-3, 3-4c). This is in contrast to biofilms of NH, where 
bacterial density within the copious extracellular matrix is low and in addition, the mucoid 
biofilm is not adherent as it was removed from the glass slides with minimal washing. The 
identity of the extracellular matrix of P. aeruginosa SCVs is not well characterised, 
although is presumably key to their ability to form highly adherent biofilms, both on 
abiotic surfaces and in the lung during infection.  Different drying techniques were used 
prior to obtaining an optimum image of the intricate biofilm network, as can be seen in 
figure 3-3 below. 
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Figure 3-33-3.  TEM images showing adherent biofilm on a glass coverslip 
A) SCVJan biofilm fixed using 2.5% glutaraldehyde. B) SCVJan biofilm prepared using ethylene 
glycol and 1,2-pentanediol in place of classical dehydration methods.  C) NH biofilm fixed using 
2.5% glutaraldehyde.  D) NH biofilm prepared using ethylene glycol and 1,2-pentanediol in place 
of classical dehydration methods. 
 
 
 
 Negative TEM staining showed that similar to SCVs isolated from some patients with CF, 
and in contrast to the mucoid parent strain SCVJan is hyperpilliated (Figure 3-4d). This 
characteristic may also enhance biofilm formation.  
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Figure 3-43-4  Phenotypic differences between NHMuc and SCVJan  
a) and b) Growth of NH and SCVJan on LB agar at 37 °C after 48 hours. There are marked 
differences in colony size and morphology.  c) SEM images of biofilm of NH and SCVJan grown 
on a glass coverslip for 24 h in LB broth at 37 °C. d) SEM image of NH and SCVJan with negative 
staining shows that in contrast to NH, SCVJan is highly pilliated. 
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3.2.4  P. aeruginosa SCV phenotype produces highly adherent biofilm  
In addition to the EM images above (figure 3-3, 3-4) which clearly demonstrates the 
complex and intricate adherent biofilm produced by the SCV strain on the glass coverslip, 
a biofilm assay was performed to compare against control strains.  Previous studies have 
implicated the mucoid strain as being most associated with biofilm production54,290, 
however this study would suggest that the mucoid strain is unable to produce an adherent 
biofilm.  Figure 3-5 below clearly demonstrates gross biofilm production by the SCV strain 
which has more residual crystal violet staining in the wells as compared to PA01.  The 
mucoid strain has no adherent biofilm following a simple washing technique. 
 
 
 
 
Figure 3-53-5.  Microtitre biofilm assay 
A. Comparing the three control strains (PA01, GRI and YH5) against the test strains NH and SCV 
 PA01 is the generic control strain, GRI is a clinical strain from a patient with ventilator associated 
pneumonia and YH5 is a mucoid strain from a paediatric CF patient.  B. The optical density of 
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crystal violet stain in the wells is directly proportional to the biofilm production as demonstrated by 
the A595 reading. . 
 
Previous studies have suggested that formation of the SCV phenotype is associated with 
altered flagellar function and reduced motility.  Often all three types of motility are 
affected, namely swimming, swarming and twitching motility.  However, the parent NH 
strain is non-motile and no differences in swimming motility were observed for the SCV 
strains (Figure 3-6, 3-7)   The differences in the EM images in Figure 3-4d above would 
suggest that the SCV has increased pili at the terminal end of the bacteria however this 
does not appear to affect motility (Figure 3-6, 3-7).  This may be responsible for the 
formation of the highly adherent biofilm structure. 
 
Figure 3-63-6.  Swimming motility of the a) SCV strain and d)NH with  c) PA01 and b) GRI 
as control organisms. 
Tryptone swim plates (1% tryptone, 0.5% NaCl, 0.3% agar) were inoculated with a sterile 
toothpick and incubated for 16h at 25°C.  Motility was then assessed qualitatively by examining 
the circular turbid zone formed by the bacteria migrating away from the point of inoculation.  GRI 
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and PA01 are both non-mucoid strains.  GRI is a clinical strain isolated from a ventilator associated 
pneumonia patient.   
 
Figure 3-73-7.  Twitching motilities of the control strains a) GRI and b) PA01 against the test 
strains c) NH and d) SCV  
GRI and PA01 are both non-mucoid strains.  GRI is a clinical strain isolated from a ventilator 
associated pneumonia patient.  1% LB agar plates were prepared.  A sterile toothpick was then used 
to inoculate the agar plates in the centre of the agar through to the petri-dish with each test strain.  
Plates were incubated for 24 hours at 37°C.  The twitching motility is represented by a halo of 
growth between the agar and the petri-dish.  This was visualised by flooding the agar plate with 
crystal violet. 
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3.2.5 The phenotype of isolated SCVs is highly stable  
Following repeated subculture of  the SCV and mucoid strains under different growth 
conditions as described in section 1.15.2,  reversion back to the wild-type morphotype was 
not observed.  Samples were subcultured 10 times.  Repeated subculture through BHI and 
minimal media at a range of temperatures from 21°C to 42°C over a two week period 
failed to revert the phenotype back to the mucoid morphotype.   Previous studies have 
suggested that SCVs formed under antibiotic pressure in vitro are unstable and revert back 
the wild-type in as few as one passage59.   
 
The phenotype is also highly reproducible and was isolated from various mouse models 
during the course of the experiment.  The reproducible and constant phenotypic change 
would suggest that the same genetic alteration has occurred each time, rather than small 
SNP’s or insertions which would result in a slightly different result each time. 
 
3.2.6  Isolated SCVs display a reduced growth rate and increased 
virulence  
To further characterise the SCV phenotype, we performed various assays to establish the 
virulence potential in comparison to the mucoid wild type.  A growth assay was performed 
which revealed an extended lag phase of growth in the SCV strain.  For SCVJan an OD of 
0.5 was achieved in 8 hours, in comparison to the mucoid strain which achieved an OD of 
0.5 in 3 hours.  This prolonged growth phase enables the bacteria to evade the immune 
system and also antibiotics which may target the growth and replication cycle of the 
bacteria66,282.  
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The slow growth of the SCV also poses another significant diagnostic problem.  The 
colonies appear over a prolonged incubation period and often go undetected in the clinical 
laboratory.    To avoid misidentification, a prerequisite for the recovery and isolation of 
SCVs is the application of extended conventional culture and identification techniques.  
They become rapidly overgrown by the wild type morphotypes on agar and often they are 
deficient or reduced biochemical reactions.  In addition, the slow growth rate of SCVs 
makes standardisation of susceptibility testing difficult because a slow growth rate alters 
diffusion times and affects automated systems which are reliant on a typically growth 
cycle. 
 
Figure 3-83-8.  Growth curves 
Revealing a slower growth phase in the SCV strain as compared to the NH and the control strain 
PA01. All isolates grown in LB broth and incubated for 24 hours at 37°C with OD600 recorded at 3 
hourly intervals using a spectrophotometer. 
 
An observation made when carrying out the growth curve analysis was the overproduction 
of pyoverdine by the SCV strain in LB broth both at both room temperature and 37°C 
(Figure 3-9).  The SCV also developed the characteristic P. aeruginosa odour on 
incubation when compared to the mucoid strain.  Production of siderophores including 
pyoverdine and pyochelin allows the bacteria to survive in hostile environments and 
chelate iron which promotes growth and survival48,49.  These two siderophores are found to 
be important in biofilm formation and virulence105,291. 
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Figure 3-93-9.  Pyoverdine production 
The appearances of the NH and SCV strain inoculated into LB and incubated overnight at 37°C.  
The green colour of the SCV broth confirms increased pyoverdine production. 
 
Because the toxicity of H2O2 released by phagocytes has been implicated in the innate 
immune responses, bacterial pathogens exploit catalytic enzymes to survive the host 
environments.  A catalase assay, shown in figure 3-10a was performed to compare the 
amount of catalase activity in the SCV as compared to the NHSCV and establish whether it 
is  more adapted to survive in the host environment. 
 
The cytotoxic effects of SCV and NH on J774A.1 cells were determined by the 
quantification of lactate dehydrogenase (LDH) released in culture medium. 
The SCV strain showed increased LDH release following infection of J774A.1 cells as 
shown in figure 3-10b.  The increased LDH was observed after a 10 hour incubation period 
where the percentage of LDH released was 98% in comparison to only 40% in the mucoid 
strain.  This is a highly significant finding and would suggest that the SCV has the 
potential to cause direct tissue damage at the site of infection in the host and may be 
responsible for the lung damage seen in CF. 
 
To determine whether the SCV was more pathogenic to a host on direct infection, Galleria 
mellonella larvae were infected with each strain and observed post-infection for 72 hours.  
Phosphate buffered saline (PBS) was used for untreated controls.  The results in Figure 3-
10c show 82% mortality after 72 hours following infection with the SCV strain as 
compared to 63% mortality following infection with the mucoid strain. 
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Figure 3-103-10.  SCVJan displays increased virulence as compared to the NH strain 
a) Catalase assay.  Overnight cultures of bacterial strains were grown in LB broth, diluted 1:100 in 
the same medium and grown to an OD600 of 0.4. 20μl of each serial dilution of overnight culture 
were added to 3 wells in a 96 well plate to allow for average readings for each sample. Plate 
absorbance was read at 520nm. 
b). LDH release assay.  J774A.1 cells were infected with NH and SCV and LDH release was 
measured after 4hr and 10hr.  Lactate dehydrogenase release was determined using the Cytotox 96 
cytotoxicity assay kit (Promega USA) as described in the manufacturer’s protocol. 
c) Galleria mellonella killing assay.  Five-microliter aliquots of the serial dilutions of each isolate 
were injected using a Hamilton syringe into G. mellonella larvae, via the hindmost left proleg.  
Death of the larvae was monitored over a 72 hour period. 
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To determine if the SCV displayed increased production of known virulence factors, a type 
III secretion system assay was performed to compare against the mucoid strain.  PA01 and 
the GRI strain were used as controls as both were used in previous assays and known to 
express both ExoS and ExoT.  During the initial protein purification steps it was clear that 
there was increased protein secretion in the SCV broth as can be seen from figure 3-11.  
Following centrifugation there was a large pellet formed in the Falcon tube. 
 
Figure 3-113-11.  Type III Secretion protein production 
Secreted proteins during the type III secretion assay can be directly visualised as a pellet following 
centrifugation. 
Following protein purification and extraction, specific antibodies for ExoS and ExoT were 
used and analysed using SDS-PAGE and Western blot hybridisation.  Figure 3-12 clearly 
shows expression of ExoS and ExoT by the SCV, with no evidence of a band from the 
mucoid strain.  The type III secretion system facilitate bacterial pathogenesis by injecting 
proteins into the host cell and interfering with host cell function71,159. 
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Figure 3-123-12.  Type III secretion assay. 
Western blot analysis following type III secretion assay. Secreted protein profiles for SCV, NH and 
the control strains (GRI and PA01) were analysed by SDS-PAGE and immunoblot analysis after 
specific induction of type III proteins.  Specific antibodies for ExoS and ExoT were used and 
analysed using SDS-PAGE and Western blot hybridisation.  Assay and analysis was performed as 
previously described 
As in most gram-negative bacteria, the LPS of P. aeruginosa forms an integral part of the 
outer membrane and several studies suggest that LPS contributes substantially to its 
virulence93,292.  LPS was extracted using the hot aqueous phenol method as previously 
described and the SDS-PAGE stained using silver staining to visualise the results.  Figure 
3-13 below shows that there is a  no difference in the LPS banding pattern between the NH 
and SCV phenotypes. 
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Figure 3-133-13  LPS characterisation  
Silver stained SDS-PAGE gel of LPS from the different P. aeruginosa strains.  Use of E. coli as a 
control strain in addition to PA01, GRI and YH5 strains. 15ul were separated on a 12% SDS-
polyacrylamide gel and stained with Pro-Q Emerald 300 as per the manufacturer’s instructions. 
3.2.7  P. aeruginosa SCV phenotype shows increased susceptibility on 
regular antibiotic sensitivity testing methods but reduced 
susceptibility in the biofilm form 
In contrast to previous reports, we did not observe a generally enhanced antibiotic 
resistance in the planktonic state on conversion to the SCV phenotype however when 
tested in the biofilm state, the SCV showed increased antibiotic resistance.  This suggests 
that in the host these SCVs are more antibiotic resistant.293,294  Indeed, in the planktonic 
state, relative to the parent strain, SCV displayed increased sensitivity to four of the 17 
antibiotics tested and decreased sensitivity to only one (Table 3-1 ).  This is a significant 
problem with antibiotic sensitivity testing in the clinical laboratory and does not correlate 
with the environment and growth state in the host.  The slow growth rate of the SCV also 
adversely affects the interpretation of automated sensitivity testing, including the Vitek II.  
The incubation times are set within the platform and result in a time-out of the slow 
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growing SCV, or a false result suggesting the SCV is sensitive rather than resistant due to 
lack of growth. 
 
Table 3-1.  Antibiotic sensitivity pattern of SCV versus NH using Vitek II.  Breakpoints as 
per EUCAST (European Committee on Antimicrobial Susceptibility Testing) guidelines.   
 (Confirmation using E-test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 NH SCV 
Antimicrobial MIC Interpretation MIC Interpretation 
Temocillin >/= 32 R >/= 32 R 
Ticarcillin >/= 128 S >/= 128 R 
Ticarcillin/Clavulanic Acid >/= 128 R >/= 128 R 
Piperacillin/Tazobactam >/= 128 R >/= 128 R 
Cefotaxime >/= 64 R >/= 64 R 
Ceftazidime 32 R 32 R 
Imipenem 2 S </= 0.25 S 
 
Meropenem 2 S </= 0.25 S 
 
Amikacin 32 I 16 S 
 
Gentamicin >/= 16 R >/= 16 R 
Tobramycin 2 S </= 1 S 
 
Ciprofloxacin 2 I 2 I 
Minocycline >/= 16 R >/= 16 R 
Tigecycline >/= 8 R >/= 8 R 
Chloramphenicol 32 R >/= 64 R 
Colistin </= 0.5 S </= 0.5 S 
Trimethorpim/Sulphamethox
azole 
40 R 40 R 
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To further investigate the fact that previous studies suggest SCVs have increased resistance 
to most antibiotics used in clinical practice, three commonly used antibiotics for CF 
exacerbations were used to determine MICs in liquid culture and minimum biofilm 
eliminating concentration (MBEC)  Table 3-2 below shows a clear increase in resistance of 
the SCV to these three antibiotics when grown in the biofilm state and would also suggest 
that the sensitivity results being produced in the clinical laboratory have limited clinical 
meaning. 
Table 3-2 Antibiotic sensitivity pattern comparing SCV and NH using broth microdilution 
and PEG biofilm assays (MBECTM). 
Antibiotic SCV MIC NH MIC 
Broth MBECTM Broth  MBECTM  
Ciprofloxacin 2 4 2 2 
Tobramycin 1 6 1 2 
Ceftazidime 32 64 32 32 
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3.3  Discussion 
This work demonstrates that during the course of infection in a murine model of CF, the 
SCV form of a mucoid P. aeruginosa strain evolves naturally during the course of 
infection and is able to effectively colonise the lung tissue.  In this case, the isolated SCV 
has a stable phenotype and shows increased virulence when compared to the mucoid parent 
strain.   The initial phenotypic analysis would suggest that SCVs are more virulent, able to 
produce subacute, persistant, recurrent and antibiotic resistant infections. 
 
Bacterial phenotypic switching is considered to be an insurance policy against harmful 
environmental change including exhaustion of nutrients or antibiotic therapy.233,281    A 
unique feature of the CF lung is the recovery of different P. aeruginosa morphotypes from 
a single sputum sample, with up to six different colonial variations present.  All six 
morphotypes including SCVs have been isolated from post mortem lung specimens180,218, 
but despite the clear association with these strain and poor outcomes, attention remains 
focused on the most common mucoid phenotype in the clinical laboratory setting. SCVs 
have been well described for >100 years as previously discussed295 yet their significance 
has been limited by the fact that their occurrence in clinical specimens is rarely reported. 
From the routine culturing of the sputum samples obtained from 50 CF patients undergoing 
an infective exacerbation, we were able to identify all of these six morphotypes.  Given 
that there is a strong correlation between the presence of SCV’s and worsening 
outcomes218,287,296, the identification and reporting of these organisms is of paramount 
importance.  The appearance of the SCV, being small, rough and atypical in colour means 
that these colonies will most often be ignored in a mixed culture in the clinical laboratory.  
The phenotypic characterisation of the SCV illustrates that these SCV’s isolated during the 
murine model of infection are similar and consistent with SCV’s isolated from CF patients. 
The slow growth rate observed in the SCV allows the bacteria to persist in the host, 
evading the immune system and antibiotic pressure.  In a laboratory setting, marked 
antibiotic tolerance can be produced by starving bacteria of nutrients244.  This starvation 
also occurs during infection where nutrients are limited and when bacteria adopt the 
biofilm form of growth where there is a dense population of bacteria and limited diffusion 
due to the intricate network.  The starvation is thought to result in a growth arrest and 
subsequent inactivity of the antibiotic targets; thus if targets are inactive, quinolones will 
produce less DNA breaks, aminoglycosides less protein mistranslation and β-lactams will 
cause lower levels of peptidoglycan accumulation triggering lysis. This slow growth also 
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results in misidentification and difficulty in culturing in the clinical laboratory setting 
given that the automated sensitivity methods including VitekII have a short incubation and 
run time set for typical P. aeruginosa growth phase. 
 
As found in other studies28,199,297,298, the SCV produces a highly adherent and intricate 
biofilm on prosthetic material and therefore host lung tissue.  Biofilm growth selects for P. 
aeruginosa colony morphology variants that have biofilm related phenotypes, namely 
hyperadherence to abiotic surfaces.  Previous studies implicated the mucoid morphotype as 
the one responsible for significant biofilm production causing human disease265,289,299.  The 
results of this study however would argue against this and although the alginate 
hyperproduction results in a large volume of extracellular material which may form a 
physical layer on the lung structures, it would appear that the SCV strain is the one which 
adheres to the tissue and would be highly significant in the direct tissue damage and  
colonisation of a prosthetic device298, intravenous line or catheter. 
 
Electron microscope images from the single bacteria suggest that the SCV is hyperpiliated 
in comparison to the mucoid strain.  This hyperpiliation may be in part responsible for its 
ability to produce the highly adherent biofilm seen on EM. There were no clear differences 
in swimming, swarming or twitching motility between these two strains which previous 
studies have shown30,44,158.  Previous studies have suggested that formation of the SCV 
phenotype is associated with altered flagellar function and reduced motility.  In this study, 
the parent mucoid strain and the SCV were both found to be non-motile.  This may be in 
part due to the alginate hyperproduction of the mucoid strain and difficulty interpreting the 
results in this setting. 
 
Phenotypic switching has been linked with persistence in host tissue, treatment failure and 
the development of persistent infections for a variety of bacteria229,281,282,300.  It is not clear 
whether the switch is a constitutive process selected for in vivo or occurs only in response 
to particular environmental triggers including the antibiotic gentamicin201,301.  Previous 
studies suggest that there is expansion of the SCV subpopulation under selective pressure, 
which can then revert back to the wild-type phenotype when the pressure is removed.  
These SCVs are thought to have unstable changes allowing them to revert back easily233.  
SCVJan in comparison was found to be a stable phenotype with no reversion back to the 
wild-type despite significant attempts.   
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Further characterisation of the SCV revealed that it displayed similar growth 
characteristics to those previously described47,165,199.  The lag phase was 8 hours in 
comparison to the mucoid strains 3 hour period.  As already discussed, this poses a 
significant diagnostic problem requiring extended incubation in the clinical laboratory and 
use of manual sensitivity testing methods, which are not validated for these organisms.  
The observed production of pyoverdine during routine incubation of the SCV in LB broth 
clearly demonstrates the increased virulence potential of this organism.   As a free-living 
organism, P. aeruginosa is able to excrete large amounts of the siderophores pyoverdine 
and pyochelin into its environment which both function as powerful iron chelators302,303.  
To meet its needs for iron, the bacteria must compete with the host for iron which is tightly 
bound to host proteins therefore this would suggest that the SCV is more adept at utilising 
host iron supplies for survival.  Further evidence to suggest the SCV is more suited to the 
hostile environment is highlighted in the fact that the SCV displays increased catalase 
activity, increased cytotoxicity in the LDH release assay, expression of the Type III 
secretion system and increased mortality when inoculated into the Galleria mellonella 
model.  Previous studies have suggested that mucoid P. aeruginosa strains produce more 
cyanide than the non-mucoid strains which may result in an increase in pathogenicity in the 
human host108,109.  In this study we observed an immediate toxic effect following injection 
of the mucoid strain which may be related to the cyanide, however when washed cells were 
injected, the SCV demonstrated an increased killing potential.   
 
Several studies have suggested that oxidative stress selects for phenotypic diversification 
in vitro and it has since been speculated that oxidative stress similarly causes phenotypic 
variation in vivo162,222,304.  The increased catalase activity seen in the SCV would support 
this theory.  The Type III secretion system and its secreted protein products are considered 
to be a major virulence factor of P. aeruginosa and other gram negative bacterial 
pathogens.  After attachment to the eukaryotic host cells, the type III secretion system 
enables these bacteria to inject effector proteins directly into the cytosol of the host 
cells73,159.  In this study we demonstrated expression of the ExoS and ExoT proteins by the 
SCV in particular.  To test if this upregulation was biologically meaningful, we determined 
the in vitro cytotoxicity by using the murine macrophage cell line J774 and the Galleria 
mellonella model.  These two assays confirmed an increase in the cytotoxic effects of the 
SCV compared with the mucoid parent strain.  It is generally accepted that the habitat of a 
chronically infected CF lung selects for less virulent P. aeruginosa strains305,306.   
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Previously, isolates from CF patients were reported to produce lower levels of protease, 
elastase and exotoxin A307 and lower levels of type III secretion proteins such as ExoS and 
ExoT81.  The results of this study however, contradict this finding and show that the SCV 
under study here displays increased type III secretion mediated virulence. 
 
In this study we demonstrated that routine clinical microbiology laboratory antibiotic 
sensitivity testing (VitekII and E-tests) fail to identify the increased antibiotic resistance of 
the SCV phenotype.  By comparing the MIC of common anti-Pseudomonal antibiotics 
using the standard methods against peg biofilm cultures, it was evident that the SCV 
biofilm is highly resistant to most antibiotics.  The structure of the wild-type and the SCV 
biofilms may have an effect on the ability of antibiotics to effectively eradicate bacteria in 
this stage and should be taken into account when interpreting laboratory generated 
antimicrobial sensitivity patterns. 
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3.4  Conclusions and future work 
Overall, the phenotypic differences between the NH strain and the SCVJan strain begin to 
reveal the importance of in vivo diversification for P. aeruginosa and the ways in which it 
differs from in vitro observations.  Given the observed differences in phenotype and 
virulence between the two strains, and the fact that this phenotypic switch seems to be a 
mechanism utilised by most bacteria, it would follow that a common genetic mechanism 
was responsible.  There have been numerous  studies suggesting possible mechanisms 
behind the switch182,285,293,308, however nothing consistent in the literature.  The next step 
aimed to genetically characterise the phenotypic switch and to establish a mechanism 
which may be common to all bacteria allowing them to set up and form chronic infection 
in the host. 
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Chapter 4 Genotypic characterisation 
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4.1  Introduction 
4.1.1  Genetic basis of P. aeruginosa adaptation in infection 
The advent of next generation sequencing has resulted in an explosion of prokaryotic 
genome projects.  The first completely sequenced strain of P. aeruginosa was the 
laboratory strain PAO119 which revealed a genetic complexity including a large number of  
secretion and efflux systems, consistent with its ability to thrive in a wide variety of 
environments.  The assembled genome sequence was found to be in excellent agreement 
with the physical map of the P. aeruginosa genome309,310 with the exception of an 
inversion of over a quarter of the genome in the PAO1 isolate relative to DSM-1707, the 
PAO1-derived isolate previously mapped.   The inversion seems to have resulted from 
homologous recombination between the rrnA and rrnB loci which are orientated in 
opposite directions and separated by 1.7 Mbp.  Earlier observations have suggested that 
similar large-scale genome rearrangements between oppositely orientated ribosomal DNA 
loci in E. coli and S. typhimurium have led to the proposal that these reversible genome 
rearrangements may have important adaptive significance311. Since then, numerous P. 
aeruginosa genomes have been sequenced, including PA14271 which is a more virulent 
strain and has additional genes clustered into genomic islands, but a core set similar to that 
of PAO1.  The sequence of the Liverpool Epidemic Strain LESB58189 indicated that both 
the core genome and the genomic islands are involved in in vivo competitiveness.   
 
Adaptation, of P. aeruginosa to the lung during chronic CF infection can also be driven by 
point mutation as in the well characterised phenotypic switch from a nonmucoid to a 
mucoid phenotype, which results in copious amounts of the capsular polysaccharide 
alginate being produced289.  
 
Several studies using PFGE have identified a large-scale genome rearrangement which 
may be responsible for a change in phenotype of different bacterial species184,312.  The 
study by Schmidt and subsequent next-generation sequencing of PAO1 in particular 
suggests that the bacterial chromosomes are able to invert at the rrn loci.  
 
Several SCVs have been sequenced and recently the complete genome sequence of a 
highly adherent P. aeruginosa small colony variant (SCV20265) was published181.  This 
SCV was isolated from the lung of a CF patient in the Hanover Medical School together 
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with a clonally identical wild-type.  Phenotypically, it was noted to be hyper-piliated, 
exhibit increased twitching motility and capacity for biofilm formation and express 
elevated levels of cyclic diguanylate monophosphate (cyclic-di-GMP).  The assembled 
SCV20265 genome consists of a circular chromosome, 6,725,183 bp which exceeds 10 of 
the 13 currently sequenced P. aeruginosa strains. 
 
P. aeruginosa has a large number of genes devoted to command and control systems 
including environmental sensors and transcriptional regulators.  These regulatory genes 
modulate the diverse genetic and biochemical abilities of this bacterium in changing 
environmental conditions.  Several studies have suggested specific mutations which may 
be implicated in the SCV phenotype59,60,182,183,293,313.  The majority of work has focused on 
S. aureus SCVs and several studies suggest that the presence of mutator strains leads to the 
SCV phenotype in particular defects in the mutator gene mutS.183  In this study however, 
sequencing of the mutS gene failed to indicate a specific mutation.  Further work looking at 
the emergence of phenotypic variants upon mismatch repair disruption in P. aeruginosa 
revealed the emergence of new morphotypes when the mutS gene was inactivated314.  
These variants displayed altered antibiotic sensitivity, altered motility and behaviour and 
increased pyoverdine and pyocyanin production.  Several groups suggest that the SCV 
morphotype is strongly linked to elevated levels of cyclic-di-GMP, a ubiquitous bacterial 
second messenger able to regulate the transition between motile and sessile 
lifestyles59,60,182,313.  Further, genetic experiments indicate that YfiN-mediated induction of 
the Pel and Psl exopolysaccharides plays a pivotal role in the SCV morphotype. Disruption 
of either exopolysaccharide operon leads to a partial phenotype, whereas disruption of both 
systems produced colonies with wild type morphology55,182.  The GacS/GacA (global 
activator of antibiotic and cyanide synthesis) regulatory system is another pathway thought 
to be involved in the SCV phenotype285,308,315.  This system regulates the expression of 
virulence factors, metabolism genes, motility proteins and stress tolerance genes.  The 
response regulator GacA also plays a key role in biofilm formation and maturation. 
Sequencing technology has advanced significantly in the last 20 years.   From the 
introduction of Sanger sequencing in 1975 through to PCR based sequencing, 
pyrosequencing and most recently next generation sequencing, it is now routine practice to 
produce complete bacterial genomes rapidly and at low cost.  Illumina have dominated the 
sequencing industry over the last few years and set the standards for high throughput 
massively parallel sequencing with the HiSeq 2000.  There are several problems with the 
Illumina sequencing technology, firstly the amplification steps may introduce a false bias 
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and secondly, the read lengths of only 100 bp do not allow for the identification of large 
scale genetic rearrangements.  Pacific Biosciences have developed a method for real time 
sequencing of single DNA molecules with a rate of several bases per second and read 
lengths into the kilobase range.  This technology allows for the identification of large-scale 
rearrangements however is less sensitive in the detection of SNPs.  Combination of the 
results from the two platforms allow for a highly accurate and complete finished genome. 
Having established that SCVs phenotypically similar to those isolated from CF patients 
could be obtained from our in vivo model in the absence of antibiotic selection, we sought 
to understand the genetic basis of this phenotypic change.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
99 
4.2  Results 
4.2.1  MLST reveals closest identity to DK2 strain 
Given that the NH strain was a clinically obtained strain from the Netherlands which had 
never been previously sequenced, we aimed to establish its place in the P. aeruginosa 
lineage prior to genome analysis.  Following Illumina sequencing of both the NH and SCV 
strains, we performed an MLST search against all of the sequenced strains on Genbank.  
This revealed that out of all the whole-genome sequenced strains, the most closely related 
strain by MLST is DK2, sharing 3/7 alleles as seen in Table 4-1 below.  DK2 is a highly 
adapted pathogenic strain which was sampled over 35 years ago from CF patients 
attending the Copenhagen CF clinic at the University Hospital316. 
Table 4-1 MLST results 
Revealing the most closely related strain to the NH and SCV is DK2 which shares 3/7 alleles. 
By use of the MLST Web server, the strains which we sequenced using Illumina Hi-Seq were 
typed.  Shown are the names of the loci of the MLST scheme, the percentage of nucleotides that are 
identical in the best matching MLST allele in the database.  Note that for a perfectly matching 
allele the percentage of identity will be 100%. 
 acs sro gua mut nuo pps trp 
RP73 98% 99% 100% 99% 99% 99% 99% 
DK2 99% 99% 100% 99% 100% 99% 100% 
M18 99% 99% 99% 99% 100% 99% 99% 
LESB58 98% 99% 100% 99% 100% 99% 99% 
PAO1 99% 99% 99% 99% 100% 99% 99% 
 
4.2.2 Illumina HiSeq and PFGE fail to identify genetic differences 
between the mucoid and small colony variant 
We initially performed Illumina HiSeq whole-genome sequencing and genomic 
comparison (using multiple genome alignment pipelines) between NH and the two separate 
SCVs (SCVJan and SCVFeb) isolated from independent in vivo experiments. However, 
despite their gross phenotypic differences, this analysis failed to identify any genetic 
differences between the SCVs and the parent strain.  QC was performed in Liverpool 
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Genomics after processing and trimming of the reads.  The read coverage was excellent for 
each sample, with an average of 15 million reads per sample and complete genome 
coverage, see table 4-2 below. 
 
Table 4-2  Samples showing read length following Illumina HiSeq sequencing. 
Average of 15 millions reads obtained with excellent coverage of the entire genome. 
Sample Total number of 
individual reads 
Reads 
aligned 
Coverage (assuming 6.3 Mb 
genome) 
SCVJan 17933333 95.53% 284x 
SCVFeb 16079082 95.71% 255x 
NH 13791071 94.5% 218x 
 
 
The Illumina HiSeq was chosen because of its genome coverage and high quality data.   
Based on the recent finding in S. aureus that switching between the normal colony and 
SCV phenotype is mediated by a reversible inversion of a large portion of the genome184, 
we utilised PFGE technology with three different restriction enzymes in an attempt to 
identify a large scale genetic rearrangement (Figure 4-1).  However, no genetic differences 
between the strains were identified using this approach.  PFGE technology is limited in the 
fact that the restriction enzymes may fail to cut the genome at sites that will result in 
differences in the fragment size.  
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Figure 4-14-1.  PFGE analysis of the SCV and NH genomes. 
This analysis revealed no differences in band pattern between isolates.  Three restriction enzymes 
were used, XbaI1, SpeI1 and AvrII2.  Lanes 1 and 2 correspond to NH, lanes 3 and 4 correspond to 
SCVJan and lane 5 corresponds to SCVFeb. 
 
4.2.3   PacBio analysis reveals a large-scale chromosomal 
rearrangement 
In order to further investigate the genetic basis of conversion to the SCV phenotype we 
utilised the ultra-long reads produced by single-molecule real-time PacBio sequencing to 
attempt to identify any large scale genome rearrangements.  The read data from the PacBio 
was combined with Illumina to provide a highly accurate, complete closed circular 
genome.   
Using this technique we identified a large scale genomic inversion accompanying 
conversion from the parent mucoid to SCV phenotype in both SCVJan and SCVFeb 
(Figure 4-2).  
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Figure 4-24-2  Alignments of genomes 
a) SCVJan, b) NH and c) SCVFeb showing large scale genome inversion which is conserved 
between top a) and bottom c) SCV strains. 
 
Closer inspection of the genome sequence identified the start and end points of the 
inversion, which for both SCVJan and SCVFeb begins at the first rRNA operon (0.72 
Mbp) and ends at the third rRNA operon (5.21 Mbp). Exact chromosomal breakpoints 
were identified in the corresponding 16S rRNA genes by performing a MAUVE 
breakpoint analysis (Figure 4-3).  
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Figure 4-34-3.  A common large scale chromosomal inversion in three P. aeruginosa strains is 
the genetic basis of conversion to the SCV phenotype. 
From top to bottom strains NHMuC, SCVJan, SCVFeb and SCV20265 are displayed. Dashed lines 
indicate the inversion breakpoints present in the 16S rRNA genes. An inversion with highly similar 
breakpoints is present in the genome of strain SCV20265 a SCV isolated from a patient with CF. 
Within strains SCVJan and SCVFeb a unique truncated version of the 16S rRNA gene (16St) could 
be resolved, which could not be detected in strain SCV20265.   
 
Furthermore, genome analysis revealed a 250 bp shortened 16S rRNA gene (16St) in both 
SCV strains, which is reflected in the reduced genome sizes of the SCVs (SCVJan 
6,213,026, SCVFeb 6,213,029; Figure 4-4b) compared to the parent strain, NHmuc 
(6,213,276 bp; Figure 4-4a).  
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Figure 4-44-4 Chromosomal maps of P. aeruginosa NHmuc (a) and SCVJan/SCVFeb (b).  
The circular genomes of both strains are shown. Genomes of both SCV strains are 250 bp smaller 
compared to the parental strain NHmuc. Exact genome sizes are given in lower left corner. In blue 
(circle1) genes lying on the forward strand are shown and in red (circle 2) those on the reverse 
strand. In circle 3 tRNA genes are shown in brown, often clustered together with green rRNA 
genes, which have been additionally marked by vertical arrows. The red arrow shows the 
transposition of rRNA operon 3 in addition to that of a large tRNA region (green ellipse) due to the 
described chromosomal inversion. Circle 4 shows the GC content, whereas in circle 5 a GC skew is 
shown. Number of CDS, rRNAs, tRNAs and ncRNAs are identical in all strains (upper right corner 
according to GenBank submission). This map has been created using DNAplotter317 (Carver et al., 
2009).  
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Figure 4-54-5  Multifasta files containing the 16S rRNA sequences per strain.    
A)  The full length 16S rRNA sequence (NH: all four 16S, SCV: 1st, 2nd and 4th 16S) 
B) in the SCVs both 16S with the locus_tag 4870 are identically truncated as shown above.   
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Prediction of rRNA secondary structure of the truncated sequences of the SCVs using 
RNAfold indicates that the truncated rRNA species does not adopt a fold similar to the 
wild-type rRNA (Figure 4-5).   
 
 
Figure 4-64-6.  Detailed secondary structure models of the rRNA molecules.   
a) 1 and 2 represent the 2 16S rRNA from the NH strain, b) 1 and 2 represent the 2 16S rRNA from 
the SCV.  This analysis was performed using RNAfold. 
 
There were no further differences in the number of protein coding genes (5619), rRNAs 
(12) or tRNAs (57) between SCVs and the parent strain. No SNPs could be identified in 
protein coding genes.  Interestingly, comparison of the SCVJan and SCVFeb  genomes 
with that of an SCV (SCV20265) isolated from a CF patient181, which has recently been 
sequenced by PacBio sequencing, revealed an almost identical chromosomal inversion. 
However, in the case of SCV20265 the inversion was not accompanied by truncation of the 
16S rRNA gene in the third rRNA operon (Figure 4-3). 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
107 
 
 
 
 
 
 
4.2.4   Methylation differences between the SCV and NH strains are not 
observed 
Epigenetic modifications affect a broad range of biological processes including gene 
expression, host-pathogen interactions, DNA damage and repair, environmental response 
and the inheritance of traits from one generation to another318. Changes in gene expression 
are known to occur through epigenetic modifications, with DNA methylation and histone 
modification being the most studied of these changes233,319–321.   Gene expression can be 
controlled through the action of repressor proteins that attach to silencer regions of the 
DNA.  These epigenetic changes can be controlled through the action of repressor proteins 
which attach to silencer regions of DNA. Recent work has also shown that adaptive 
antibiotic resistance in bacteria requires epigenetic inheritance and heterogeneity of gene 
expression patterns associated with the production of porins and efflux pumps320.   
 
Epigenetic changes do not affect the structure of the DNA or the nucleotide sequence and 
therefore are not identified using most NGS technology.   To date, detection of modified 
bases has not routinely been a component of sequence analyses and it has posed significant 
technical challenges.   Single Molecule, Real Time (SMRT) Sequencing directly detects 
epigenetic modifications by measuring kinetic variation during base incorporation. 
Using the PacBio SMRT portal software, we analysed the sequence data using the 
modification and motif protocol for any evidence of DNA modification which is shown 
below in Figure 4.6.  This analysis compares the modification signal to an additional 
computational model for three modification types: 6-mA, 4-mC and Tet-converted 5mC.  
Coverage requirements vary with modification type, due to differences in their kinetic 
signatures, specifically detection of native 5-mC requires higher coverage to achieve 
reliable detection. There was no evidence of any methylation differences between SCVJan, 
SCVFeb or the parent strain NH.  Modified bases would be represented as a distinct red 
cloud outwith the normal curve seen in the figure 4-6 below. 
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Figure 4-74-7.  Methylation profiles of a) NH, b) SCVJan and c) SCVFeb.   
Analysis was performed using the PacBio software.  Using the PacBio SMRT portal software, we 
analysed the sequence data using the modification and motif protocol for any evidence of DNA 
modification.   This analysis compares the modification signal to an additional computational 
model for three modification types: 6-mA, 4-mC and Tet-converted 5mC.  Coverage requirements 
vary with modification type, due to differences in their kinetic signatures, specifically detection of 
native 5-mC requires higher coverage to achieve reliable detection. 
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4.3  Discussion 
Previous studies aiming to identify the genetic basis for SCV conversion and phenotypic 
variation have suggested a range of SNPs and specific metabolic pathways may be 
involved in this phenotypic change. However, there is little consistency in the literature 
and specific genetic changes associated with conversion to the SCV phenotype during 
infection remain to be established 47,164,183,184,293,313.  Several studies have suggested the 
SCV phenotype may be the result of either thymidine auxotrophy caused by mutations in 
the thymidylate synthase gene322 or an interruption in the electron transport chain, 
specifically resulting from an absence of menadione or hemin biosynthesis and 
metabolism173,322.   Given the consistent phenotype seen in the SCVs between different 
bacterial strains and the recent identification of a genome inversion as the genetic basis for 
SCV conversion in an S. aureus strain184, it would seem plausible that genome 
rearrangements may be a common mechanism of SCV conversion.  
 
A key strength of our study was the availability of the parent strain used to establish 
infection for sequencing. This allowed a meaningful comparative genetic analysis to be 
performed enabling the determination the genetic basis of conversion to the SCV 
phenotype. Surprisingly, SNPs and INDELs were not identified in the SCV genome 
by Illumina sequencing and single-molecule real-time sequencing was subsequently 
used to show that the two sequenced SCVs carried a large genomic inversion within 16S 
rRNA genes.  Genome rearrangements are known to have a profound effect on the 
organismal phenotype, affect gene expression and can result in loss of gene function when 
a rearrangement breakpoint occurs inside a reading frame21,310.  P. aeruginosa is well 
known for its ability to alter the size and structure of its genome and although it possesses 
a relatively conserved core genome, insertions and deletions result in genomes ranging 
from 5.2 Mb to 7 Mb dramatically diversifying the genetic capacity of this species323,324.  A 
number of studies have shown that a high proportion of CF P. aeruginosa isolates contain 
large chromosomal inversions310,325, which may be selected for in that specific ecological 
niche as the resulting phenotype has features allowing it to survive in the environment of 
the chronically infected lung. 
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Appropriate maturation and folding of the 16S rRNA during 30S subunit biogenesis is 
known to be vital for translational fidelity326–328.  The truncated genomes observed on 
analysis revealed a 250 bp shortened 16S rRNA gene (16St) in both SCV strains, which is 
reflected in the reduced genome sizes of the SCVs (SCVJan 6,213,026, SCVFeb 
6,213,029) compared to the parent strain.  This may partially explain the differences seen 
in gene expression as compared to the mucoid strain.  This truncation may also explain 
why the SCV phenotypes in the strains isolated are stable, with no reversion back to the 
wild type strain from this in vivo experiment. 
 
Although no methylation changes between the SCV and NH strain were observed, there 
are other epigenetic changes which could be responsible in part for the genome inversion 
and the phenotypic switch.  Epigenetic changes represent heritable changes in gene 
expression without a change in the DNA sequence.  Recently additional complexity was 
added to the epigenetic landscape by the discovery of a crucial role of small RNAs, non-
coding RNAs, microRNAs and RNA-binding proteins in dynamic changes of the 
chromatin structure and spatial organisation of the genome inside the nucleus329–332.   
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4.4  Conclusions and future work 
The mechanistic details of how the observed genomic inversion lead to the coordinated 
expression changes observed here is currently not known, but the observation that a 
clinical SCV strain (SCV20265) obtained from the lung of a CF patient strain recently 
sequenced using the same strategy of combining SMRT and Illumina sequencing possesses 
a similar 16S rRNA based inversion, indicates that this inversion may be a clinically 
relevant route to the SCV phenotype (Figure 4-3). Other large scale genome 
rearrangements including large chromosomal inversions have previously been described in 
P. aeruginosa but these were not associated with conversion to the SCV phenotype. A 
reversible genomic inversion has also recently been shown to mediate the reversible 
conversion between normal colony and SCV phenotypes in S. aureus. However, in the case 
of the SCVs isolated in our work the SCV phenotype is stable and revertants to the parent 
phenotype were not observed.  
 
In conclusion, we have shown here a P. aeruginosa SCV has originated in the lungs of an 
animal with chronic colonization with this microbe and that the observed phenotype would 
appear to result from a large chromosomal inversion. SCVs have a clear selective 
advantage in the context of the CF lung, and a better understanding of the drivers that 
produce the genomic rearrangement observed in this study may provide alternative 
therapeutic approaches to prevent the appearance of such damaging phenotypic variants.  
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Chapter 5 Transcriptomic Characterisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
113 
5.1  Introduction 
5.1.1  Transcriptomic adaptations during chronic infection 
The versatility of P. aeruginosa in adapting to a wide range of environments including that 
of the human body is attributed to a large genomic repertoire consisting of an extremely 
diverse set of genes which encode metabolic functions suited for proliferation in 
environments with a wide range of available nutrients19,223,333.  Rapid adaptations to 
changing environments by bacteria is accompanied by reprogramming of their regulatory 
networks to activate the expression of genes essential for their survival in the new 
environment while repressing those that are unnecessary or potentially deleterious.  At the 
transcriptional level, this can be achieved by responding to various environmental cues that 
are often mediated by specific signal transduction pathways.  A number of new regulatory 
mechanisms have been uncovered based on the activities of non-coding RNA239,334,335.  
Riboregulation, or RNA-based regulation is now recognised as an important mechanism 
for control of gene expression as it enables alteration of the translation of mRNA and 
transcript turnover336,337.   
There have been recent advances in sequencing technology allowing more accurate 
quantification of RNA levels in bacteria (RNA-seq) providing significant advances over 
the previous microarrays338,339.  High throughput sequencing of cDNA libraries has the 
potential to study transcription at the single nucleotide level and therefore yield more detail 
on RNA transcripts present in a population of microbial cells.  It does, however, remain a 
challenge as compared to eukaryotic mRNA, since bacterial mRNAs do not have a poly-A 
tail and hence cannot be isolated from other RNA sources by hybridisation to immobilised 
poly-T236.  In addition, bacterial RNA samples usually contain up to 80% rRNA and tRNA 
and the residual mRNA component has a very short half-life and is hence unstable340.  A 
further limitation of these studies is that the sequencing technologies employed to date are 
unable to distinguish between de novo transcription and post-transcriptional events as they 
only record the levels of RNA (cDNA) present, a weakness shared with microarray 
technology.  Removal of the rRNA and tRNA may have an unknown adverse effect on the 
composition of the total RNA fraction and results in a biased cDNA library.  During the 
construction of the cDNA libraries steps include amplification of the cDNA and hence 
there is the potential to introduce an over-representation of shorter transcripts in the 
libraries constructed for sequencing. 
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During chronic CF infection, P. aeruginosa strains often acquire mutations which cause 
them to undergo a phenotypic switch from a non-mucoid strain to a mucoid strain.  The 
resulting production of alginate aids the organism in the evasion of phagocytosis and in 
resistance to neutrophils and macrophages and also antibiotic resistance107,289.  One major 
regulator of alginate biosynthesis is the transcriptional regulator AlgR which belongs to the 
two-component signalling system superfamily.  AlgR regulates various virulence factors 
including twitching motility, biofilm formation, quorum sensing and hydrogen cyanide 
production62,226,341.  On the other hand, studies have shown that the SCV is implicated in 
increased mortality and morbidity in CF patients due to the increased persistence potential.  
It would seem that SCVs are selected for during the course of chronic infection due to a 
fitness advantage in this unique environment.  Several studies have focused on the link to 
the second messenger cyclic-di-GMP (c-di-GMP) related system and the association that 
elevated levels are associated with a sessile and cooperative lifestyle59,287,313.  On the 
contrary, low levels of c-di-GMP promote a unicellular, free-swimming lifestyle.  The c-
di-GMP system is controlled by activation of the YfiBNR regulatory system182,313 therefore 
it would be interesting to compare the transcriptome between the two phenotypically 
different strains in this study to establish whether these previously investigated pathways 
are upregulated in this phenotypic switch.  Biofilm formation is also previously described 
in the literature to be under the control of the LasR-Lasl and RhlR-Rhll cell density 
quorum sensing (QS) systems and a large number of the two-component regulatory 
systems38,342,343. 
In this study we have shown that in fact the SCV phenotype is likely to play a major role in 
the disease process in CF patients as relative to the parent strain isolated SCVs show 
increased cytotoxicity towards epithelial cells and display increased antibiotic resistance in 
the biofilm state.  The mechanism behind the switch to this SCV phenotype would 
potentially enable us to develop novel therapies to target these virulent phenotypes. 
In this chapter we compare the global transcriptome of the two SCV strains with the NH 
mucoid strain in an attempt to elucidate a mechanism behind the phenotypic switch. 
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5.2  Results 
5.2.1  Over 554 genes are differentially expressed between the SCV and 
NH phenotypes 
To determine the transcriptional changes associated with conversion to the SCV 
phenotype, we performed RNA sequencing (RNA-Seq) analysis of the parent strain, NH, 
and two SCV strains (SCVJan and SCVFeb isolated from independent in vivo experiments) 
grown in LB broth. RNA-Seq data for all strains was collected in triplicate and data for 
SCVJan and SCVFeb were combined to compare with NHMuc.  Prior to transcriptome 
analysis, quality control of the total reads was performed on CLC Workbench to ensure 
comparable read coverage between strains.  Figure 5-1 outlines the total read coverage 
following total RNA sequencing of the different strains, with an average of 18 million 
reads in certain parts of the genome in all strains apart from slightly lower values of 10 
million in SCVFeb.  It can also be clearly visualised that the gene expression differs 
significantly between the SCV and NH strains, with increased expression across the 
genome in the NH strain. 
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Figure 5-15-1.  Transcriptome read coverage 
Comparison of transcriptome reads data and coverage across entire genome between NH, SCV1 
and SCV 2.  Results show a similar coverage pattern between both SCVs in comparison to NH. 
   
 
 
117 
 
The Volcano plot in Figure 5-2 demonstrates global increase in total gene expression in the 
NH strain as compared to the SCV.   
 
 
Figure 5-25-2.  Volcano plot of SCV versus NH transcriptome data 
Differential gene expression between SCV and NH strains.  Gene expression is upregulated in NH 
compared to SCV. 
 
The box plots in Figure 5-3 display an overall gene expression value following statistical 
correction.  The expression values all follow a similar distribution which allows for 
accurate data interpretation and analysis.   
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Figure 5-35-3.  Box plot of original gene expression values  
Total gene expression for SCV1 (SCVJan), SCV2 (SCVFeb), and NH.  Similar levels observed in 
the box plot ensure adequate read coverage prior to analysis. 
 
 
In order for a gene to be classified as differentially expressed, two criteria had to be 
fulfilled: the average change in expression (n-fold) must be >2 and the P value must be 
<0.05 (one-way analysis of variance).  Relative to NHMuc, 190 genes showed >2-fold 
upregulation and 364 genes showed >2-fold downregulation in SCVJan/SCVFeb.  
 
 
5.2.2  Differential expression of genes revealed downregulation of genes 
involved in growth and metabolism whereas genes involved in 
oxidative stress and iron acquisition were upregulated 
Major functional classes of genes downregulated in SCVJan/SCVFeb include those 
involved in energy metabolism, amino acid and protein biosynthesis, DNA replication and 
recombination and cell wall/LPS/capsule biosynthesis, which together are consistent with 
the slow growth rate observed for SCVs (Figure 5-4). Notably, genes encoding heat shock 
proteins and other molecular chaperones (IbpA, GrpE, HtpG, ClpB, DnaK, GroES, DnaJ 
and ClpX) are highly represented among the most strongly downregulated genes in the 
SCVs (Table 5-2). 
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Figure 5-45-4 Function classification of genes differentially regulated in SCV relative to NH 
An EDGE test was performed using CLC Software and the differentially expressed groups 
organised into functional categories. Groups with a positive EDGE test fold change are those which 
are upregulated in the SCVs. Groups with a negative EDGE test fold change are downregulated in 
SCVs relative to NH. 
 
 
Conversely, genes that function in the response to oxidative stress and those that encode 
secreted virulence factors are largely upregulated in SCVJan/SCVFeb. Indeed, five of the 
ten most highly upregulated genes in SCVJan/SCVFeb are those associated with the 
response to oxidative stress (Table 5-1). Highly upregulated oxidative stress genes include, 
katA344 which encodes the major catalase of P. aeruginosa, ahpB, ahpC and ahpF304,345,346, 
which encode subunits of alkyl hydroperoxide reductase and trxB2 that encodes 
thioredoxin reductase 2192,347,348. Consistent with the observed transcriptional changes, 
catalase activity was strongly increased in SCVJan relative to NH (Figure 3-10a). 
 
   
 
 
120 
Genes encoding a number of secreted virulence factors such as the proteases LasA, LasB 
and AprA, the fructose-binding lectin LecB349 and the chitin binding protein CbpD and 
chitinase ChiC350 were also highly upregulated. Similarly genes encoding hydrogen 
cyanide synthase and a number of enzymes that function in phenazine biosynthesis are also 
upregulated (Table 5-1)50,60,104,106,293,351. Phenazines have previously been shown to 
enhance killing of Caenorhabditis elegans by P. aeruginosa352. The apparent increase in 
the production of virulence factors by SCVJan/SCVFeb relative to NH suggests increased 
virulence of the SCV. To directly test this we used an infection model based on infection 
of the murine macrophage cell line J774A.1. Cell death of J774A.1 through LDH release 
was measured at 4 and 10 hours post infection with NH and SCVJan. At 4 hours, levels of 
LDH release were similar for NH and SCVJan, whereas at 10 hours LDH release was 
significantly increased for SCVJan; 96% vs 38%, p < 0.0001 (Figure 3-10b). 
To determine if the increased virulence of the SCV observed against a murine cell line 
translated to increased virulence in an animal model of infection, we utilised an 
invertebrate model of infection utilising the larva of the wax moth Galleria mellonella. 
Similar to the macrophage infection assay, SCVJan displayed increased virulence in the G. 
mellonella infection model. Mortality of larvae was measured at 24, 48 and 72 hours post 
infection. No significant differences in mortality were detected at 24 or 48 hours, whereas 
at 72 hours % mortality was 86% and 63% (p < 0.01) for SCVJan and NH infected larvae, 
respectively (Figure 3-10c). Data from both infection models shows that SCVJan shows 
increased virulence, relative to NHMuc, which is consistent with the phenotype of SCVs 
obtained from the human host.156,296 
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Table 5-1 Top 35 representative genes upregulated in SCV versus NH 
Feature/gene 
IDa 
Fold 
Changeb 
P-Valuec Protein description and/or interspecies homology 
 
NHmuc_04720 62 3.24 -16 hypothetical protein 
trxB2 55 3.9 8-16 thioredoxin reductase 2 
NHmuc_01300 35 3.74 -15 putative alkyl hydroperoxide reductase 
NHmuc_02350 28 1.36 -26 putative acyl carrier protein 
ahpF 28 8.39 -13 alkyl hydroperoxide reductase subunit F 
kata 23 7.12 -10 catalase 
NHmuc_03862 20 6.84 -21 putative ankyrin domain-containing protein 
NHmuc_03863 19 1.81 -18 putative hydrolase 
NHmuc_00257 19 1.36 -12 putative CBS domain protein 
ahpC 18 8.97 -08 alkyl hydroperoxide reductase subunit C 
chiC 17 1.45 -09 chitinase 
NHmuc_04185 17 6.67 -06 RNA polymerase sigma factor RpoS 
aprA 12 5.10 -08 alkaline metalloproteinase 
NHmuc_04924 11 3.24 -16 CsbD family protein 
NHmuc_04718 11 1.47 -11 hypothetical protein 
NHmuc_04925 11 2.20 -08 transport-associated 
NHmuc_00127 10 5.84 -07 putative hemolysin 
Snr1 10 4.84 -07 cytochrome c Snr1 
lecB 9 5.93 -08 fucose-binding lectin PA-IIL 
NHmuc_03413 8 9.13 -15 Phage terminase, small subunit 
katB 8 9.04 -15 catalase 
NHmuc_04074 8 9.04 -06 leucyl-tRNA synthetase 
phzG2_2 7 2.23 -12 pyridoxamine 5'-phosphate oxidase 
NHmuc_03358 7 3.34 -06 putative protein associated with synthesis and 
assembly of refractile inclusion bodies 
phzE1_1 7 3.15 -06 phenazine biosynthesis protein PhzE 
NHmuc_00055 7 6.09 -07 hypothetical protein 
NHmuc_01628 7 1.29 -08 hypothetical protein 
cbpD 7 4.11 -06 chitin-binding protein CbpD 
NHmuc_00546 6 0.0020 LysR transcriptional regulator 
rhlR 6 0.0001 transcriptional regulator RhlR 
gcdH 6 4.26 -05 glutaryl-CoA dehydrogenase 
NHmuc_01422 6 0.0004 putative dna-binding stress protein 
NHmuc_04078 6 1.51 -10 oxidoreductase probably involved in sulfite 
reduction 
rsaL 6 0.01 regulatory protein RsaL 
 
a See appendix for corresponding PAO1 feature ID/gene ID 
b The magnitude of gene expression (fold change) was determined by comparing transcription in three replicates of NH 
with that in three replicates each of the two SCV strains. 
c P values were assessed by performing an EDGE test using CLC software 
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Table 4-2 Top 35 representative genes downregulated in SCV versus NH 
Feature/gene 
IDa 
Fold 
Changeb 
P-Valuec Protein description and/or interspecies homology 
 
NHmuc_01025 -75 2.59 -11 putative acetyltransferase 
mexC -53 1.07 -11 Resistance-Nodulation-Cell Division (RND) 
multidrug efflux membrane fusion protein MexC 
precursor 
ibpA -31 1.09 -07 heat-shock protein IbpA 
algD -30 1.01 -09 GDP-mannose 6-dehydrogenase AlgD 
NHmuc_05385 -29 8.47 -08 17 kDa surface antigen 
NHmuc_04138 -29 1.25 -10 periplasmic metal-binding protein 
grpE -25 1.22 -07 heat shock protein GrpE 
htpG -23 3.58 -07 heat shock protein 90 
NHmuc_0100 -22 1.76 -05 hypothetical, unclassified, unknown 
clpB -20 6.45 -06 ClpB protein 
nfxB -20 3.72 -07 transcriptional regulator NfxB 
fsxA -18 7.85 -08 FxsA protein 
NHmuc_04950 -17 3.34 -06 molecular chaperone DnaK 
NHmuc_05744 -17 5.76 -05 putative lipoprotein 
dapB -17 2.75 -06 dihydrodipicolinate reductase 
hslV -17 4.13 -07 ATP-dependent protease peptidase subunit 
NHmuc_01173 -16 4.70 -06 hypothetical protein 
NHmuc_01024 -16 6.05 -07 putative transporter 
NHmuc_04180 -16 3.30 -06 recombinase A 
mexD -15 9.52 -07 Resistance-Nodulation-Cell Division (RND) 
multidrug efflux transporter MexD 
NHmuc_04776 -15 6.06 -06 PAS/PAC sensor signal transduction histidine kinase 
rsmA -14 0.0007 carbon storage regulator 
NHmuc_01174 -14 3.26 -07 hypothetical protein 
NHmuc_01594 -13 2.08 -05 putative oxidoreductase 
mucA -12 7.40 -05 anti-sigma factor MucA 
NHmuc_03262 -12 2.48 -09 hypothetical protein 
NHmuc_04386 -12 6.83 -05 Surface antigen 
amrZ -12 3.01 -05 alginate and motility regulator Z 
glnA -12 5.84 -06 glutamine synthetase 
groES -12 3.92 -05 co-chaperonin GroES 
dnaJ -12 7.54 -05 chaperone protein DnaJ 
algU -11 0.00002 RNA polymerase sigma factor AlgU 
clpX -11 0.00004 ATP-dependent protease ATP-binding subunit ClpX 
NHmuc_04521 -10 1.92 -06 periplasmic ligand-binding sensor protein 
 
a See appendix for corresponding PAO1 feature ID/gene ID 
b The magnitude of gene expression (fold change) was determined by comparing transcription in three replicates of NH 
with that in three replicates each of the two SCV strains. 
c P values were assessed by performing an EDGE test using CLC software 
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In an attempt to establish whether the large genomic inversion in the SCVs resulted in any 
local effects on gene expression close to the inversion site, a map of the genome with 
corresponding gene expression levels was constructed as shown in figure 5-5.  This failed 
to identify any specific local effects on gene expression at the inversion site and instead 
demonstrated that differentially expressed genes are distributed relatively evenly 
throughout the genome indicating that global changes in gene transcription are responsible 
for conversion to the SCV phenotype.  
 
Figure 5-55-5  Global changes in gene transcription on conversion to the SCV phenotype. 
Fold-changes in gene expression for SCVJan/Feb relative to NHMuc are shown in the context of 
the NHMuc genome. Breakpoints that define the genomic inversion present in SCVJan and 
SCVFeb are indicated by red rectangles. 
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5.3  Discussion 
In this study we demonstrate that the differential gene expression of a naturally occurring 
SCV from a mouse model in comparison with its wild type counterpart correlates with 
several other studies156,246 which also found that functional properties such as iron uptake, 
resistance against oxidative stress, cytotoxicity and reduced growth are all upregulated on 
conversion to the SCV phenotype. 
SCVs for many bacteria are well known for adopting a slow-growing phenotype which has 
altered carbon metabolism, antibiotic resistance and increased intracellular 
persistence176,287.  Persister cells are able to enter a dormant state making them almost 
refractory to the effects of the immune system and antibiotics66,229,281,282.    Genes involved 
in energy metabolism, growth, replication and recombination and cell biosynthesis were all 
downregulated in both SCV isolates which together are consistent with the slow growth 
rate observed for SCVs.  
 
This slow growth rate,  and lack of protein production and defective ribosomes seen in the 
SCV phenotype would also account for the genes encoding heat shock proteins and other 
molecular chaperones (IbpA, GrpE, HtpG, ClpB, DnaK, GroES, DnaJ and ClpX) being 
amongst the most highly downregulated genes in the SCV.  The ability of bacteria to 
rapidly adapt to changes in their environment is essential for survival and they have 
evolved complex regulatory circuits to induce the synthesis of heat shock proteins after a 
sudden increase in ambient temperatures.  The principle function of these heat shock 
proteins is to assist in protein folding, assembly, transport and degradation during normal 
growth353.     
 
Several studies have suggested that exposure of bacteria to sublethal concentrations of 
hydrogen peroxide can lead to formation of SCV’s via a mutagenic DNA repair pathway 
and enhancing the size of the SCV population192,222,354.  Responses to oxidative stress 
involve complex mechanisms which include alterations in gene expression patterns and the 
activation of a cascade of enzymes which prevent ROS accumulation.   Genes that function 
in the response to oxidative stress and those that encode secreted virulence factors are 
largely upregulated in the SCV in this study.  Five of the ten most highly upregulated 
genes in the SCV are those associated with the response to oxidative stress. Highly 
upregulated oxidative stress genes include, katA344 which encodes the major catalase of P. 
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aeruginosa, ahpB, ahpC and ahpF304,345,346, which encode subunits of alkyl hydroperoxide 
reductase and trxB2 that encodes thioredoxin reductase 2192,347,348. S. aureus is also known 
to utilise a number of defence molecules including catalase (KatA) to combat reactive 
oxygen species354.  Consistent with the observed transcriptional changes, catalase activity 
was strongly increased in SCV relative to NHMuc.   It has been proposed that bactericidal 
antibiotics can induce cell death through a common oxidative damage mechanism that 
relies on the production of ROS. Antibiotics are able to activate cellular respiration, 
leading to superoxide formation and release of iron.  Iron is then able to activate a 
chemical reaction to produce ROS in the form of hydroxyl radicals which can damage 
proteins, lipids and DNA188,240,241.  Bacteria are able to protect themselves from ROS by 
upregulating anti-oxidant molecules therefore there is potential to target these bacterial 
defence mechanisms as means of enhancing killing efficacy of bactericidal agents.   
One of the most important micronutrients for bacterial growth is iron, which is an 
important cofactor playing an essential role in many cellular processes.  Bacteria employ a 
wide variety of mechanisms to regulate intracellular iron concentrations preventing the 
toxic effects and also sequestration through the production and secretion of 
siderophores247,302,303.  In this study, there are a number of genes involved in iron 
acquisition upregulated in the SCV as compared to the mucoid strain including hemH, 
feoC, napF, ccmH and cycH.  These all enable the SCV to persist within a more hostile 
environment, with a slower growth rate and conserving vital nutrients.  There have been 
numerous studies investigating the effect of iron limitation on the global gene expression 
in P. aeruginosa showing differential expression of over 554 genes247,355.  Certain genes 
have further been implicated as part of the regulon involved in the iron response, including 
those coding for siderophore receptors, iron transport, regulators, sensors and sigma 
factors239,246.  
Previous studies have suggested that SCVs are typically less virulent due to their slower 
growth and reduced expression of virulence factors however the SCVs isolated in this 
study reveal increased virulence as seen in chapter 3 which is also reflected in the 
transcriptome results.  Genes encoding a number of secreted virulence factors such as the 
proteases LasA, LasB and AprA, the frucose-binding lectin LecB349 and the chitin binding 
protein CbpD and chitinase ChiC350 were also highly upregulated. Similarly genes 
encoding hydrogen cyanide synthase and a number of enzymes that function in phenazine 
biosynthesis are also upregulated50,60,104,106,293,351.  Phenazines have previously been shown 
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to enhance killing of Caenorhabditis elegans by P. aeruginosa352 and are well 
characterized virulence factors.   Phenazines are nitrogen containing secondary metabolites 
that serve as signalling molecules influencing gene expression during environmental 
adaptations and biofilm formation.  They are capable of producing ROS toxic to eukaryotic 
cells and other bacteria60,106. The apparent increase in the production of virulence factors 
by SCVJan/SCVFeb relative to NHMuc suggests increased virulence of the SCV. To 
directly test this we used an infection model based on infection of the murine macrophage 
cell line J774A.1. Cell death of J774A.1 through LDH release was measured at 4 and 10 
hours post infection with NHMuc and SCVJan. At 4 hours, levels of LDH release were 
similar for NHMuc and SCVJan, whereas at 10 hours LDH release was significantly 
increased for SCVJan; 96% vs 38%, p < 0.0001. 
 
To determine if the increased virulence of the SCV observed against a murine cell line 
translated to increased virulence in an animal model of infection, we utilised an 
invertebrate model of infection utilising the larva of the wax moth Galleria mellonella. 
Similar to the macrophage infection assay, SCVJan displayed increased virulence in the G. 
mellonella infection model. Mortality of larvae was measured at 24, 48 and 72 hours post 
infection. No significant differences in mortality were detected at 24 or 48 hours, whereas 
at 72 hours % mortality was 86% and 63% (p < 0.01) for SCVJan and NHMuc infected 
larvae, respectively. Data from both infection models shows that SCVJan shows increased 
virulence, relative to NHMuc, which is consistent with the phenotype of SCVs obtained 
from the human host.156,296 
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5.4 Conclusion and future work 
From the results in this chapter we can conclude that it is likely that the large genome 
inversion found in the isolated SCVs results in a global change in gene transcription.  We 
are unsure as to exactly how this has occurred or to what extent different transcriptional 
regulators are involved.  RsmA has been previously described as a small post-
transcriptional regulatory protein which controls the expression of many virulence genes 
and QS signalling molecule synthesis and a global transcriptional regulator35,39,356.  In this 
study, the expression of RsmA is markedly downregulated in the SCV which may account 
for the global reduction in gene expression in this phenotype.  
Collectively, the phenotypic data in combination with the whole genome analysis and 
transcriptome data has allowed us to get an in depth correlation between phenotypic traits 
(antibiotic resistance, type III secretion expression, biofilm formation, cell cytotoxicity) 
and gene expression data.  Given the large genome rearrangement and the resultant gross 
phenotypic change with altered gene expression, it would appear the change in orientation 
of part of the genome functions as a ‘switch’ for gene expression and control. 
Further work is required to produce a high-resolution transcriptome map with detailed 
operon organisation, coding and non-coding transcripts and their sites of transcription 
initiation to further establish the effects of the inversion on the control of major 
transcriptional regulators.  Identification and characterisation of essential genes for the 
establishment and/or maintenance of chronic infection may be the basis to elaborate novel 
and effective antimicrobials against bacteria, especially if these are conserved genes 
between different bacterial species. 
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Chapter 6 Optimisation of RNA extraction from CF 
sputum samples 
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6.1  Introduction 
The cystic fibrosis (CF) lung provides a well characterised and clinically relevant 
environment to study bacterial transcriptional responses to antibiotic challenge. CF patients 
are peculiarly susceptible to infection with the Gram-negative bacterium Pseudomonas 
aeruginosa and chronic infection with this opportunistic pathogen can lead to progressive 
lung damage and ultimately respiratory failure.  P. aeruginosa has a large genome, with 
6.26 million base pairs, comprising almost 90 percent protein coding genes19.  The large 
genome size at least partly explains the ability of P. aeruginosa to adapt and thrive in a 
wide range of diverse environments.  Initially, during teenage years, CF patients show 
transient colonization with P. aeruginosa that can be cleared by antibiotic therapy. 
However, as the disease develops, chronic colonization occurs in about 80% of patients 
that cannot be eradicated by antibiotics. Frequent respiratory exacerbations occur in 
association with chronic colonization and although these may respond to anti-pseudomonal 
treatment, increasing levels of multidrug resistance present a considerable therapeutic 
challenge. Such patients are maintained on regular inhaled antibiotics and receive 
intravenous treatment for exacerbations.  Resistance rates of P. aeruginosa strains from CF 
patients are significantly higher than those from non-CF patients which is a direct 
consequence of the extensive use of antibiotics in this patient group and the consequent 
selective pressure for the development of resistance.    
 
Recent years have witnessed a revolution in the field of bacterial transcriptomics, starting 
with the development of DNA microarrays, which provides a tool to globally quantify gene 
expression.  In 2008, RNA-Seq was introduced, which involves deep sequencing of cDNA 
generated from RNA preparations and has overcome some of the drawbacks of 
microarrays: providing single-base resolution and improved signal to noise ratio owing to a 
reduced background and a higher dynamic range236,340.  
 
Since mRNA has both a short half-life and makes up only a small fraction of the total 
RNA, one of the main hurdles in the use of these technologies remains the extraction of 
sufficient bacterial mRNA to enable meaningful transcriptomic analysis. This may be 
particularly problematic when studying host-pathogen interactions using infection models 
or patient derived samples where the presence of host RNA and DNA is a complicating 
factor.  In addition, mRNA enrichment is challenging in prokaryotes, as prokaryotic 
mRNA lacks the 3’-end poly (A) tail that marks mature mRNA in eukaryotes and 
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amplification of microbial RNA by methods that utilise synthetic polyadenylation is not 
applicable for samples containing large amounts of eukaryotic mRNA.  A study by Wei 
Lim et al, published in July 2012 explored numerous different methods to successfully 
extract and purify RNA directly from a cystic fibrosis sputum sample275.  They found that 
following RNA extraction and further rRNA depletion precluded subsequent rRNA-based 
analysis of the sample as there was bias and relative abundance of certain microbial taxa in 
the sample.   In other published attempts to analyse microbial metatranscriptomics from 
infected animal tissues, the results highlighted the difficulty in obtaining meaningful 
microbial data.  In a study by Wittekindt et al (2010), 99.3% of the taxonomically assigned 
reads were host derived and only <0.01% were of microbial origin357.    
 
The initial aim of the work described in this chapter was to optimise bacterial DNA and 
mRNA extraction from human CF sputum samples by implementing various methods of 
enrichment, targeting and depletion whilst minimizing contamination with host nucleic 
acid.  In summary, the original aims were: 
 
1. To optimize the recovery and sequencing of P. aeruginosa mRNA from patients 
chronically colonized with this microbe and to follow the stability of this transcriptional 
profile over time and in response to inhaled antibiotics. 
2. To determine the transcriptional changes following antibiotic therapy in patients newly 
colonized with Pseudomonas aeruginosa. 
3. To determine the transcriptional changes following antibiotic therapy in chronically 
colonized patients who are receiving intravenous antibiotics for a respiratory exacerbation. 
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6.2  Results 
6.2.1 RNA extraction from CF sputum 
In order to obtain samples for RNA extraction ten sputum samples were collected from 
five CF volunteers (CF1 through to CF5) at the adult CF clinic (Gartnavel General 
Hospital, Glasgow) by expectoration into a sterile cup.  All collection was in accordance 
with the University of Glasgow Ethics Committee Review panel, reference 13/WS/0051.  
Patient information sheets (Appendix A) and consent forms (Appendix B) were distributed 
as per policy.  Each sample was from a patient who was known to be colonised with P. 
aeruginosa.  Following collection, samples were immediately placed on ice to prevent 
RNA degradation.  Each sample was syringe homogenised and divided into aliquots for 
transcriptomic analysis, culture and storage.  Samples were then processed according to the 
protocol outlined in section 2.6.3.1. 
 
Ideally, high quality transcriptomic data contain relatively few rRNA reads and an 
unbiased sampling of different RNAs. The initial amplification step during preparation of a 
cDNA sequencing library is, however, a potential source of transcript size induced bias.  In 
addition, the sputum samples obtained were from patients undergoing an infective 
exacerbation, which reduces the chance of obtaining a high proportion of microbial RNA, 
given the large quantity of human immune and epithelial cells that are invariably present in 
such samples. 
 
In order to begin to develop a method to extract high levels of total RNA from CF sputum 
samples, three commercially available RNA extraction kits were tested and the RNA yields 
compared.  As shown in Table 6-1 a much greater RNA yield was obtained using the 
Zymo Clean and Concentrator method than either the Qiagen Saliva kit or the Ribo pure 
kit.  One possible reason for the low yields obtained using the Qiagen Saliva kit and 
RiboPure kit is that the enzymatic sputum lysis stage may have been inadequate given the 
purulence of the sputum.  Cystic fibrosis sputum samples, especially from patients 
undergoing an infective exacerbation have highly viscous sputum with a high proportion of 
human inflammatory cells and DNA358.  Prior to the Zymo Clean and Concentrator spin 
column, the sputum was digested chemically using Trizol and the purulent nature with 
dense inflammatory cell infiltrates was physically disrupted using zirconia beads. 
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Table 6-1:  Comparison of total RNA yield between Qiagen Saliva Kit, Ribo Pure and Zymo 
Clean and Concentrator.  
Sample 1: RNA isolated directly from the cystic fibrosis sputum (CF1), Sample 2: RNA isolated 
from the sputum (CF1) inoculated into LB broth, Sample 3: RNA isolated directly from the cystic 
fibrosis sputum (CF2), Sample 4: RNA isolated from the sputum (CF2) inoculated into LB broth, 
Sample 5: RNA isolated directly from the cystic fibrosis sputum (CF3), Sample 6: RNA isolated 
from the sputum (CF3) inoculated into LB broth.  
 Total RNA Yield µg 
Sample Qiagen Saliva Kit 
 
Ribo Pure Zymo Clean and Concentrator 
1 0.10 0.56 26.12 
2 0.28 0.72 41.11 
3 0.25 1.08 34.52 
4 0.34 1.12 12.54 
5 0.67 1.15 9.87 
6 0.55 1.24 24.29 
 
 
Having established that sufficiently high RNA yields could be obtained from CF sputum 
samples using the Zymo Clean and Concentrator kit, RNA purified by this method was 
treated in order to deplete rRNA levels. rRNA depletion is an essential step prior to 
sequencing as this makes up a significant proportion of the total RNA.  Table 6-2 shows 
the total RNA yield of the extracted RNA before and after rRNA depletion.  The ratio of 
absorbance at 260nm and 280nm is used to assess the purity (not quality) of both DNA and 
RNA.  A ratio of ~1.8 is generally accepted as ‘pure’ for DNA and a ratio of ~2.0 is 
generally accepted as ‘pure’ for RNA.  If the ratio is significantly lower in either case it 
may indicate the presence of protein, phenol or other contaminants that absorb strongly at 
280nm.  The A260/A280 ratios are inadequate confirmation of quality prior to sequencing. 
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Table 6-2: RNA concentration before and after rRNA depletion using Epicentre Ribozero 
Epidemiology Kit.  Sample 1: RNA isolated directly from the cystic fibrosis sputum (CF1), Sample 
2: RNA isolated from the sputum (CF1) inoculated into LB broth, Sample 3: RNA isolated directly 
from the cystic fibrosis sputum (CF2), Sample 4: RNA isolated from the sputum (CF2) inoculated 
into LB broth, Sample 5: RNA isolated directly from the cystic fibrosis sputum (CF3), Sample 6: 
RNA isolated from the sputum (CF3) inoculated into LB broth.   
 Before rRNA depletion After rRNA depletion 
Sample Total RNA µg A260/A280 Total RNA µg A260/A280 
1 26.15 1.93 1.59 1.71 
2 41.11 1.59 0.29 1.56 
3 10.08 2.08 0.71 0.47 
4 10.50 2.09 0.78 1.71 
5 8.38 2.08 0.36 1.75 
6 8.25 2.01 0.44 1.89 
 
In an attempt to further enrich for microbial mRNA, different combinations of methods 
including Zymo Clean and Clear with Microbenrich, Ribozero then MEGAclear were 
tested to obtain optimum yields of microbial mRNA.  MEGAclear is designed for final 
cleanup of RNA from any residual buffers, enzymes or other inhibitory factors.  However, 
this was unfortunately found to reduce the final yield of purified RNA to a level 
insufficient for sequencing.  The final method which was implemented consisted of the 
following steps: 
 
1. Trizol and zirconia bead treatment of CF sputum 
2. Zymo Clean and Clear 
3. Microbenrich 
4. Ribozero 
 
Following rRNA depletion, qPCR was performed to ensure that Pseudomonal RNA was 
present in the samples.  The primers used were targeted against gyrB which is specific for 
Pseudomonas spp.  The amplification plot is shown in Figure 1, which shows amplification 
in each of samples 1-5 confirming the presence of Pseudomonal mRNA.   
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Figure 6-10-1:  Amplification plot showing Pseudomonas aeruginosa RNA present in each of 
the samples tested as confirmed by successful amplification of all samples. 
From left (red line) to right (yellow line) samples are 2, 1, 6, 5, 4 and 3, respectively as listed in 
Table 6-2.  
 
 
 
6.3 Transcriptomic analysis 
Following mRNA extraction, rRNA depletion and microbial mRNA enrichment, samples 
were sent to Liverpool University Genomics Research laboratory for preparation of 
RNAseq libraries using the Epicentre kit to prepare strand specific cDNA.  Paired end 
sequencing (2 x 100bp) of RNAseq libraries on the Illumina Hi-Seq platform was 
performed, which generated data in excess of 120M clusters per lane.  Post processing of 
the reads including QC, resolution of indexes and transfer of fastq files was additionally 
performed. 
 
Initial QC results from Liverpool using an Agilent Bioanalyser suggested very poor 
quality, degraded RNA.  An example of a Bioanalyser trace using these samples is shown 
in figure 6-2. This indicates due to the absence of distinct peaks that the RNA was most 
likely significantly degraded.  However, on further investigation it was evident that this 
may not be the case and the analysis was likely compromised due the carryover of ethanol 
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in the sample from the ethanol precipitation step during the rRNA depletion275,359. 
Subsequently, the quality of the extracted RNA samples was confirmed by successful 
generation of high quality cDNA libraries and transcriptomic analysis.  
 
a) 
 
b) 
 
c) 
 
Figure 6-20-2  Agilent Bioanalyser Traces 
Trace a) shows the ideal total RNA trace from the Agilent Bioanalyser.  Ideally the traces would 
reveal defined peaks in the 18S and 28S in a human sample and 16S and 23S in a microbial sample.   
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Trace b) an example of the trace from the Agilent Bioanalyser following total RNA from human 
CF sputum samples and rRNA depletion. The trace reveals no peaks corresponding to high 
molecular weight rRNA and lots of small sized RNA (a wide smear at <20 nucleotides) which 
indicates RNA degradation.  Trace c) following cDNA library preparation, which represents high 
quality RNA to cDNA conversion suitable for downstream transcriptomic analysis. 
 
After establishing the quality of purified RNA obtained from CF sputum samples using the 
above methods, RNAseq was performed using an Illumina HiSeq 2000 platform.  
Sequencing was performed with paired end reads, 100bp length and raw reads were QC 
checked for read quality and degradation using FastQC (Babraham Bioinformatics).  As 
shown in Table 6-3 a large number of reads were obtained and data analysed using CLC 
Workbench 7 (CLC Bio).  Sequences were imported, trimmed accordingly and aligned 
against the human genome and the PA01 genome to establish the relative proportions of 
transcripts present.   Unfortunately despite extensive optimisation of methods, enrichment 
procedures and rRNA depletion, sufficient P. aeruginosa RNA reads could not be obtained 
from these samples to allow for meaningful transcriptomic analysis.  Given the cost 
associated with the process, it was felt that this line of investigation would not be 
financially viable in this particular project. 
Table 6-3:  Proportion of human and PA transcripts isolated from human CF sputum 
samples. 
Sample Preparation Total number of  
Reads  
Human 
Reads 
(%) 
P. 
aeruginosa 
Reads (%) 
1 Trizol, Zymo, Ribozero 16,168,456 99.56 0.01 
2 Trizol, Zymo, Ribozero 16,539,890 99.23 0.02 
3 Trizol, Zymo, MicrobEnrich, 
Ribozero 
12,503,240 98.35 0.04 
4 Trizol, Zymo, MicrobEnrich, 
Ribozero 
18,033,754 98.95 0.05 
5 Trizol, Zymo, Ribozero 14,305,226 99.45 0.01 
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Analysis using Metaphlam revealed the most common bacterial taxa found within theses 
samples included P. aeruginosa, Bacteroides, Prevotella, Firmicutes, Staphylococcus and 
Streptococcus, with Pseudomonas being the lowest percentage. 
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6.4  Discussion 
As discussed throughout this chapter, extraction and purification of adequate 
concentrations and quality of bacterial RNA from CF sputum samples is an extremely 
difficult process.  Following extensive method optimization, it was apparent that the initial 
processing step using two of the commercial kits (Ribopure and Qiagen Saliva Kit) failed 
to produce adequate concentrations of RNA and this was likely due to inadequate enzyme 
lysis of the purulent sputum sample and inflammatory cells.  The Trizol bead beating 
method on the other hand combines both enzymatic and mechanical lysis, enabling 
disruption of the human cells and DNA present in the purulent samples.  There is very little 
published data surrounding this to date and the main paper from Lim et al275 in 2013 
suggests they experienced similar difficulties when trying to sequence the 
metatranscriptome from CF sputum samples during an exacerbation.   
 
The additional problem of the apparent poor quality of the purified RNA, as determined 
from Agilent Bioanalyser traces was shown to be an artifact, likely due carryover of 
ethanol at the precipitation stage, as high quality cDNA libraries could be obtained from 
these samples.  It is well known that use of low-quality RNA compromises the derived 
expression results, reproducibility and relevance of gene expression results.  Reliable 
isolation techniques must yield intact, high quality RNA that is free of RNases, proteins 
and genomic DNA. Spectrophometric methods often fail in sensitivity, are highly variable 
and give no indication as to the basic integrity of the RNA.  The Agilent Bioanalyser and 
the Experion (Bio-Rad Laboratories) allow analysis of very small amounts of RNA and are 
becoming standard for analysis. 
 
RNA purified by the methods outlined in this chapter were then sent to Liverpool 
Genomics for RNA-Seq using the HiSeq platform.  Following successful construction of 
high quality cDNA libraries, it was immediately apparent that the samples were highly 
contaminated with human genetic material.  Numerous studies have shown that saturation 
of sequence data by abundant transcripts remains a major limiting factor as when analyzing 
bacterial gene expression within host tissue. 
 
Ideally, high quality transcriptomic data contains relatively few rRNA reads and an 
unbiased sampling of different RNAs. The initial amplification step during preparation of a 
cDNA sequencing library, however, is a potential source of transcript size induced bias.  In 
   
 
 
139 
addition, the sputum samples obtained were from patients undergoing an infective 
exacerbation, which reduces the chance of obtaining a high proportion of microbial RNA 
given the large quantity of human immune and epithelial cells that are invariably present in 
such samples. 
 
Given the financial restraints of this particular research project it was not feasible to 
continue optimizing methods for RNA extraction from the CF sputum samples.  Efforts are 
being made to look at isolating RNA from a single bacterial cell within host tissue which 
would reduce the quantity of starting material required and reduce the contamination from 
human genetic material and in this case other bacteria present within the specimen.  Use of 
single cell transcriptomics however would not give an indication of the microbial 
community present and the gross changes in gene expression which would have been vital 
in this research project as each different bacteria within a biofilm utilizes a different 
number of genes. 
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Chapter 7 Final Discussion 
In this work we show that P. aeruginosa SCVs, that share key phenotypic features with 
SCVs isolated from chronically infected CF patients, can be isolated from a chronic murine 
lung infection model in the absence of antibiotic selection. Interestingly, SCVs were 
isolated significantly less from the bronchoalveolar lavage fluid (53%) of chronically 
infected mice compared with the lung homogenate samples (88%). Clinically this is likely 
to be highly significant, as it suggests that the presence of SCVs, in lung infection may be 
widely underestimated as sputum samples, rather than deeper tissue samples which are 
routinely used for bacterial isolation. The general upregulation of virulence associated 
genes in the SCVs, relative to the mucoid parent strain, and the increased virulence 
demonstrated in two infection models may begin to explain the link between the 
appearance of SCVs in chronic lung infection and the associated decline in lung 
function360. In addition, the upregulation of genes that mediate the response to oxidative 
stress immediately suggests why the isolated SCVs are rapidly selected for in a chronic 
infection model in which the host immune system is strongly activated. 
 
From a clinical microbiology point of view, it would seem that CF microbiology and 
current culturing techniques are somewhat redundant.  The swarming of the agar plates by 
the mucoid colonies and of other potential pathogens makes interpretation very difficult. 
The difficulty in obtaining a suitable sample for culturing results in inappropriate testing of 
isolated from thick upper airway secretions rather than deep samples from the lung tissue 
which contain the persister cells and small colony variants.  Bronchoscopy and deeper 
sampling is not appropriate in this patient cohort given the high mortality associated with 
the procedure.  Although next generation sequencing is advancing, the same problems 
would arise given the difficulty of sampling.  The PEG biofilm assay also highlights a 
major problem with interpreting sensitivity results from automated systems such as the 
Vitek.  Given their slow growth and biofilm form, the SCV’s are significantly more 
resistant to antibiotics in the form found in the host.  Clinical laboratories would release 
these isolates as antibiotic sentitive. 
 
A key strength of our study was the availability of the parent strain used to establish 
infection for sequencing. This allowed a meaningful comparative genetic analysis to be 
performed enabling the determination the genetic basis of conversion to the SCV 
phenotype. Surprisingly, SNPs and INDELs were not identified in the SCV genome 
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by Illumina sequencing and single-molecule real-time sequencing was subsequently 
used to show that the two sequenced SCVs carried a large genomic inversion within 16S 
rRNA genes. Interestingly, the transcriptional changes associated with genomic inversion 
and that drive conversion to the SCV phenotype are not restricted to genes close to or 
within the inversion breakpoints, with major upregulated and downregulated genes 
distributed relatively evenly throughout the genome.  Instead the major changes in gene 
expression are largely restricted to specific functional classes of genes including those that 
mediate the response to oxidative stress, virulence, DNA repair and recombination, the 
chaperone network and metabolism. This global rewiring of the cellular transcriptomic 
output results in concerted transcriptional changes to these normally differentially 
regulated genes. The mechanistic details of how the observed genomic inversion lead to 
these coordinated expression changes is currently not known, but the observation that a 
clinical SCV strain (SCV20265) obtained from the lung of a CF patient strain recently 
sequenced using the same strategy of combining SMRT and Illumina sequencing possesses 
a similar 16S rRNA based inversion, indicates that this inversion may be a highly clinically 
relevant route to the SCV phenotype181. A reversible genomic inversion has also recently 
been shown to mediate the reversible conversion between normal colony and SCV 
phenotypes in S. aureus184. However, in the case of the SCVs isolated in our work the SCV 
phenotype is stable and revertants to the parent phenotype are not observed. A possible 
explanation for this observation is that a number of genes encoding proteins involved in 
DNA repair and recombination, including RecA, are downregulated in the SCV relative to 
the parent strain. 
 
It is generally accepted that the habitat of a chronically infected CF lung selects for less 
virulent P. aeruginosa phenotypes, with previous studies showing lower levels of protease, 
elastase and exotoxinA93,306 and lower levels of type III secretion toxins including ExoS, 
ExoT and ExoU.  However, the results of this study, in agreement with some other SCV 
studies155,156 reveals that these SCV morphotypes exhibit an increased virulence potential 
and therefore would explain why the presence of these phenotypes have an adverse effect 
on the mortality of CF patients.  Given the impact on prognosis and the difficulties in 
detection within the clinical laboratory, there should be strict precautions in place to ensure 
adequate detection of this otherwise easily missed phenotype. 
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It is currently common knowledge that growth of microorganisms in biofilm can enhance 
their resistnace to antimicrobial agents.  Numerous studies361,362 have discussed the role of 
quorum sensing inhibitors in biofilm formation and these molecules have also been shown 
to be promising antibiofilm agents and may be of great value in the future treatment of 
bacterial infections.  A major benefit of quorum sensing inhibitors is that they are not 
directly involved in the inhibition of bacterial growth therefore do not impose harsh 
selective pressure for the development of resistance.  The activities and pathways of 
microorganisms in biofilms present many novel drug targets because the activities and 
pathways are distinct from those important in free-floating microbial cells.  From this study 
it is clear that rather than focusing on the mucoid P. aeruginosa we need to concentrate on 
the persistent small colony variant which is able to adopt a non-growing phase.  It should 
be possible to potentiate the action of a conventional antibiotic by providing appropriate 
metabolic stimuli to ‘wake up’ persister cells.  A further potential target would be to 
prevent the attachment or adhesion of a bacterial cell to a surface whether it be the lung 
epithelium or biomaterial.  Microorganisms in biofilms are protected from killing by 
antimicrobial agents therefore another potential strategy would be to disrupt the biofilm 
matrix.  Currently DNAses are used in CF, however there are many different pathways 
which could be explored. 
 
Future work that may lead from this area of research could include setting up a respiratory 
tissue cell culture to look at whether small colony variants can be isolated from a tissue 
culture rather than a living host.  From here it would be possible to establish other factors 
involved in the phenotypic switch and large scale genome rearrangement.  It would be 
interesting to look at adjuncts to antibiotic therapy which could be able to target the 
intricate biofilm and extracellular matrix as antibiotics in general only target the bacteria 
specifically.  Currently in Glasgow University there is work underway to establish whether 
synthetic lamellar bodies have any effect on the composition of the biofilm.  There are 
numerous studies looking into compounds such as Manuka honey363 which has the ability 
to reduce the oxidative stress and break down the biofilm structure therefore other potential 
compounds could be trialled in a similar fashion to be used in the human host.  If small 
molecules can be identified that potentiate oxidative stress or subvert cellular processes 
that protect against reactive oxygen species, these small molecules have the potential to 
effectively eradicate infections that currently defy our antibiotic arsenal.  These new agents 
may serve the dual function of acting on bacteria as primary antibiotics as well as 
impairing the bacterial defence to host immunity. 
   
 
 
143 
 
 
 
References 
1. ANDERSEN, D. H. CYSTIC FIBROSIS OF THE PANCREAS AND ITS 
RELATION TO CELIAC DISEASE. Am. J. Dis. Child. 56, 344 (1938). 
2. Smyth, A. R. et al. European Cystic Fibrosis Society Standards of Care: Best 
Practice guidelines. J. Cyst. Fibros. 13 Suppl 1, S23-42 (2014). 
3. Boucher, R. . An overview of the pathogenesis of cystic fibrosis lung disease. Adv. 
Drug Deliv. Rev. 54, 1359–1371 (2002). 
4. Sobonya RE, Taussig LM (1986) Quantitative aspects of lung pathology in cystic 
fibrosis. Am Rev Respir Dis 134: 290-295. PubMed: 3740655. - Open Access 
Library. at <http://www.oalib.com/references/10863319> 
5. O’Sullivan, B. P. & Freedman, S. D. Cystic fibrosis. Lancet 373, 1891–904 (2009). 
6. Davies, J. C. Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and 
persistence. Paediatr. Respir. Rev. 3, 128–134 (2002). 
7. Pressler, T. et al. Chronic Pseudomonas aeruginosa infection definition: 
EuroCareCF Working Group report. J. Cyst. Fibros. 10, S75–S78 (2011). 
8. CF Registry - Annual Data Reports - Cystic Fibrosis Trust. at 
<http://www.cysticfibrosis.org.uk/research-care/uk-cf-registry/cf-registry-reports> 
9. Waters, V. et al. Chronic Stenotrophomonas maltophilia infection and mortality or 
lung transplantation in cystic fibrosis patients. J. Cyst. Fibros. 12, 482–6 (2013). 
10. Livermore, D. M. Multiple mechanisms of antimicrobial resistance in Pseudomonas 
aeruginosa: our worst nightmare? Clin. Infect. Dis. 34, 634–40 (2002). 
11. Häussler, S. et al. Fatal outcome of lung transplantation in cystic fibrosis patients 
due to small-colony variants of the Burkholderia cepacia complex. Eur. J. Clin. 
Microbiol. Infect. Dis. 22, 249–53 (2003). 
12. Pinto-de-Oliveira, A. et al. 109 The Burkholderia cepacia small colony variants 
(SCV) are a more pathogenic bacterial form that may facilitate persistent respiratory 
infections in CF patients. J. Cyst. Fibros. 12, S76 (2013). 
13. Chaparro, C. et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome 
following lung transplantation. Am. J. Respir. Crit. Care Med. 163, 43–8 (2001). 
14. MRSA in Patients With Cystic Fibrosis Linked to Shorter Survival Time. at 
<http://www.medscape.org/viewarticle/723623> 
15. Goss, C. H. & Muhlebach, M. S. Review: Staphylococcus aureus and MRSA in 
cystic fibrosis. J. Cyst. Fibros. 10, 298–306 (2011). 
16. Cullen, A. R., Cannon, C. L., Mark, E. J. & Colin, A. A. Mycobacterium abscessus 
infection in cystic fibrosis. Colonization or infection? Am. J. Respir. Crit. Care Med. 
161, 641–5 (2000). 
   
 
 
144 
17. Gellatly, S. L. & Hancock, R. E. W. Pseudomonas aeruginosa: new insights into 
pathogenesis and host defenses. Pathog. Dis. 67, 159–73 (2013). 
18. Smith, E. E. et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of 
cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 103, 8487–92 (2006). 
19. Stover, C. K. et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, 
an opportunistic pathogen. Nature 406, 959–64 (2000). 
20. Lee, D. G. et al. Genomic analysis reveals that Pseudomonas aeruginosa virulence is 
combinatorial. Genome Biol. 7, R90 (2006). 
21. Darling, A. E., Miklós, I. & Ragan, M. A. Dynamics of Genome Rearrangement in 
Bacterial Populations. PLoS Genet. 4, e1000128 (2008). 
22. Juhas, M., Eberl, L. & Tummler, B. Quorum sensing: the power of cooperation in 
the world of Pseudomonas. Environ. Microbiol. 7, 459–471 (2005). 
23. Wolfgang, M. C. et al. Conservation of genome content and virulence determinants 
among clinical and environmental isolates of Pseudomonas aeruginosa. Proc. Natl. 
Acad. Sci. U. S. A. 100, 8484–9 (2003). 
24. Hogardt, M. & Heesemann, J. Adaptation of Pseudomonas aeruginosa during 
persistence in the cystic fibrosis lung. Int. J. Med. Microbiol. 300, 557–62 (2010). 
25. Strateva, T. & Mitov, I. Contribution of an arsenal of virulence factors to 
pathogenesis of Pseudomonas aeruginosa infections. Ann. Microbiol. 61, 717–732 
(2011). 
26. Kipnis, E., Sawa, T. & Wiener-Kronish, J. Targeting mechanisms of Pseudomonas 
aeruginosa pathogenesis. Médecine Mal. Infect. 36, 78–91 (2006). 
27. Persat, A., Inclan, Y. F., Engel, J. N., Stone, H. A. & Gitai, Z. Type IV pili 
mechanochemically regulate virulence factors in Pseudomonas aeruginosa. Proc. 
Natl. Acad. Sci. U. S. A. 112, 7563–8 (2015). 
28. Déziel, E., Comeau, Y. & Villemur, R. Initiation of biofilm formation by 
Pseudomonas aeruginosa 57RP correlates with emergence of hyperpiliated and 
highly adherent phenotypic variants deficient in swimming, swarming, and 
twitching motilities. J. Bacteriol. 183, 1195–204 (2001). 
29. Chiang, P. & Burrows, L. L. Biofilm Formation by Hyperpiliated Mutants of 
Pseudomonas aeruginosa. J. Bacteriol. 185, 2374–2378 (2003). 
30. Burrows, L. L. Pseudomonas aeruginosa twitching motility: type IV pili in action. 
Annu. Rev. Microbiol. 66, 493–520 (2012). 
31. Feldman, M. et al. Role of Flagella in Pathogenesis of Pseudomonas aeruginosa 
Pulmonary Infection. Infect. Immun. 66, 43–51 (1998). 
32. Drake, D. & Montie, T. C. Flagella, motility and invasive virulence of Pseudomonas 
aeruginosa. J. Gen. Microbiol. 134, 43–52 (1988). 
33. Montie, T. C., Doyle-Huntzinger, D., Craven, R. C. & Holder, I. A. Loss of 
virulence associated with absence of flagellum in an isogenic mutant of 
Pseudomonas aeruginosa in the burned-mouse model. Infect. Immun. 38, 1296–1298 
(1982). 
34. Wagner, V. E., Bushnell, D., Passador, L., Brooks, A. I. & Iglewski, B. H. 
Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: effects 
of growth phase and environment. J. Bacteriol. 185, 2080–95 (2003). 
   
 
 
145 
35. Pessi, G. et al. The global posttranscriptional regulator RsmA modulates production 
of virulence determinants and N-acylhomoserine lactones in Pseudomonas 
aeruginosa. J. Bacteriol. 183, 6676–83 (2001). 
36. Pesci, E. C., Pearson, J. P., Seed, P. C. & Iglewski, B. H. Regulation of las and rhl 
quorum sensing in Pseudomonas aeruginosa. J. Bacteriol. 179, 3127–32 (1997). 
37. Ben Haj Khalifa, A., Moissenet, D., Vu Thien, H. & Khedher, M. [Virulence factors 
in Pseudomonas aeruginosa: mechanisms and modes of regulation]. Ann. Biol. Clin. 
(Paris). 69, 393–403 
38. Gambello, M. J. & Iglewski, B. H. Cloning and characterization of the Pseudomonas 
aeruginosa lasR gene, a transcriptional activator of elastase expression. J. Bacteriol. 
173, 3000–9 (1991). 
39. Burrowes, E., Baysse, C., Adams, C. & O’Gara, F. Influence of the regulatory 
protein RsmA on cellular functions in Pseudomonas aeruginosa PAO1, as revealed 
by transcriptome analysis. Microbiology 152, 405–18 (2006). 
40. Lalaouna, D., Fochesato, S., Barakat, M., Ortet, P. & Achouak, W. Multiple 
transcription-activating sequences regulate the RsmZ regulatory small RNA of 
Pseudomonas brassicacearum. J. Bacteriol. 194, 4888–93 (2012). 
41. Duss, O. et al. Structural basis of the non-coding RNA RsmZ acting as a protein 
sponge. Nature 509, 588–92 (2014). 
42. Heurlier, K. et al. Positive control of swarming, rhamnolipid synthesis, and lipase 
production by the posttranscriptional RsmA/RsmZ system in Pseudomonas 
aeruginosa PAO1. J. Bacteriol. 186, 2936–45 (2004). 
43. Lequette, Y. & Greenberg, E. P. Timing and localization of rhamnolipid synthesis 
gene expression in Pseudomonas aeruginosa biofilms. J. Bacteriol. 187, 37–44 
(2005). 
44. Caiazza, N. C., Merritt, J. H., Brothers, K. M. & O’Toole, G. A. Inverse regulation 
of biofilm formation and swarming motility by Pseudomonas aeruginosa PA14. J. 
Bacteriol. 189, 3603–12 (2007). 
45. Boles, B. R., Thoendel, M. & Singh, P. K. Rhamnolipids mediate detachment of 
Pseudomonas aeruginosa from biofilms. Mol. Microbiol. 57, 1210–23 (2005). 
46. McKnight, S. L., Iglewski, B. H. & Pesci, E. C. The Pseudomonas Quinolone Signal 
Regulates rhl Quorum Sensing in Pseudomonas aeruginosa. J. Bacteriol. 182, 2702–
2708 (2000). 
47. Wei, Q. et al. Phenotypic and genome-wide analysis of an antibiotic-resistant small 
colony variant (SCV) of Pseudomonas aeruginosa. PLoS One 6, e29276 (2011). 
48. Meyer, J., Neely, A., Stintzi, A., Georges, C. & Holder, I. Pyoverdin is essential for 
virulence of Pseudomonas aeruginosa. Infect. Immun. 64, 518–523 (1996). 
49. Taguchi, F. et al. The siderophore pyoverdine of Pseudomonas syringae pv. tabaci 
6605 is an intrinsic virulence factor in host tobacco infection. J. Bacteriol. 192, 
117–26 (2010). 
50. Pessi, G. et al. The global posttranscriptional regulator RsmA modulates production 
of virulence determinants and N-acylhomoserine lactones in Pseudomonas 
aeruginosa. J. Bacteriol. 183, 6676–83 (2001). 
51. Christiaen, S. E. A. et al. Bacteria that inhibit quorum sensing decrease biofilm 
   
 
 
146 
formation and virulence in Pseudomonas aeruginosa PAO1. Pathog. Dis. 70, 271–9 
(2014). 
52. Mikkelsen, H. et al. Biofilms and type III secretion are not mutually exclusive in 
Pseudomonas aeruginosa. Microbiology 155, 687–98 (2009). 
53. Høiby, N., Bjarnsholt, T., Givskov, M., Molin, S. & Ciofu, O. Antibiotic resistance 
of bacterial biofilms. Int. J. Antimicrob. Agents 35, 322–32 (2010). 
54. Wozniak, D. J. et al. Alginate is not a significant component of the extracellular 
polysaccharide matrix of PA14 and PAO1 Pseudomonas aeruginosa biofilms. Proc. 
Natl. Acad. Sci. U. S. A. 100, 7907–12 (2003). 
55. Colvin, K. M. et al. The Pel and Psl polysaccharides provide Pseudomonas 
aeruginosa structural redundancy within the biofilm matrix. Environ. Microbiol. 14, 
1913–28 (2012). 
56. Starkey, M. et al. Pseudomonas aeruginosa rugose small-colony variants have 
adaptations that likely promote persistence in the cystic fibrosis lung. J. Bacteriol. 
191, 3492–503 (2009). 
57. Ventre, I. et al. Multiple sensors control reciprocal expression of Pseudomonas 
aeruginosa regulatory RNA and virulence genes. Proc. Natl. Acad. Sci. U. S. A. 103, 
171–6 (2006). 
58. Wong, A., Rodrigue, N. & Kassen, R. Genomics of adaptation during experimental 
evolution of the opportunistic pathogen Pseudomonas aeruginosa. PLoS Genet. 8, 
e1002928 (2012). 
59. Malone, J. G. et al. YfiBNR mediates cyclic di-GMP dependent small colony 
variant formation and persistence in Pseudomonas aeruginosa. PLoS Pathog. 6, 
e1000804 (2010). 
60. Wang, D. et al. Adaptation genomics of a small-colony variant in a Pseudomonas 
chlororaphis 30-84 biofilm. Appl. Environ. Microbiol. 81, 890–9 (2015). 
61. Tralau, T. et al. Transcriptomic analysis of the sulfate starvation response of 
Pseudomonas aeruginosa. J. Bacteriol. 189, 6743–50 (2007). 
62. Martin, D. W., Schurr, M. J., Yu, H. & Deretic, V. Analysis of promoters controlled 
by the putative sigma factor AlgU regulating conversion to mucoidy in 
Pseudomonas aeruginosa: relationship to sigma E and stress response. J. Bacteriol. 
176, 6688–96 (1994). 
63. Werner, E. et al. Stratified growth in Pseudomonas aeruginosa biofilms. Appl. 
Environ. Microbiol. 70, 6188–96 (2004). 
64. Folsom, J. P. et al. Physiology of Pseudomonas aeruginosa in biofilms as revealed 
by transcriptome analysis. BMC Microbiol. 10, 294 (2010). 
65. Borriello, G. et al. Oxygen limitation contributes to antibiotic tolerance of 
Pseudomonas aeruginosa in biofilms. Antimicrob. Agents Chemother. 48, 2659–64 
(2004). 
66. Keren, I., Kaldalu, N., Spoering, A., Wang, Y. & Lewis, K. Persister cells and 
tolerance to antimicrobials. FEMS Microbiol. Lett. 230, 13–8 (2004). 
67. Diaz, M. H. & Hauser, A. R. Pseudomonas aeruginosa cytotoxin ExoU is injected 
into phagocytic cells during acute pneumonia. Infect. Immun. 78, 1447–56 (2010). 
68. Wong-Beringer, A., Wiener-Kronish, J., Lynch, S. & Flanagan, J. Comparison of 
   
 
 
147 
type III secretion system virulence among fluoroquinolone-susceptible and -resistant 
clinical isolates of Pseudomonas aeruginosa. Clin. Microbiol. Infect. 14, 330–6 
(2008). 
69. Jain, M. et al. Type III secretion phenotypes of Pseudomonas aeruginosa strains 
change during infection of individuals with cystic fibrosis. J. Clin. Microbiol. 42, 
5229–37 (2004). 
70. Galle, M., Carpentier, I. & Beyaert, R. Structure and function of the Type III 
secretion system of Pseudomonas aeruginosa. Curr. Protein Pept. Sci. 13, 831–42 
(2012). 
71. Coburn, B., Sekirov, I. & Finlay, B. B. Type III secretion systems and disease. Clin. 
Microbiol. Rev. 20, 535–49 (2007). 
72. Hauser, A. R. The type III secretion system of Pseudomonas aeruginosa: infection 
by injection. Nat. Rev. Microbiol. 7, 654–65 (2009). 
73. Hauser, A. R. & Engel, J. N. Pseudomonas aeruginosa induces type-III-secretion-
mediated apoptosis of macrophages and epithelial cells. Infect. Immun. 67, 5530–7 
(1999). 
74. Feltman, H. et al. Prevalence of type III secretion genes in clinical and 
environmental isolates of Pseudomonas aeruginosa. Microbiology 147, 2659–69 
(2001). 
75. Miyata, S., Casey, M., Frank, D. W., Ausubel, F. M. & Drenkard, E. Use of the 
Galleria mellonella Caterpillar as a Model Host To Study the Role of the Type III 
Secretion System in Pseudomonas aeruginosa Pathogenesis. Infect. Immun. 71, 
2404–2413 (2003). 
76. McCaw, M. L., Lykken, G. L., Singh, P. K. & Yahr, T. L. ExsD is a negative 
regulator of the Pseudomonas aeruginosa type III secretion regulon. Mol. Microbiol. 
46, 1123–33 (2002). 
77. Kudoh, I., Wiener-Kronish, J. P., Hashimoto, S., Pittet, J. F. & Frank, D. 
Exoproduct secretions of Pseudomonas aeruginosa strains influence severity of 
alveolar epithelial injury. Am. J. Physiol. 267, L551-6 (1994). 
78. Allewelt, M., Coleman, F. T., Grout, M., Priebe, G. P. & Pier, G. B. Acquisition of 
expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased 
bacterial virulence in a murine model of acute pneumonia and systemic spread. 
Infect. Immun. 68, 3998–4004 (2000). 
79. Phillips, R. M., Six, D. A., Dennis, E. A. & Ghosh, P. In vivo phospholipase activity 
of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells 
with phospholipase A2 inhibitors. J. Biol. Chem. 278, 41326–32 (2003). 
80. Sawa, T. et al. Active and passive immunization with the Pseudomonas V antigen 
protects against type III intoxication and lung injury. Nat. Med. 5, 392–8 (1999). 
81. Roy-Burman, A. et al. Type III protein secretion is associated with death in lower 
respiratory and systemic Pseudomonas aeruginosa infections. J. Infect. Dis. 183, 
1767–74 (2001). 
82. Vance, R. E., Rietsch, A. & Mekalanos, J. J. Role of the type III secreted 
exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in 
vivo. Infect. Immun. 73, 1706–13 (2005). 
83. Miao, E. A. et al. Innate immune detection of the type III secretion apparatus 
   
 
 
148 
through the NLRC4 inflammasome. Proc. Natl. Acad. Sci. U. S. A. 107, 3076–80 
(2010). 
84. Sutterwala, F. S. et al. Immune recognition of Pseudomonas aeruginosa mediated by 
the IPAF/NLRC4 inflammasome. J. Exp. Med. 204, 3235–45 (2007). 
85. Faure, E. et al. Pseudomonas aeruginosa type-3 secretion system dampens host 
defense by exploiting the NLRC4-coupled inflammasome. Am. J. Respir. Crit. Care 
Med. 189, 799–811 (2014). 
86. Twining, S. S. Fluorescein isothiocyanate-labeled casein assay for proteolytic 
enzymes. Anal. Biochem. 143, 30–4 (1984). 
87. Tang, H. et al. Contribution of specific Pseudomonas aeruginosa virulence factors to 
pathogenesis of pneumonia in a neonatal mouse model of infection. Infect. Immun. 
64, 37–43 (1996). 
88. Van Delden, C. & Iglewski, B. H. Cell-to-cell signaling and Pseudomonas 
aeruginosa infections. Emerg. Infect. Dis. 4, 551–60 
89. Hobden, J. A. Pseudomonas aeruginosa proteases and corneal virulence. DNA Cell 
Biol. 21, 391–6 
90. Baltch, A. L. et al. Production of cytotoxin by clinical strains of Pseudomonas 
aeruginosa. Can. J. Microbiol. 33, 104–111 (1987). 
91. King, J. D., Kocíncová, D., Westman, E. L. & Lam, J. S. Review: 
Lipopolysaccharide biosynthesis in Pseudomonas aeruginosa. Innate Immun. 15, 
261–312 (2009). 
92. Cryz, S. J., Pitt, T. L., Fürer, E. & Germanier, R. Role of lipopolysaccharide in 
virulence of Pseudomonas aeruginosa. Infect. Immun. 44, 508–13 (1984). 
93. Pier, G. B. Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, 
initiator of inflammation and target for effective immunity. Int. J. Med. Microbiol. 
297, 277–95 (2007). 
94. Hao, Y., King, J. D., Huszczynski, S., Kocíncová, D. & Lam, J. S. Five new genes 
are important for common polysaccharide antigen biosynthesis in Pseudomonas 
aeruginosa. MBio 4, e00631-12 (2013). 
95. Tang, H. B. et al. Contribution of specific Pseudomonas aeruginosa virulence 
factors to pathogenesis of pneumonia in a neonatal mouse model of infection. Infect. 
Immun. 64, 37–43 (1996). 
96. Young, L. S. Human Immunity to Pseudomonas aeruginosa. II. Relationship 
between Heat-Stable Opsonins and Type-Specific Lipopolysaccharides. J. Infect. 
Dis. 126, 277–287 (1972). 
97. Pennington, J. E., Reynolds, H. Y., Wood, R. E., Robinson, R. A. & Levine, A. S. 
Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and 
cystic fibrosis. Am. J. Med. 58, 629–36 (1975). 
98. Young, L. S., Meyer, R. D. & Armstrong, D. Pseudomonas aeruginosa vaccine in 
cancer patients. Ann. Intern. Med. 79, 518–27 (1973). 
99. Pier, G. B., Sidberry, H. F. & Sadoff, J. C. Protective immunity induced in mice by 
immunization with high-molecular-weight polysaccharide from Pseudomonas 
aeruginosa. Infect. Immun. 22, 919–25 (1978). 
100. Schaad, U. B., Lang, A. B., Wedgwood, J., Buehlamnn, U. & Fuerer, E. Serotype-
   
 
 
149 
specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in 
cystic fibrosis: correlation to disease, subclass distribution, and experimental 
protective capacity. Pediatr. Res. 27, 508–13 (1990). 
101. Schalk, I. J. & Guillon, L. Pyoverdine biosynthesis and secretion in Pseudomonas 
aeruginosa: implications for metal homeostasis. Environ. Microbiol. 15, 1661–73 
(2013). 
102. Usher, L. R. et al. Induction of neutrophil apoptosis by the Pseudomonas aeruginosa 
exotoxin pyocyanin: a potential mechanism of persistent infection. J. Immunol. 168, 
1861–8 (2002). 
103. Wilson, R. et al. Measurement of Pseudomonas aeruginosa phenazine pigments in 
sputum and assessment of their contribution to sputum sol toxicity for respiratory 
epithelium. Infect. Immun. 56, 2515–7 (1988). 
104. Lau, G. W., Ran, H., Kong, F., Hassett, D. J. & Mavrodi, D. Pseudomonas 
aeruginosa pyocyanin is critical for lung infection in mice. Infect. Immun. 72, 4275–
8 (2004). 
105. Lau, G. W., Hassett, D. J., Ran, H. & Kong, F. The role of pyocyanin in 
Pseudomonas aeruginosa infection. Trends Mol. Med. 10, 599–606 (2004). 
106. Mavrodi, D. V et al. Functional analysis of genes for biosynthesis of pyocyanin and 
phenazine-1-carboxamide from Pseudomonas aeruginosa PAO1. J. Bacteriol. 183, 
6454–65 (2001). 
107. Williams, H. D., Zlosnik, J. E. A. & Ryall, B. Oxygen, cyanide and energy 
generation in the cystic fibrosis pathogen Pseudomonas aeruginosa. Adv. Microb. 
Physiol. 52, 1–71 (2007). 
108. Lenney, W. & Gilchrist, F. J. Pseudomonas aeruginosa and cyanide production. Eur. 
Respir. J. 37, 482–3 (2011). 
109. Gallagher, L. A. & Manoil, C. Pseudomonas aeruginosa PAO1 kills Caenorhabditis 
elegans by cyanide poisoning. J. Bacteriol. 183, 6207–14 (2001). 
110. Williams, B. J., Dehnbostel, J. & Blackwell, T. S. Pseudomonas aeruginosa: host 
defence in lung diseases. Respirology 15, 1037–56 (2010). 
111. Barton, A. D., Ryder, K., Lourenço, R. V, Dralle, W. & Weiss, S. G. Inflammatory 
reaction and airway damage in cystic fibrosis. J. Lab. Clin. Med. 88, 423–6 (1976). 
112. Murphy, T. F. et al. Pseudomonas aeruginosa in chronic obstructive pulmonary 
disease. Am. J. Respir. Crit. Care Med. 177, 853–60 (2008). 
113. Valderrey, A. D. et al. Chronic colonization by Pseudomonas aeruginosa of patients 
with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic 
obstructive pulmonary disease. Diagn. Microbiol. Infect. Dis. 68, 20–7 (2010). 
114. Martínez-Solano, L., Macia, M. D., Fajardo, A., Oliver, A. & Martinez, J. L. 
Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary 
disease. Clin. Infect. Dis. 47, 1526–33 (2008). 
115. Cohen, T. S. & Prince, A. Cystic fibrosis: a mucosal immunodeficiency syndrome. 
Nat. Med. 18, 509–19 (2012). 
116. Linnane, B. M. et al. Lung function in infants with cystic fibrosis diagnosed by 
newborn screening. Am. J. Respir. Crit. Care Med. 178, 1238–44 (2008). 
117. Hartl, D. et al. Innate immunity in cystic fibrosis lung disease. J. Cyst. Fibros. 11, 
   
 
 
150 
363–82 (2012). 
118. Ratner, D. & Mueller, C. Immune Responses in Cystic Fibrosis. Am. J. Respir. Cell 
Mol. Biol. (2012). at <http://www.atsjournals.org/doi/full/10.1165/rcmb.2011-
0399RT#.VfBQ1-mNeS0> 
119. Massengale, A. R. et al. Reduced interleukin-8 production by cystic fibrosis airway 
epithelial cells. Am. J. Respir. Cell Mol. Biol. 20, 1073–80 (1999). 
120. Kelly, E., Greene, C. M. & McElvaney, N. G. Targeting neutrophil elastase in cystic 
fibrosis. Expert Opin. Ther. Targets 12, 145–57 (2008). 
121. Gifford, A. M. & Chalmers, J. D. The role of neutrophils in cystic fibrosis. Curr. 
Opin. Hematol. 21, 16–22 (2014). 
122. Gaggar, A. et al. The role of matrix metalloproteinases in cystic fibrosis lung 
disease. Eur. Respir. J. 38, 721–7 (2011). 
123. Conese, M., Copreni, E., Di Gioia, S., De Rinaldis, P. & Fumarulo, R. Neutrophil 
recruitment and airway epithelial cell involvement in chronic cystic fibrosis lung 
disease. J. Cyst. Fibros. 2, 129–35 (2003). 
124. Moser, C. et al. The immune response to chronic Pseudomonas aeruginosa lung 
infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS 108, 
329–35 (2000). 
125. Milagres, L. G. et al. Antibody response to Pseudomonas aeruginosa in children 
with cystic fibrosis. Pediatr. Pulmonol. 44, 392–401 (2009). 
126. Amin, R., Lam, M., Dupuis, A. & Ratjen, F. The effect of early Pseudomonas 
aeruginosa treatment on lung function in pediatric cystic fibrosis. Pediatr. 
Pulmonol. 46, 554–8 (2011). 
127. Powderly, W. G., Schreiber, J. R., Pier, G. B. & Markham, R. B. T cells recognizing 
polysaccharide-specific B cells function as contrasuppressor cells in the generation 
of T cell immunity to Pseudomonas aeruginosa. J. Immunol. 140, 2746–52 (1988). 
128. Wientzen, R., Prestidge, C. B., Kramer, R. I., McCracken, G. H. & Nelson, J. D. 
Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin 
and placebo therapy. Am. J. Dis. Child. 134, 1134–8 (1980). 
129. Gold, R., Carpenter, S., Heurter, H., Corey, M. & Levison, H. Randomized trial of 
ceftazidime versus placebo in the management of acute respiratory exacerbations in 
patients with cystic fibrosis. J. Pediatr. 111, 907–13 (1987). 
130. Elphick, H. E. & Tan, A. Single versus combination intravenous antibiotic therapy 
for people with cystic fibrosis. Cochrane database Syst. Rev. CD002007 (2005). 
doi:10.1002/14651858.CD002007.pub2 
131. Blumer, J. L., Saiman, L., Konstan, M. W. & Melnick, D. The efficacy and safety of 
meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute 
pulmonary exacerbations in patients with cystic fibrosis. Chest 128, 2336–46 
(2005). 
132. Cheng, K. et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic 
fibrosis clinic. Lancet 348, 639–42 (1996). 
133. Banjanac, M. et al. Anti-inflammatory mechanism of action of azithromycin in LPS-
stimulated J774A.1 cells. Pharmacol. Res. 66, 357–62 (2012). 
134. Yamauchi, K. et al. Azithromycin suppresses interleukin-12p40 expression in 
   
 
 
151 
lipopolysaccharide and interferon-gamma stimulated macrophages. Int. J. Biol. Sci. 
5, 667–78 (2009). 
135. Murphy, B. S. et al. Azithromycin alters macrophage phenotype. J. Antimicrob. 
Chemother. 61, 554–60 (2008). 
136. Ianaro, A. et al. Anti-inflammatory activity of macrolide antibiotics. J. Pharmacol. 
Exp. Ther. 292, 156–63 (2000). 
137. Cystic fibrosis: long-term azithromycin | Key-points-from-the-evidence | Advice | 
NICE. at <https://www.nice.org.uk/advice/esuom37/chapter/key-points-from-the-
evidence> 
138. Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del 
CFTR — NEJM. at 
<http://www.nejm.org/doi/full/10.1056/NEJMoa1409547#t=articleBackground> 
139. Eckford, P. D. W., Li, C., Ramjeesingh, M. & Bear, C. E. Cystic fibrosis 
transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens 
the defective channel gate of mutant CFTR in a phosphorylation-dependent but 
ATP-independent manner. J. Biol. Chem. 287, 36639–49 (2012). 
140. Yu, H. et al. Ivacaftor potentiation of multiple CFTR channels with gating 
mutations. J. Cyst. Fibros. 11, 237–45 (2012). 
141. Wang, Y. et al. CFTR potentiators partially restore channel function to A561E-
CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-
CFTR. Br. J. Pharmacol. 171, 4490–503 (2014). 
142. Eckford, P. D. W., Li, C., Ramjeesingh, M. & Bear, C. E. Cystic fibrosis 
transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens 
the defective channel gate of mutant CFTR in a phosphorylation-dependent but 
ATP-independent manner. J. Biol. Chem. 287, 36639–49 (2012). 
143. Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del 
CFTR — NEJM. 
144. Cystic fibrosis (F508del mutation) - lumacaftor (with ivacaftor) [ID786] | Guidance 
and guidelines | NICE. at <https://www.nice.org.uk/guidance/indevelopment/gid-
tag530> 
145. Yu, H. et al. Ivacaftor potentiation of multiple CFTR channels with gating 
mutations. J. Cyst. Fibros. 11, 237–45 (2012). 
146. Wang, Y. et al. CFTR potentiators partially restore channel function to A561E-
CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-
CFTR. Br. J. Pharmacol. 171, 4490–503 (2014). 
147. Henke, M. O. & Ratjen, F. Mucolytics in cystic fibrosis. Paediatr. Respir. Rev. 8, 
24–9 (2007). 
148. Robinson, P. J. Dornase alfa in early cystic fibrosis lung disease. Pediatr. Pulmonol. 
34, 237–41 (2002). 
149. Konstan, M. W. et al. Clinical use of dornase alpha is associated with a slower rate 
of FEV1 decline in cystic fibrosis. Pediatr. Pulmonol. 46, 545–53 (2011). 
150. Chernick, W. S. & Barbero, G. J. COMPOSITION OF TRACHEOBRONCHIAL 
SECRETIONS IN CYSTIC FIBROSIS OF THE PANCREAS AND 
BRONCHIECTASIS. Pediatrics 24, 739–745 (1959). 
   
 
 
152 
151. Kirchner, K. K., Wagener, J. S., Khan, T. Z., Copenhaver, S. C. & Accurso, F. J. 
Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with 
cystic fibrosis. Am. J. Respir. Crit. Care Med. 154, 1426–9 (1996). 
152. Rosenfeld, M. et al. Early pulmonary infection, inflammation, and clinical outcomes 
in infants with cystic fibrosis. Pediatr. Pulmonol. 32, 356–66 (2001). 
153. Nash, E. F., Stephenson, A., Ratjen, F. & Tullis, E. Nebulized and oral thiol 
derivatives for pulmonary disease in cystic fibrosis. Cochrane database Syst. Rev. 
CD007168 (2009). doi:10.1002/14651858.CD007168.pub2 
154. Flume, P. A. et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. 
Respir. Care 54, 522–37 (2009). 
155. Haussler, S. Highly adherent small-colony variants of Pseudomonas aeruginosa in 
cystic fibrosis lung infection. J. Med. Microbiol. 52, 295–301 (2003). 
156. von Götz, F. et al. Expression analysis of a highly adherent and cytotoxic small 
colony variant of Pseudomonas aeruginosa isolated from a lung of a patient with 
cystic fibrosis. J. Bacteriol. 186, 3837–47 (2004). 
157. Hogardt, M. et al. Stage-specific adaptation of hypermutable Pseudomonas 
aeruginosa isolates during chronic pulmonary infection in patients with cystic 
fibrosis. J. Infect. Dis. 195, 70–80 (2007). 
158. Murray, T. S., Ledizet, M. & Kazmierczak, B. I. Swarming motility, secretion of 
type 3 effectors and biofilm formation phenotypes exhibited within a large cohort of 
Pseudomonas aeruginosa clinical isolates. J. Med. Microbiol. 59, 511–520 (2010). 
159. Miyata, S., Casey, M., Frank, D. W., Ausubel, F. M. & Drenkard, E. Use of the 
Galleria mellonella Caterpillar as a Model Host To Study the Role of the Type III 
Secretion System in Pseudomonas aeruginosa Pathogenesis. Infect. Immun. 71, 
2404–2413 (2003). 
160. Boucher, J. C. et al. Two distinct loci affecting conversion to mucoidy in 
Pseudomonas aeruginosa in cystic fibrosis encode homologs of the serine protease 
HtrA. J. Bacteriol. 178, 511–23 (1996). 
161. Schurr, M. J., Martin, D. W., Mudd, M. H. & Deretic, V. Gene cluster controlling 
conversion to alginate-overproducing phenotype in Pseudomonas aeruginosa: 
functional analysis in a heterologous host and role in the instability of mucoidy. J. 
Bacteriol. 176, 3375–82 (1994). 
162. Déziel, E., Comeau, Y. & Villemur, R. Initiation of biofilm formation by 
Pseudomonas aeruginosa 57RP correlates with emergence of hyperpiliated and 
highly adherent phenotypic variants deficient in swimming, swarming, and 
twitching motilities. J. Bacteriol. 183, 1195–204 (2001). 
163. Maduka-Ezeh, A. N. et al. Antimicrobial susceptibility and biofilm formation of 
Staphylococcus epidermidis small colony variants associated with prosthetic joint 
infection. Diagn. Microbiol. Infect. Dis. 74, 224–9 (2012). 
164. Allegrucci, M. & Sauer, K. Formation of Streptococcus pneumoniae non-phase-
variable colony variants is due to increased mutation frequency present under 
biofilm growth conditions. J. Bacteriol. 190, 6330–9 (2008). 
165. Zbinden, A. et al. Characterization of Streptococcus tigurinus small-colony variants 
causing prosthetic joint infection by comparative whole-genome analyses. J. Clin. 
Microbiol. 52, 467–74 (2014). 
   
 
 
153 
166. Wellinghausen, N. et al. Characterization of clinical Enterococcus faecalis small-
colony variants. J. Clin. Microbiol. 47, 2802–11 (2009). 
167. Rea, R., Hill, C. & Gahan, C. G. M. Listeria monocytogenes PerR mutants display a 
small-colony phenotype, increased sensitivity to hydrogen peroxide, and 
significantly reduced murine virulence. Appl. Environ. Microbiol. 71, 8314–22 
(2005). 
168. Cano, D. A., Pucciarelli, M. G., Martínez-Moya, M., Casadesús, J. & García-del 
Portillo, F. Selection of small-colony variants of Salmonella enterica serovar 
typhimurium in nonphagocytic eucaryotic cells. Infect. Immun. 71, 3690–8 (2003). 
169. Roggenkamp, A., Hoffmann, H. & Hornef, M. W. Growth control of small-colony 
variants by genetic regulation of the hemin uptake system. Infect. Immun. 72, 2254–
62 (2004). 
170. Jacob, J., Hort, G. M., Overhoff, P. & Mielke, M. E. A. In vitro and in vivo 
characterization of smooth small colony variants of Brucella abortus S19. Microbes 
Infect. 8, 363–71 (2006). 
171. Morton, H. E. & Shoemaker, J. The Identification of Neisseria gonorrhoeae by 
Means of Bacterial Variation and the Detection of Small Colony Forms in Clinical 
Material. J. Bacteriol. 50, 585–7 (1945). 
172. Day, M. Yeast petites and small colony variants: for everything there is a season. 
Adv. Appl. Microbiol. 85, 1–41 (2013). 
173. Kahl, B. C. Small colony variants (SCVs) of Staphylococcus aureus--a bacterial 
survival strategy. Infect. Genet. Evol. 21, 515–22 (2014). 
174. Tuchscherr, L. et al. Staphylococcus aureus small-colony variants are adapted 
phenotypes for intracellular persistence. J. Infect. Dis. 202, 1031–40 (2010). 
175. Seifert, H., Wisplinghoff, H., Schnabel, P. & von Eiff, C. Small colony variants of 
Staphylococcus aureus and pacemaker-related infection. Emerg. Infect. Dis. 9, 
1316–8 (2003). 
176. Brouillette, E., Martinez, A., Boyll, B. J., Allen, N. E. & Malouin, F. Persistence of 
a Staphylococcus aureus small-colony variant under antibiotic pressure in vivo. 
FEMS Immunol. Med. Microbiol. 41, 35–41 (2004). 
177. Gröbner, S., Beck, J., Schaller, M., Autenrieth, I. B. & Schulte, B. Characterization 
of an Enterococcus faecium small-colony variant isolated from blood culture. Int. J. 
Med. Microbiol. 302, 40–4 (2012). 
178. Benes, J. et al. Relapsing endocarditis caused by Enterococcus faecalis forming 
small colony variants. Scand. J. Infect. Dis. 45, 800–3 (2013). 
179. Roggenkamp, A. et al. Chronic prosthetic hip infection caused by a small-colony 
variant of Escherichia coli. J. Clin. Microbiol. 36, 2530–4 (1998). 
180. Häussler, S., Tümmler, B., Weissbrodt, H., Rohde, M. & Steinmetz, I. Small-colony 
variants of Pseudomonas aeruginosa in cystic fibrosis. Clin. Infect. Dis. 29, 621–5 
(1999). 
181. Eckweiler, D., Bunk, B., Spröer, C., Overmann, J. & Häussler, S. Complete Genome 
Sequence of Highly Adherent Pseudomonas aeruginosa Small-Colony Variant 
SCV20265. Genome Announc. 2, e01232-13 (2014). 
182. Malone, J. G. et al. YfiBNR mediates cyclic di-GMP dependent small colony 
   
 
 
154 
variant formation and persistence in Pseudomonas aeruginosa. PLoS Pathog. 6, 
e1000804 (2010). 
183. Schaaff, F., Bierbaum, G., Baumert, N., Bartmann, P. & Sahl, H.-G. Mutations are 
involved in emergence of aminoglycoside-induced small colony variants of 
Staphylococcus aureus. Int. J. Med. Microbiol. 293, 427–35 (2003). 
184. Cui, L., Neoh, H., Iwamoto, A. & Hiramatsu, K. Coordinated phenotype switching 
with large-scale chromosome flip-flop inversion observed in bacteria. Proc. Natl. 
Acad. Sci. U. S. A. 109, E1647-56 (2012). 
185. Wolter, D. J. et al. Staphylococcus aureus small-colony variants are independently 
associated with worse lung disease in children with cystic fibrosis. Clin. Infect. Dis. 
57, 384–91 (2013). 
186. Sadowska, B. et al. Characteristics of Staphylococcus aureus , isolated from airways 
of cystic fibrosis patients, and their small colony variants. FEMS Immunol. Med. 
Microbiol. 32, 191–197 (2002). 
187. Bayston, R., Ashraf, W. & Smith, T. Triclosan resistance in methicillin-resistant 
Staphylococcus aureus expressed as small colony variants: a novel mode of evasion 
of susceptibility to antiseptics. J. Antimicrob. Chemother. 59, 848–53 (2007). 
188. Grant, S. S. & Hung, D. T. Persistent bacterial infections, antibiotic tolerance, and 
the oxidative stress response. Virulence 4, 273–83 (2013). 
189. Salunkhe, P. et al. A cystic fibrosis epidemic strain of Pseudomonas aeruginosa 
displays enhanced virulence and antimicrobial resistance. J. Bacteriol. 187, 4908–20 
(2005). 
190. Palma, M., DeLuca, D., Worgall, S. & Quadri, L. E. N. Transcriptome Analysis of 
the Response of Pseudomonas aeruginosa to Hydrogen Peroxide. J. Bacteriol. 186, 
248–252 (2003). 
191. Drenkard, E. & Ausubel, F. M. Pseudomonas biofilm formation and antibiotic 
resistance are linked to phenotypic variation. Nature 416, 740–3 (2002). 
192. Zhou, A. et al. Hydrogen peroxide-induced oxidative stress responses in 
Desulfovibrio vulgaris Hildenborough. Environ. Microbiol. 12, 2645–57 (2010). 
193. Folkesson, A. et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis 
airway: an evolutionary perspective. Nat. Rev. Microbiol. 10, 841–51 (2012). 
194. Simpson, J. A., Smith, S. E. & Dean, R. T. Scavenging by alginate of free radicals 
released by macrophages. Free Radic. Biol. Med. 6, 347–353 (1989). 
195. Meshulam, T., Verbrugh, H. A. & Verhoef, J. Opsonization and phagocytosis of 
mucoid and non-mucoidPseudomonas aeruginosa strains. Eur. J. Clin. Microbiol. 1, 
112–117 (1982). 
196. Meshulam, T., Obedeanu, N., Merzbach, D. & Sobel, J. D. Phagocytosis of mucoid 
and nonmucoid strains of Pseudomonas aeruginosa. Clin. Immunol. Immunopathol. 
32, 151–165 (1984). 
197. Wood, L. F. & Ohman, D. E. Identification of genes in the σ22 regulon of 
Pseudomonas aeruginosa required for cell envelope homeostasis in either the 
planktonic or the sessile mode of growth. MBio 3, e00094-12- (2012). 
198. Starkey, M. et al. Pseudomonas aeruginosa rugose small-colony variants have 
adaptations that likely promote persistence in the cystic fibrosis lung. J. Bacteriol. 
   
 
 
155 
191, 3492–503 (2009). 
199. Häussler, S. Biofilm formation by the small colony variant phenotype of 
Pseudomonas aeruginosa. Environ. Microbiol. 6, 546–51 (2004). 
200. Besier, S. et al. Prevalence and clinical significance of Staphylococcus aureus small-
colony variants in cystic fibrosis lung disease. J. Clin. Microbiol. 45, 168–72 
(2007). 
201. Kahl, B. et al. Persistent infection with small colony variant strains of 
Staphylococcus aureus in patients with cystic fibrosis. J. Infect. Dis. 177, 1023–9 
(1998). 
202. WHO | Antimicrobial resistance: global report on surveillance 2014. at 
<http://www.who.int/drugresistance/documents/surveillancereport/en/> 
203. Harris, S. R. et al. Evolution of MRSA during hospital transmission and 
intercontinental spread. Science 327, 469–74 (2010). 
204. Scottish Medicines Consortium About the Scottish Antimicrobial Prescribing Group 
(SAPG). at 
<https://www.scottishmedicines.org.uk/SAPG/Scottish_Antimicrobial_Prescribing_
Group__SAPG_> 
205. Technical Report The bacterial challenge: Time to react. at 
<http://ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Chal
lenge_Time_to_React.pdf> 
206. Lister, P. D., Wolter, D. J. & Hanson, N. D. Antibacterial-resistant Pseudomonas 
aeruginosa: clinical impact and complex regulation of chromosomally encoded 
resistance mechanisms. Clin. Microbiol. Rev. 22, 582–610 (2009). 
207. Giwercman, B., Lambert, P. A., Rosdahl, V. T., Shand, G. H. & Høiby, N. Rapid 
emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to 
in-vivo selection of stable partially derepressed beta-lactamase producing strains. J. 
Antimicrob. Chemother. 26, 247–59 (1990). 
208. Giwercman, B., Meyer, C., Lambert, P. A., Reinert, C. & Høiby, N. High-level beta-
lactamase activity in sputum samples from cystic fibrosis patients during 
antipseudomonal treatment. Antimicrob. Agents Chemother. 36, 71–6 (1992). 
209. Stewart, P. S. Mechanisms of antibiotic resistance in bacterial biofilms. Int. J. Med. 
Microbiol. 292, 107–13 (2002). 
210. Delcour, A. H. Outer membrane permeability and antibiotic resistance. Biochim. 
Biophys. Acta 1794, 808–16 (2009). 
211. Schwartz, T. et al. Whole genome and transcriptome analyses of environmental 
antibiotic sensitive and multi-resistant Pseudomonas aeruginosa isolates exposed to 
waste water and tap water. Microb. Biotechnol. 8, 116–30 (2015). 
212. Hancock, R. E. W. & Brinkman, F. S. L. Function of pseudomonas porins in uptake 
and efflux. Annu. Rev. Microbiol. 56, 17–38 (2002). 
213. Li, H., Luo, Y.-F., Williams, B. J., Blackwell, T. S. & Xie, C.-M. Structure and 
function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to 
novel therapies. Int. J. Med. Microbiol. 302, 63–8 (2012). 
214. El Amin, N. et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: 
alterations of porin OprD and efflux proteins do not fully explain resistance patterns 
   
 
 
156 
observed in clinical isolates. APMIS 113, 187–96 (2005). 
215. MacLeod, D. L. et al. Aminoglycoside-resistance mechanisms for cystic fibrosis 
Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled 
tobramycin treatment. J. Infect. Dis. 181, 1180–4 (2000). 
216. Boles, B. R., Thoendel, M. & Singh, P. K. Self-generated diversity produces 
‘insurance effects’ in biofilm communities. Proc. Natl. Acad. Sci. U. S. A. 101, 
16630–16635 (2004). 
217. Zhao, K. et al. Psl trails guide exploration and microcolony formation in 
Pseudomonas aeruginosa biofilms. Nature 497, 388–91 (2013). 
218. Haussler, S. Highly adherent small-colony variants of Pseudomonas aeruginosa in 
cystic fibrosis lung infection. J. Med. Microbiol. 52, 295–301 (2003). 
219. Davies, D. Understanding biofilm resistance to antibacterial agents. Nat. Rev. Drug 
Discov. 2, 114–22 (2003). 
220. Driffield, K., Miller, K., Bostock, J. M., O’Neill, A. J. & Chopra, I. Increased 
mutability of Pseudomonas aeruginosa in biofilms. J. Antimicrob. Chemother. 61, 
1053–6 (2008). 
221. Molin, S. & Tolker-Nielsen, T. Gene transfer occurs with enhanced efficiency in 
biofilms and induces enhanced stabilisation of the biofilm structure. Curr. Opin. 
Biotechnol. 14, 255–61 (2003). 
222. Ciofu, O., Riis, B., Pressler, T., Poulsen, H. E. & Høiby, N. Occurrence of 
hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with 
the oxidative stress caused by chronic lung inflammation. Antimicrob. Agents 
Chemother. 49, 2276–82 (2005). 
223. Oliver, A., Cantón, R., Campo, P., Baquero, F. & Blázquez, J. High frequency of 
hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 
288, 1251–4 (2000). 
224. de Beer, D., Stoodley, P. & Lewandowski, Z. Measurement of local diffusion 
coefficients in biofilms by microinjection and confocal microscopy. Biotechnol. 
Bioeng. 53, 151–8 (1997). 
225. Bagge, N. et al. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit 
changes in global gene expression and beta-lactamase and alginate production. 
Antimicrob. Agents Chemother. 48, 1175–87 (2004). 
226. Wood, L. F., Leech, A. J. & Ohman, D. E. Cell wall-inhibitory antibiotics activate 
the alginate biosynthesis operon in Pseudomonas aeruginosa: Roles of sigma (AlgT) 
and the AlgW and Prc proteases. Mol. Microbiol. 62, 412–26 (2006). 
227. Hansen, C. R., Pressler, T. & Høiby, N. Early aggressive eradication therapy for 
intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 
15 years experience. J. Cyst. Fibros. 7, 523–30 (2008). 
228. Al-Dhaheri, R. S. & Douglas, L. J. Absence of amphotericin B-tolerant persister 
cells in biofilms of some Candida species. Antimicrob. Agents Chemother. 52, 
1884–7 (2008). 
229. Lewis, K. Multidrug tolerance of biofilms and persister cells. Curr. Top. Microbiol. 
Immunol. 322, 107–31 (2008). 
230. Roberts, M. E. & Stewart, P. S. Modelling protection from antimicrobial agents in 
   
 
 
157 
biofilms through the formation of persister cells. Microbiology 151, 75–80 (2005). 
231. Motta, S. S. et al. Adaptive Resistance in Bacteria Requires Epigenetic Inheritance, 
Genetic Noise, and Cost of Efflux Pumps. PLoS One 10, e0118464 (2015). 
232. Turner, K. H., Vallet-Gely, I. & Dove, S. L. Epigenetic control of virulence gene 
expression in Pseudomonas aeruginosa by a LysR-type transcription regulator. PLoS 
Genet. 5, e1000779 (2009). 
233. Veening, J.-W., Smits, W. K. & Kuipers, O. P. Bistability, epigenetics, and bet-
hedging in bacteria. Annu. Rev. Microbiol. 62, 193–210 (2008). 
234. Fang, G. et al. Genome-wide mapping of methylated adenine residues in pathogenic 
Escherichia coli using single-molecule real-time sequencing. Nat. Biotechnol. 30, 
1232–9 (2012). 
235. Motta, S. S. et al. Adaptive Resistance in Bacteria Requires Epigenetic Inheritance, 
Genetic Noise, and Cost of Efflux Pumps. PLoS One 10, e0118464 (2015). 
236. Croucher, N. J. & Thomson, N. R. Studying bacterial transcriptomes using RNA-
seq. Curr. Opin. Microbiol. 13, 619–24 (2010). 
237. Woolhouse, M. & Farrar, J. Policy: An intergovernmental panel on antimicrobial 
resistance. Nature 509, 555–557 (2014). 
238. Gilbert, K. B., Kim, T. H., Gupta, R., Greenberg, E. P. & Schuster, M. Global 
position analysis of the Pseudomonas aeruginosa quorum-sensing transcription 
factor LasR. Mol. Microbiol. 73, 1072–85 (2009). 
239. Yu, X. et al. Transcriptional analysis of the global regulatory networks active in 
Pseudomonas syringae during leaf colonization. MBio 5, e01683-14 (2014). 
240. Kalghatgi, S. et al. Bactericidal antibiotics induce mitochondrial dysfunction and 
oxidative damage in Mammalian cells. Sci. Transl. Med. 5, 192ra85 (2013). 
241. Side effects of long-term antibiotic use linked to oxidative stress | Scope Blog. at 
<http://scopeblog.stanford.edu/2013/07/05/side-effects-of-long-term-antibiotic-use-
linked-to-oxidative-stress/> 
242. Hassett, D. J. & Imlay, J. A. Bactericidal antibiotics and oxidative stress: a radical 
proposal. ACS Chem. Biol. 2, 708–10 (2007). 
243. Kuczyńska-Wiśnik, D. et al. Antibiotics promoting oxidative stress inhibit 
formation of Escherichia coli biofilm via indole signalling. Res. Microbiol. 161, 
847–53 (2010). 
244. Nguyen, D. et al. Active starvation responses mediate antibiotic tolerance in 
biofilms and nutrient-limited bacteria. Science 334, 982–6 (2011). 
245. Shatalin, K., Shatalina, E., Mironov, A. & Nudler, E. H2S: a universal defense 
against antibiotics in bacteria. Science 334, 986–90 (2011). 
246. Ochsner, U. A., Wilderman, P. J., Vasil, A. I. & Vasil, M. L. GeneChip expression 
analysis of the iron starvation response in Pseudomonas aeruginosa: identification of 
novel pyoverdine biosynthesis genes. Mol. Microbiol. 45, 1277–87 (2002). 
247. Palma, M., Worgall, S. & Quadri, L. E. N. Transcriptome analysis of the 
Pseudomonas aeruginosa response to iron. Arch. Microbiol. 180, 374–9 (2003). 
248. Teitzel, G. M. et al. Survival and growth in the presence of elevated copper: 
transcriptional profiling of copper-stressed Pseudomonas aeruginosa. J. Bacteriol. 
   
 
 
158 
188, 7242–56 (2006). 
249. Aspedon, A., Palmer, K. & Whiteley, M. Microarray analysis of the osmotic stress 
response in Pseudomonas aeruginosa. J. Bacteriol. 188, 2721–5 (2006). 
250. Dötsch, A. et al. The Pseudomonas aeruginosa Transcriptome in Planktonic 
Cultures and Static Biofilms Using RNA Sequencing. PLoS One 7, e31092 (2012). 
251. Wurtzel, O. et al. The single-nucleotide resolution transcriptome of Pseudomonas 
aeruginosa grown in body temperature. PLoS Pathog. 8, e1002945 (2012). 
252. Koboldt, D. C., Steinberg, K. M., Larson, D. E., Wilson, R. K. & Mardis, E. R. The 
next-generation sequencing revolution and its impact on genomics. Cell 155, 27–38 
(2013). 
253. Next Generation Sequencing Channel, A Revolution in Technology | Bitesize Bio. 
at <http://bitesizebio.com/13543/introducing-the-next-generation-sequencing-
channel-part-1-ngs-a-revolution-in-technology/> 
254. Mardis, E. R. Next-generation sequencing platforms. Annu. Rev. Anal. Chem. (Palo 
Alto. Calif). 6, 287–303 (2013). 
255. Quick, J. et al. Real-time, portable genome sequencing for Ebola surveillance. 
Nature 530, 228–232 (2016). 
256. Azarian, T. et al. Whole-genome sequencing for outbreak investigations of 
methicillin-resistant Staphylococcus aureus in the neonatal intensive care unit: time 
for routine practice? Infect. Control Hosp. Epidemiol. 36, 777–85 (2015). 
257. Harris, S. R. et al. Whole-genome sequencing for analysis of an outbreak of 
meticillin-resistant Staphylococcus aureus: a descriptive study. Lancet. Infect. Dis. 
13, 130–6 (2013). 
258. Peacock, S. J. & Weinstock, G. M. Microbial sequencing to improve individual and 
population health. Genome Med. 6, 103 (2014). 
259. Quail, M. A. et al. A tale of three next generation sequencing platforms: comparison 
of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 
13, 341 (2012). 
260. Korlach, J. et al. Real-time DNA sequencing from single polymerase molecules. 
Methods Enzymol. 472, 431–55 (2010). 
261. Roberts, R., Carneiro, M. & Schatz, M. The advantages of SMRT sequencing. 
Genome Biol. 14, 405 (2013). 
262. Koren, S. et al. Reducing assembly complexity of microbial genomes with single-
molecule sequencing. Genome Biol. 14, R101 (2013). 
263. Powers, J. G. et al. Efficient and accurate whole genome assembly and methylome 
profiling of E. coli. BMC Genomics 14, 675 (2013). 
264. Murray, I. A. et al. The methylomes of six bacteria. Nucleic Acids Res. 40, 11450–
62 (2012). 
265. van Heeckeren, A. M. & Schluchter, M. D. Murine models of chronic Pseudomonas 
aeruginosa lung infection. Lab. Anim. 36, 291–312 (2002). 
266. Davis, M. R. & Goldberg, J. B. Purification and visualization of lipopolysaccharide 
from Gram-negative bacteria by hot aqueous-phenol extraction. J. Vis. Exp. (2012). 
doi:10.3791/3916 
   
 
 
159 
267. Erlandsen, S. L., Kristich, C. J., Dunny, G. M. & Wells, C. L. High-resolution 
visualization of the microbial glycocalyx with low-voltage scanning electron 
microscopy: dependence on cationic dyes. J. Histochem. Cytochem. 52, 1427–35 
(2004). 
268. Secretion Assay in Shigella flexneri —BIO-PROTOCOL. at <http://www.bio-
protocol.org/e1302> 
269. Dasgupta, N., Ashare, A., Hunninghake, G. W. & Yahr, T. L. Transcriptional 
induction of the Pseudomonas aeruginosa type III secretion system by low Ca2+ and 
host cell contact proceeds through two distinct signaling pathways. Infect. Immun. 
74, 3334–41 (2006). 
270. Ramarao, N., Nielsen-Leroux, C. & Lereclus, D. The insect Galleria mellonella as a 
powerful infection model to investigate bacterial pathogenesis. J. Vis. Exp. e4392 
(2012). doi:10.3791/4392 
271. Jander, G., Rahme, L. G. & Ausubel, F. M. Positive correlation between virulence 
of Pseudomonas aeruginosa mutants in mice and insects. J. Bacteriol. 182, 3843–5 
(2000). 
272. Hoegy, F., Mislin, G. L. A. & Schalk, I. J. Pyoverdine and pyochelin measurements. 
Methods Mol. Biol. 1149, 293–301 (2014). 
273. Grothues, D., Koopmann, U., von der Hardt, H. & Tümmler, B. Genome 
fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis 
siblings with closely related strains. J. Clin. Microbiol. 26, 1973–7 (1988). 
274. Grothues, D., Koopmann, U., von der Hardt, H. & Tümmler, B. Genome 
fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis 
siblings with closely related strains. J. Clin. Microbiol. 26, 1973–7 (1988). 
275. Lim, Y. W. et al. Metagenomics and metatranscriptomics: Windows on CF-
associated viral and microbial communities. J. Cyst. Fibros. 12, 154–164 (2013). 
276. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–
8 (2001). 
277. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and 
quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5, 621–8 
(2008). 
278. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics 25, 1754–60 (2009). 
279. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration 
discovery in cancer by exome sequencing. Genome Res. 22, 568–76 (2012). 
280. Seemann, T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30, 
2068–9 (2014). 
281. Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L. & Leibler, S. Bacterial persistence 
as a phenotypic switch. Science 305, 1622–5 (2004). 
282. Lewis, K. Persister cells: molecular mechanisms related to antibiotic tolerance. 
Handb. Exp. Pharmacol. 121–33 (2012). doi:10.1007/978-3-642-28951-4_8 
283. Dawson, C. C., Intapa, C. & Jabra-Rizk, M. A. ‘Persisters’: survival at the cellular 
level. PLoS Pathog. 7, e1002121 (2011). 
   
 
 
160 
284. Marrakchi, M., Liu, X. & Andreescu, S. Oxidative stress and antibiotic resistance in 
bacterial pathogens: state of the art, methodologies, and future trends. Adv. Exp. 
Med. Biol. 806, 483–98 (2014). 
285. Nelson, L. K. et al. Phenotypic diversification in vivo: Pseudomonas aeruginosa 
gacS- strains generate small colony variants in vivo that are distinct from in vitro 
variants. Microbiology 156, 3699–709 (2010). 
286. Moisan, H. et al. Transcription of virulence factors in Staphylococcus aureus small-
colony variants isolated from cystic fibrosis patients is influenced by SigB. J. 
Bacteriol. 188, 64–76 (2006). 
287. Malone, J. G. Role of small colony variants in persistence of Pseudomonas 
aeruginosa infections in cystic fibrosis lungs. Infect. Drug Resist. 8, 237–47 (2015). 
288. Hoffmann, N. et al. Novel mouse model of chronic Pseudomonas aeruginosa lung 
infection mimicking cystic fibrosis. Infect. Immun. 73, 2504–14 (2005). 
289. Boucher, J. C., Yu, H., Mudd, M. H. & Deretic, V. Mucoid Pseudomonas 
aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates 
and analysis of clearance in a mouse model of respiratory infection. Infect. Immun. 
65, 3838–46 (1997). 
290. Bjarnsholt, T. et al. Pseudomonas aeruginosa biofilms in the respiratory tract of 
cystic fibrosis patients. Pediatr. Pulmonol. 44, 547–58 (2009). 
291. Meyer, J. M., Neely, A., Stintzi, A., Georges, C. & Holder, I. A. Pyoverdin is 
essential for virulence of Pseudomonas aeruginosa. Infect. Immun. 64, 518–23 
(1996). 
292. Cryz, S. J. J., Pitt, T. L., Furer, E. & Germanier, R. Role of lipopolysaccharide in 
virulence of Pseudomonas aeruginosa. Infect. Immun. 44, 508–513 (1984). 
293. Wang, D. et al. Adaptation genomics of a small-colony variant in a Pseudomonas 
chlororaphis 30-84 biofilm. Appl. Environ. Microbiol. 81, 890–9 (2015). 
294. Besier, S. et al. Prevalence and clinical significance of Staphylococcus aureus small-
colony variants in cystic fibrosis lung disease. J. Clin. Microbiol. 45, 168–72 
(2007). 
295. Morris, J. F., Barnes, C. G. & Sellers, T. F. An Outbreak of Typhoid Fever Due to 
the Small Colony Variety of Eberthella typhosa*. (1943). 
296. Sabra, W., Haddad, A. M. & Zeng, A.-P. Comparative physiological study of the 
wild type and the small colony variant of Pseudomonas aeruginosa 20265 under 
controlled growth conditions. World J. Microbiol. Biotechnol. 30, 1027–36 (2014). 
297. Mah, T. F. & O’Toole, G. A. Mechanisms of biofilm resistance to antimicrobial 
agents. Trends Microbiol. 9, 34–9 (2001). 
298. Neut, D., Hendriks, J. G. E., van Horn, J. R., van der Mei, H. C. & Busscher, H. J. 
Pseudomonas aeruginosa biofilm formation and slime excretion on antibiotic-loaded 
bone cement. Acta Orthop. 76, 109–14 (2005). 
299. Schwarzmann, S. & Boring, J. R. Antiphagocytic Effect of Slime from a Mucoid 
Strain of Pseudomonas aeruginosa. Infect. Immun. 3, 762–7 (1971). 
300. LaFleur, M. D., Kumamoto, C. A. & Lewis, K. Candida albicans biofilms produce 
antifungal-tolerant persister cells. Antimicrob. Agents Chemother. 50, 3839–46 
(2006). 
   
 
 
161 
301. Gerber, A. U., Vastola, A. P., Brandel, J. & Craig, W. A. Selection of 
Aminoglycoside-Resistant Variants of Pseudomonas aeruginosa in an in Vivo 
Model. J. Infect. Dis. 146, 691–697 (1982). 
302. Britigan, B. E., Rasmussen, G. T., Olakanmi, O. & Cox, C. D. Iron acquisition from 
Pseudomonas aeruginosa siderophores by human phagocytes: an additional 
mechanism of host defense through iron sequestration? Infect. Immun. 68, 1271–5 
(2000). 
303. Matthijs, S. et al. Siderophore-mediated iron acquisition in the entomopathogenic 
bacterium Pseudomonas entomophila L48 and its close relative Pseudomonas putida 
KT2440. Biometals 22, 951–64 (2009). 
304. Vinckx, T., Matthijs, S. & Cornelis, P. Loss of the oxidative stress regulator OxyR 
in Pseudomonas aeruginosa PAO1 impairs growth under iron-limited conditions. 
FEMS Microbiol. Lett. 288, 258–65 (2008). 
305. Luzar, M. A. & Montie, T. C. Avirulence and altered physiological properties of 
cystic fibrosis strains of Pseudomonas aeruginosa. Infect. Immun. 50, 572–6 (1985). 
306. Burke, V., Robinson, J. O., Richardson, C. J. & Bundell, C. S. Longitudinal studies 
of virulence factors of Pseudomonas aeruginosa in cystic fibrosis. Pathology 23, 
145–8 (1991). 
307. Burke, V., Robinson, J. O., Richardson, C. J. & Bundell, C. S. Longitudinal studies 
of virulence factors of Pseudomonas aeruginosa in cystic fibrosis. Pathology 23, 
145–8 (1991). 
308. Kay, E. et al. Two GacA-dependent small RNAs modulate the quorum-sensing 
response in Pseudomonas aeruginosa. J. Bacteriol. 188, 6026–33 (2006). 
309. Schmidt, K. D., Tümmler, B. & Römling, U. Comparative genome mapping of 
Pseudomonas aeruginosa PAO with P. aeruginosa C, which belongs to a major clone 
in cystic fibrosis patients and aquatic habitats. J. Bacteriol. 178, 85–93 (1996). 
310. Römling, U., Schmidt, K. D. & Tümmler, B. Large genome rearrangements 
discovered by the detailed analysis of 21 Pseudomonas aeruginosa clone C isolates 
found in environment and disease habitats. J. Mol. Biol. 271, 386–404 (1997). 
311. Mahan, M. J. & Roth, J. R. Ability of a bacterial chromosome segment to invert is 
dictated by included material rather than flanking sequence. Genetics 129, 1021–32 
(1991). 
312. Schmidt, K. D., Tümmler, B. & Römling, U. Comparative genome mapping of 
Pseudomonas aeruginosa PAO with P. aeruginosa C, which belongs to a major clone 
in cystic fibrosis patients and aquatic habitats. J. Bacteriol. 178, 85–93 (1996). 
313. Malone, J. G. et al. The YfiBNR signal transduction mechanism reveals novel 
targets for the evolution of persistent Pseudomonas aeruginosa in cystic fibrosis 
airways. PLoS Pathog. 8, e1002760 (2012). 
314. Smania, A. M. Emergence of phenotypic variants upon mismatch repair disruption 
in Pseudomonas aeruginosa. Microbiology 150, 1327–1338 (2004). 
315. Martínez-Granero, F. et al. The Gac-Rsm and SadB signal transduction pathways 
converge on AlgU to downregulate motility in Pseudomonas fluorescens. PLoS One 
7, e31765 (2012). 
316. Pseudomonas aeruginosa DK2 - Ensembl Genomes. at 
<http://bacteria.ensembl.org/Pseudomonas_aeruginosa_dk2/Info/Index> 
   
 
 
162 
317. Carver, T., Thomson, N., Bleasby, A., Berriman, M. & Parkhill, J. DNAPlotter: 
circular and linear interactive genome visualization. Bioinformatics 25, 119–20 
(2009). 
318. Davis, B. M., Chao, M. C. & Waldor, M. K. Entering the era of bacterial 
epigenomics with single molecule real time DNA sequencing. Curr. Opin. 
Microbiol. 16, 192–8 (2013). 
319. ANGERS, B., CASTONGUAY, E. & MASSICOTTE, R. Environmentally induced 
phenotypes and DNA methylation: how to deal with unpredictable conditions until 
the next generation and after. Mol. Ecol. 19, 1283–1295 (2010). 
320. Bierne, H., Hamon, M. & Cossart, P. Epigenetics and bacterial infections. Cold 
Spring Harb. Perspect. Med. 2, a010272 (2012). 
321. Casadesús, J. & Low, D. A. Programmed heterogeneity: epigenetic mechanisms in 
bacteria. J. Biol. Chem. 288, 13929–35 (2013). 
322. Melter, O. & Radojevič, B. Small colony variants of Staphylococcus aureus--
review. Folia Microbiol. (Praha). 55, 548–58 (2010). 
323. Mena, A. et al. Genetic adaptation of Pseudomonas aeruginosa to the airways of 
cystic fibrosis patients is catalyzed by hypermutation. J. Bacteriol. 190, 7910–7 
(2008). 
324. Marvig, R. L., Sommer, L. M., Molin, S. & Johansen, H. K. Convergent evolution 
and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat. 
Genet. 47, 57–64 (2014). 
325. Barekzi, N. et al. High-Frequency Flp Recombinase-Mediated Inversions of the 
oriC-Containing Region of the Pseudomonas aeruginosa Genome. J. Bacteriol. 182, 
7070–7074 (2000). 
326. B, R.-C., N, K. & GM, C. Appropriate maturation and folding of 16S rRNA during 
30S subunit biogenesis are critical for translational fidelity. Proc. Natl. Acad. Sci. U. 
S. A. 107, 4567–4572 (2010). 
327. Gerasimova, Y. V & Kolpashchikov, D. M. Folding of 16S rRNA in a signal-
producing structure for the detection of bacteria. Angew. Chem. Int. Ed. Engl. 52, 
10586–8 (2013). 
328. Roy-Chaudhuri, B., Kirthi, N. & Culver, G. M. Appropriate maturation and folding 
of 16S rRNA during 30S subunit biogenesis are critical for translational fidelity. 
329. Iorio, M. V., Piovan, C. & Croce, C. M. Interplay between microRNAs and the 
epigenetic machinery: An intricate network. Biochim. Biophys. Acta - Gene Regul. 
Mech. 1799, 694–701 (2010). 
330. Chuang, J. C. & Jones, P. A. Epigenetics and microRNAs. Pediatr. Res. 61, 24R–
29R (2007). 
331. Sato, F., Tsuchiya, S., Meltzer, S. J. & Shimizu, K. MicroRNAs and epigenetics. 
FEBS J. 278, 1598–609 (2011). 
332. Non-Coding RNA | What is Epigenetics? at 
<http://www.whatisepigenetics.com/non-coding-rna/> 
333. Alonso, A., Rojo, F. & Martínez, J. L. Environmental and clinical isolates of 
Pseudomonas aeruginosa show pathogenic and biodegradative properties 
irrespective of their origin. Environ. Microbiol. 1, 421–30 (1999). 
   
 
 
163 
334. Gripenland, J. et al. RNAs: regulators of bacterial virulence. Nat. Rev. Microbiol. 8, 
857–66 (2010). 
335. Waters, L. S. & Storz, G. Regulatory RNAs in bacteria. Cell 136, 615–28 (2009). 
336. Lease, R. A., Cusick, M. E. & Belfort, M. Riboregulation in Escherichia coli: DsrA 
RNA acts by RNA:RNA interactions at multiple loci. Proc. Natl. Acad. Sci. U. S. A. 
95, 12456–61 (1998). 
337. Sonnleitner, E. et al. Detection of small RNAs in Pseudomonas aeruginosa by 
RNomics and structure-based bioinformatic tools. Microbiology 154, 3175–87 
(2008). 
338. van Vliet, A. H. M. Next generation sequencing of microbial transcriptomes: 
challenges and opportunities. FEMS Microbiol. Lett. 302, 1–7 (2010). 
339. Loman, N. J. et al. High-throughput bacterial genome sequencing: an 
embarrassment of choice, a world of opportunity. Nat. Rev. Microbiol. 10, 599–606 
(2012). 
340. Giannoukos, G. et al. Efficient and robust RNA-seq process for cultured bacteria 
and complex community transcriptomes. Genome Biol. 13, R23 (2012). 
341. Mathee, K., McPherson, C. J. & Ohman, D. E. Posttranslational control of the algT 
(algU)-encoded sigma22 for expression of the alginate regulon in Pseudomonas 
aeruginosa and localization of its antagonist proteins MucA and MucB (AlgN). J. 
Bacteriol. 179, 3711–20 (1997). 
342. Stintzi, A., Evans, K., Meyer, J. & Poole, K. Quorum-sensing and siderophore 
biosynthesis in Pseudomonas aeruginosa: lasRllasI mutants exhibit reduced 
pyoverdine biosynthesis. FEMS Microbiol. Lett. 166, 341–345 (1998). 
343. Deep, A., Chaudhary, U. & Gupta, V. Quorum sensing and Bacterial Pathogenicity: 
From Molecules to Disease. J. Lab. Physicians 3, 4–11 (2011). 
344. Lee, J.-S., Heo, Y.-J., Lee, J. K. & Cho, Y.-H. KatA, the major catalase, is critical 
for osmoprotection and virulence in Pseudomonas aeruginosa PA14. Infect. Immun. 
73, 4399–403 (2005). 
345. Ochsner, U. A., Vasil, M. L., Alsabbagh, E., Parvatiyar, K. & Hassett, D. J. Role of 
the Pseudomonas aeruginosa oxyR-recG Operon in Oxidative Stress Defense and 
DNA Repair: OxyR-Dependent Regulation of katB-ankB, ahpB, and ahpC-ahpF. J. 
Bacteriol. 182, 4533–4544 (2000). 
346. Ochsner, U. A., Vasil, M. L., Alsabbagh, E., Parvatiyar, K. & Hassett, D. J. Role of 
the Pseudomonas aeruginosa oxyR-recG operon in oxidative stress defense and 
DNA repair: OxyR-dependent regulation of katB-ankB, ahpB, and ahpC-ahpF. J. 
Bacteriol. 182, 4533–44 (2000). 
347. Chung, J.-S. et al. Interaction domain on thioredoxin for Pseudomonas aeruginosa 
5’-adenylylsulfate reductase. J. Biol. Chem. 284, 31181–9 (2009). 
348. Hishinuma, S., Ohtsu, I., Fujimura, M. & Fukumori, F. OxyR is involved in the 
expression of thioredoxin reductase TrxB in Pseudomonas putida. FEMS Microbiol. 
Lett. 289, 138–45 (2008). 
349. Tielker, D. et al. Pseudomonas aeruginosa lectin LecB is located in the outer 
membrane and is involved in biofilm formation. Microbiology 151, 1313–23 (2005). 
350. Frederiksen, R. F. et al. Bacterial chitinases and chitin-binding proteins as virulence 
   
 
 
164 
factors. Microbiology 159, 833–47 (2013). 
351. Sanchez, P. Fitness of in vitro selected Pseudomonas aeruginosanalB and nfxB 
multidrug resistant mutants. J. Antimicrob. Chemother. 50, 657–664 (2002). 
352. Cezairliyan, B. et al. Identification of Pseudomonas aeruginosa phenazines that kill 
Caenorhabditis elegans. PLoS Pathog. 9, e1003101 (2013). 
353. Ulanova, M. et al. The clonal antibody response to Pseudomonas aeruginosa heat 
shock protein is highly diverse in cystic fibrosis patients. APMIS 105, 449–56 
(1997). 
354. Painter, K. L. et al. Staphylococcus aureus adapts to oxidative stress by producing 
H2O2-resistant small colony variants via the SOS response. Infect. Immun. 83, 
1830–1844 (2015). 
355. Lim, C. K. et al. The Effect of Iron Limitation on the Transcriptome and Proteome 
of Pseudomonas fluorescens Pf-5. PLoS One 7, e39139 (2012). 
356. Mikkelsen, H., Sivaneson, M. & Filloux, A. Key two-component regulatory systems 
that control biofilm formation in Pseudomonas aeruginosa. Environ. Microbiol. 13, 
1666–81 (2011). 
357. Wittekindt, N. E. et al. Nodeomics: pathogen detection in vertebrate lymph nodes 
using meta-transcriptomics. PLoS One 5, e13432 (2010). 
358. SANDERS, N. N. et al. Cystic Fibrosis Sputum. 
http://dx.doi.org/10.1164/ajrccm.162.5.9909009 (2012). 
359. Chen, Z. & Duan, X. Ribosomal RNA depletion for massively parallel bacterial 
RNA-sequencing applications. Methods Mol. Biol. 733, 93–103 (2011). 
360. Small Colony Variants of Pseudomonas aeruginosa in Cystic Fibrosis. at 
<http://cid.oxfordjournals.org/content/29/3/621.full.pdf> 
361. Brackman, G. & Coenye, T. Quorum sensing inhibitors as anti-biofilm agents. Curr. 
Pharm. Des. 21, 5–11 (2015). 
362. Høiby, N., Bjarnsholt, T., Givskov, M., Molin, S. & Ciofu, O. Antibiotic resistance 
of bacterial biofilms. Int. J. Antimicrob. Agents 35, 322–32 (2010). 
363. Mandal, M. D. & Mandal, S. Honey: its medicinal property and antibacterial 
activity. Asian Pac. J. Trop. Biomed. 1, 154–60 (2011). 
 
 
 
 
 
  
   
 
 
165 
 
Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
166 
A.  Participant Information Leaflet 
 
Please reply to: Dr Sharon Irvine 
   B429, Level 4 
   Biomedical Research Centre 
   University of Glasgow 
   G12 8QQ 
   Tel: 01413308133, Mobile: 07736231751 
   E-mail: Sharon.irvine@glasgow.ac.uk 
 
Participant Information Leaflet 
 
1. Study title 
A study to look at the changes in RNA production of bacteria within the cystic fibrosis 
lung and mechanisms by which bacteria become resistant to antibiotics. 
 
Study Doctor:  Sharon Irvine 
Chief Investigator:  Dr D Walker 
 
You are being invited to take part in a research study.  Before you decide it is important for 
you to understand why the research is being done and what it will involve.  Please take 
time to read the following information carefully and discuss it with others if you wish.  
Ask us if there is anything that is not clear or if you would like more information.  Take 
time to decide whether or not you wish to take part.  
 
2. What is the purpose of the study? 
This project aims to discover the mechanisms by which bacteria become resistant to 
antibiotics.  Such resistance is widespread and growing and the development of novel 
antibiotics is much needed. Rather than study the changes in the DNA of bacteria that 
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underlie resistance, we will study the changes in RNA produced by bacteria following 
antibiotics. RNA is the ‘messenger’ of DNA that directs which proteins the bacteria makes. 
The pattern of RNA production alters depending on the bacterial environment. We will 
study these changes in the bacterium Pseudomonas aeruginosa found in the airways of 
patients with cystic fibrosis, an inherited disease that leads to infection in the airways with 
this microbe. By following the changes in the pattern of RNA produced in patients 
following antibiotic exposure, we will identify novel targets for drugs that can prevent 
bacterial growth.  
This study will be carried out over a period of approximately 2 years. 
3. Why have I been chosen? 
You have been chosen because you have cystic fibrosis and are aged between 16 and 40.  
The bacteria which we are interested in is found in high numbers within the airways of 
cystic fibrosis patients which allows us to look at the genetic material within this organism.  
We hope to recruit approximately 20 patients to this study. 
4. Do I have to take part? 
It is up to you whether or not to take part.  If you decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form.  If you decide to take part 
you are still free to withdraw at any time without giving a reason. 
 
5. What will happen to me if I take part? 
If you are happy with the information and agree to participate you will attend the Cystic 
Fibrosis Unit in Gartnavel General where any remaining queries will be discussed. 
 
We are looking to recruit 3 different groups of patient.  The first group will be stable, on 
regular nebulised antibiotics only.  An initial sputum sample will be routinely obtained on 
day 1 and then following inhaled therapy at weekly intervals over a 3-week period.  This 
will be repeated approximately 1 year later.  The second group will be patients who have 
been newly colonised with Pseudomonas aeruginosa.  Sputum samples will be obtained on 
day 1 and then at regular intervals during routine visits while on therapy until sputum 
production ceases.  The third group will be chronically colonised patients who are 
undergoing an infective exacerbation.  Samples will be routinely collected on day 1 and 
then at regular intervals during the exacerbation until resolution. 
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Sputum samples will be obtained during your routine visits to the Cystic Fibrosis Unit 
during the study period.  It is essential that the sputum samples are immediately frozen 
following expectoration to ensure the bacteria remain in a stable state to give us an idea of 
how they behave inside your lungs.  Once the sputum samples have been collected they 
will be analysed within a separate laboratory. 
 
6.  What do I have to do? 
You can carry on as normal and there are no restrictions on your daily activities.  The only 
thing we ask is that you are able to attend the unit to enable collection of the sputum 
sample. 
 
7.  What are the possible disadvantages and risks of taking part? 
The only disadvantage of taking part is the inconvenience of having to attend the unit to 
provide the sputum samples.  No blood sampling or other invasive samples are required. 
 
8.  What are the possible benefits of taking part? 
The information gained during this study will hopefully enable future research into 
developing new antibiotic targets to treat the complex bacterial infections in cystic fibrosis. 
 
 
9.  Will my taking part be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential.  You will be identified by an ID number and any information about 
you will have your name and address removed so that you cannot be recognised from it. 
 
10.  What will happen to the results of the research study? 
The results of the study will be published and used in further research aimed at antibiotic 
development.  We will also provide full feedback from the study to all participants. 
 
11.  What will happen to my samples after the study has finished? 
The sputum samples which you provide for this study will be processed to extract 
information from the bacteria within the samples.   The samples will be analysed in such a 
way that the results will not be directly traceable to you.  This information may then be 
used for future research.  A separate aliquot of the sample will be stored for the entire 
period of the research project.  
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12.  What will happen if I don’t want to carry on with the study? 
You can withdraw at any time from the study.  If you wish to withdraw from the study, we 
will retain the data that has been collected up to your withdrawal.  However, should you 
wish for samples and data to be destroyed we will comply with this request. 
 
13.  Who is organising and funding the research? 
The study is funded by the Medical Research Council (MRC) 
 
14.  Further information 
If you wish to ask further information about the study now or at any time, please contact 
the study doctor, Dr Sharon Irvine.  She can be contacted as above, by phone or e-mail, to 
discuss anything or meet in person.  You can also contact Professor T Evans at any time to 
discuss any other details: 
Details: Dr D Walker 
  Level 2 GBRC 
  120 University Place 
  G12 8TA 
 
Other Contact: Dr Neil Ritchie 
   Level 4 GBRC 
   120 University place 
   G12 8TA 
   E-mail: neil.ritchie@glasgow.ac.uk 
  
 
Thank you for taking time to read this information sheet and for agreeing to take 
part in this study…  
 
 
 
 
 
   
 
 
170 
B.  Consent Form 
 
Centre Number:  
Study Number:  
Patient Identification number for this trial: 
 
CONSENT FORM 
 
Title of Project: Transcriptome analysis of Pseudomonas aeruginosa under 
antibiotic pressure 
 
Name of Researcher: Dr Sharon Irvine  
Principal Investigator:  Dr D Walker 
 
        Please initial box 
 
1. I confirm that I have read and understood the information sheet (version 1, 08/01/13) 
for the above study and have had the opportunity to ask questions. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any    
time, without giving any reason and without my medical care or legal rights being affected  
 
 
3. I understand that sections of any medical notes may be looked at by responsible 
individuals involved directly with this study where it is relevant to my taking part in this 
research study.  I give permission for these individuals to have access to my records. 
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4. I agree to take part in the above study. 
 
 
__________________    _____________  ___________ 
Name of subject   Date    Signature 
 
 
________________________ _________________  _______________ 
Name of researcher/Person  Date    Signature 
taking consent 
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C.  Gene expression values following analysis on CLC 
Workbench.  Fold change negative values suggest down 
regulation in SCV as compared to NH. 
Feature ID EDGE test: group 2 
vs group 1, tagwise 
dispersions - Fold 
change 
EDGE test: 
group 2 vs 
group 1, tagwise 
dispersions - 
FDR p-value 
correction 
Functional group PA01 
Mapping 
ID 
Annotations - 
Source reference id 
dnaA -4.417184334 0.01439246 DNA replication, 
recombination, 
modification and 
repair 
PA0001 NHmuc_00001 
NHmuc_00055 6.912988853 6.09029E-07 hypothetical, 
unclassified, unknown 
PA0050 NHmuc_00055 
NHmuc_00056 3.797302019 0.000467657 hypothetical, 
unclassified, unknown 
PA0050 NHmuc_00056 
NHmuc_00058 2.403837681 0.026370836 Cell 
Wall/LPS/Capsule 
PA0052 NHmuc_00058 
osmC -4.124303156 0.005184752 oxidative stress PA0059 NHmuc_00064 
NHmuc_00065 -2.695360637 0.025427029 hypothetical, 
unclassified, unknown 
PA0060 NHmuc_00065 
NHmuc_00067 -3.947267164 0.000196897 Cell 
Wall/LPS/Capsule 
PA0062 NHmuc_00067 
NHmuc_00073 3.815671061 0.000341974 transcription regulator PA0068 NHmuc_00073 
NHmuc_00107 -4.006235926 0.014124146 energy metabolism PA0102 NHmuc_00107 
NHmuc_00127 9.938974956 5.84887E-07 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA0122 NHmuc_00127 
NHmuc_00129 -2.078320785 0.03616119 phage, transposon or 
plasmid 
PA0124 NHmuc_00129 
NHmuc_00130 -6.325768289 0.000829674 transcription regulator PA0125 NHmuc_00130 
NHmuc_00133 -5.819174966 0.009065186 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA0128 NHmuc_00133 
ahpC 17.64515406 8.97871E-08 oxidative stress PA0139 NHmuc_00144 
ahpF 28.06951992 8.39621E-13 oxidative stress PA0140 NHmuc_00145 
ppk2 2.765805026 0.030434916 Energy metabolism PA0141 NHmuc_00146 
aer2 2.754846702 0.029845438 Energy metabolism PA0176 NHmuc_00180 
NHmuc_00181 4.296568205 3.1021E-06 Chemotaxis PA0177 NHmuc_00181 
NHmuc_00182 2.977963715 0.004102209 two-component 
regulatory system 
PA0178 NHmuc_00182 
NHmuc_00183 3.58660234 2.73725E-06 two-component 
regulatory system 
PA0179 NHmuc_00183 
NHmuc_00205 5.252044554 8.46278E-06 hypothetical, 
unclassified, unknown 
PA0200 NHmuc_00205 
NHmuc_00206 -2.140455628 0.034475291 energy metabolism PA0201 NHmuc_00206 
NHmuc_00215 2.618696816 0.023708185 Energy metabolism PA0209 NHmuc_00215 
mdcC 3.239568263 0.008933071 protein and amino PA0210 NHmuc_00216 
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acid biosynthesis and 
metabolism 
NHmuc_00256 4.84646436 4.05693E-09 protein and amino 
acid biosynthesis and 
metabolism 
PA0249 NHmuc_00256 
NHmuc_00257 18.74050045 1.36694E-12 Regulatory protein 
(cell cycle, immune 
response) 
PA0250 NHmuc_00257 
NHmuc_00269 2.336141528 0.003241178 hypothetical, 
unclassified, unknown 
PA0261 NHmuc_00269 
NHmuc_00280 2.082581884 0.022599324 antibiotic resistance PA0271 NHmuc_00280 
NHmuc_00329 -3.96395054 0.013287939 hypothetical, unclassified, unknown NHmuc_00329 
NHmuc_00333 2.410674132 0.001860987 hypothetical, 
unclassified, unknown 
PA0320 NHmuc_00333 
NHmuc_00359 2.178176936 0.02503635 Energy metabolism PA0344 NHmuc_00359 
pfpI -3.455682413 0.011493221 Protein and amino 
acid biosynthesis and 
metabolism 
PA0355 NHmuc_00370 
mutM -3.292712577 0.022121784 DNA replication, 
recombination, 
modification and 
repair 
PA0357 NHmuc_00372 
NHmuc_00374 -2.612659909 0.01732446 antibiotic resistance PA0359 NHmuc_00374 
rpoH -6.582541497 0.007450432 transcription regulator PA0376 NHmuc_00392 
NHmuc_00393 -3.606447893 0.001476058 hypothetical, 
unclassified, unknown 
PA0377 NHmuc_00393 
pilH -2.777035298 0.015147122 motility and 
attachement 
PA0409 NHmuc_00426 
mexA_1 -4.580523043 0.002188593 antibiotic resistance  NHmuc_00442 
mexA_2 -3.997796433 0.004328301 antibiotic resistance  NHmuc_00443 
NHmuc_00462 4.394215943 7.44869E-05 protein and amino 
acid biosynthesis and 
metabolism 
PA0446 NHmuc_00462 
gcdH 6.21517268 4.26321E-05 protein and amino 
acid biosynthesis and 
metabolism 
PA0447 NHmuc_00463 
NHmuc_00465 5.235417877 0.008316796 protein and amino 
acid biosynthesis and 
metabolism 
PA0449 NHmuc_00465 
NHmuc_00476 3.425778412 0.026370836 Energy metabolism PA0459 NHmuc_00476 
NHmuc_00479 -6.47893064 0.001072343 Ribosome 
structure/function 
PA0462 NHmuc_00479 
glcB -4.527515853 0.014774233 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA0482 NHmuc_00500 
NHmuc_00523 3.921597223 4.45334E-07 hypothetical, 
unclassified, unknown 
PA0505 NHmuc_00523 
NHmuc_00546 6.486084936 0.002005233 transcription regulator NHmuc_00546 
NHmuc_00565 -4.226238871 0.02311624 energy metabolism PA0545 NHmuc_00565 
NHmuc_00574 -3.2189795 0.008966678 Cell 
Wall/LPS/Capsule 
PA0554 NHmuc_00574 
fda -3.868306178 0.016265295 energy metabolism PA0555 NHmuc_00575 
rpoD -5.217847143 0.008037573 transcription regulator PA0576 NHmuc_00599 
NHmuc_00652 -5.3703391 0.006700525 motility and 
attachement 
PA0646 NHmuc_00652 
NHmuc_00653 -4.649814117 0.002938608 hypothetical, 
unclassified, unknown 
PA0645 NHmuc_00653 
trpG -2.439994206 0.019127209 protein and amino 
acid biosynthesis and 
metabolism 
PA0649 NHmuc_00654 
NHmuc_00658 -2.757112638 0.025731279 oxidative stress PA0653 NHmuc_00658 
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NHmuc_00715 -5.182420296 0.003271859 energy metabolism PA4657 NHmuc_00715 
NHmuc_00716 -2.934437584 0.038795247 energy metabolism PA4656 NHmuc_00716 
hemH 2.34321811 0.022137328 iron 
acquisition/virulence 
PA4655 NHmuc_00717 
upp -2.829747194 0.030156143 nucleotide 
biosynthesis 
PA4646 NHmuc_00726 
NHmuc_00733 -3.119627003 0.010261734 Cell 
Wall/LPS/Capsule 
PA4639 NHmuc_00733 
NHmuc_00734 5.522850153 3.86682E-07 hypothetical, 
unclassified, unknown 
PA4970 NHmuc_00734 
NHmuc_00735 -4.489544412 0.000178199 Cell 
Wall/LPS/Capsule 
PA4637 NHmuc_00735 
NHmuc_00754 -3.331648614 0.029757251 energy metabolism PA4621 NHmuc_00754 
NHmuc_00756 -3.360049742 0.01515352 energy metabolism PA4619 NHmuc_00756 
katB 7.785278283 9.04805E-06 oxidative stress PA4613 NHmuc_00763 
NHmuc_00764 5.483471901 4.81596E-09 Regulatory protein 
(cell cycle, immune 
response) 
PA4612 NHmuc_00764 
NHmuc_00769 3.52970777 0.028270492 hypothetical, 
unclassified, unknown 
PA4607 NHmuc_00769 
nfxB -20.58306321 3.72094E-07 transcription regulator PA4600 NHmuc_00776 
mexC -52.82022287 1.07118E-11 antibiotic resistance PA4599 NHmuc_00777 
mexD -15.43872456 9.52068E-07 antibiotic resistance PA4598 NHmuc_00778 
oprJ -4.3861873 0.001144294 antibiotic resistance PA4597 NHmuc_00779 
NHmuc_00780 -6.708913648 0.001348001 transcription regulator PA4596 NHmuc_00780 
ccpR 2.987365074 0.003065934 oxidative stress PA4587 NHmuc_00790 
fklB -3.375765517 0.005873078 Protein and amino 
acid biosynthesis and 
metabolism 
PA4572 NHmuc_00806 
rplU -5.378661115 0.023536876 Ribosome 
structure/function 
PA4568 NHmuc_00810 
rluD -3.568246296 0.033070963 RNA Processing and 
degradation 
PA4544 NHmuc_00835 
clpB -20.67680515 6.45696E-06 Heat Shock and 
chaperones 
PA4542 NHmuc_00837 
nadC -7.308412635 0.001094572 energy metabolism PA4524 NHmuc_00859 
mreB -4.612192835 0.012778889 Cell 
Wall/LPS/Capsule 
PA4481 NHmuc_00902 
NHmuc_00908 -3.331458138 0.039710924 energy metabolism PA4475 NHmuc_00908 
NHmuc_00909 -6.812659917 0.002604302 hypothetical, 
unclassified, unknown 
PA4474 NHmuc_00909 
NHmuc_00910 -3.09977908 0.021356826 Protein and amino 
acid biosynthesis and 
metabolism 
PA4473 NHmuc_00910 
pmbA -5.162599437 0.001476058 Protein and amino 
acid biosynthesis and 
metabolism 
PA4472 NHmuc_00911 
NHmuc_00925 -3.555247885 0.034475291 energy metabolism PA4458 NHmuc_00925 
NHmuc_00926 -4.424490025 0.023570287 energy metabolism PA4457 NHmuc_00926 
NHmuc_00928 -6.339799586 0.002212046 transport, Secretion, 
export 
PA4456 NHmuc_00928 
ttg2C -2.862358721 0.020689842 transport, Secretion, 
export 
PA4454 NHmuc_00930 
NHmuc_00934 -5.082510518 0.004991789 DNA replication, 
recombination, 
modification and 
repair 
PA4451 NHmuc_00934 
murA -6.996152938 0.000820513 energy metabolism PA4450 NHmuc_00935 
hisG -4.579490199 0.000153815 energy metabolism PA4449 NHmuc_00936 
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rplM -5.084477772 0.010534557 Ribosome 
structure/function 
PA4433 NHmuc_00952 
NHmuc_00963 -2.63122443 0.038264587 DNA replication, 
recombination, 
modification and 
repair 
PA4422 NHmuc_00963 
NHmuc_00965 -4.935622795 0.011389538 cell division PA4421 NHmuc_00965 
lpxC -4.735781813 0.016628566 energy metabolism PA4406 NHmuc_00980 
NHmuc_00996 -3.822944761 0.014157681 Transcription/translati
on  
PA4390 NHmuc_00996 
fabG_2 -4.024183578 0.006222881 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA4389 NHmuc_00997 
NHmuc_00998 -2.281200463 0.027606805 protein and amino 
acid biosynthesis and 
metabolism 
PA4388 NHmuc_00998 
fxsA -18.00374256 7.85429E-08 Cell 
Wall/LPS/Capsule 
PA4387 NHmuc_00999 
NHmuc_01000 -22.88183657 1.70096E-05 hypothetical, unclassified, unknown NHmuc_01000 
groES -12.23549685 3.92972E-05 Heat Shock and 
chaperones 
PA4386 NHmuc_01001 
NHmuc_01002 -8.64006117 0.00031396 Heat Shock and 
chaperones 
PA4385 NHmuc_01002 
NHmuc_01010 -3.276970611 0.032909106 DNA replication, 
recombination, 
modification and 
repair 
PA4379 NHmuc_01010 
inaA -3.869942007 0.015655542 energy metabolism PA4378 NHmuc_01011 
NHmuc_01012 3.218781827 0.003749137 Hypothetical, 
unclassified, 
Unknown 
PA4377 NHmuc_01012 
NHmuc_01024 -16.1325674 6.05419E-07 transport, Secretion, 
export 
PA4365 NHmuc_01024 
NHmuc_01025 -75.16156702 2.59164E-11 energy metabolism PA4364 NHmuc_01025 
feoC 2.684424557 0.010672553 iron 
acquisition/virulence 
PA4357 NHmuc_01033 
purU -3.027127956 0.036332027 energy metabolism PA4314 NHmuc_01076 
flp 2.806111225 0.012156795 motility and 
attachement 
PA4306 NHmuc_01085 
NHmuc_01112 2.715747751 0.008918753 hypothetical, unclassified, unknown NHmuc_01112 
NHmuc_01167 -4.197802177 0.015223029 hypothetical, 
unclassified, unknown 
PA0731 NHmuc_01167 
NHmuc_01173 -16.24166877 4.70777E-06 hypothetical, 
unclassified, unknown 
PA2756 NHmuc_01173 
NHmuc_01174 -14.2488547 3.26594E-07 hypothetical, 
unclassified, unknown 
PA0737 NHmuc_01174 
NHmuc_01175 -3.706217666 0.00149126 Cell 
Wall/LPS/Capsule 
PA0738 NHmuc_01175 
algU -11.01533341 0.000182745 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA0762 NHmuc_01201 
mucA -12.88423353 7.40696E-05 transcription regulator PA0763 NHmuc_01202 
mucB -4.557460593 0.012661257 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA0764 NHmuc_01203 
lepA -3.780130196 0.033183495 Transcription/translati
on  
PA0767 NHmuc_01206 
NHmuc_01218 -4.198920945 0.019010709 Protein and amino 
acid biosynthesis and 
metabolism 
PA0779 NHmuc_01218 
NHmuc_01255 2.764333982 0.012156795 nucleotide PA0814 NHmuc_01255 
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biosynthesis 
NHmuc_01265 2.28085322 0.017085558 hypothetical, 
unclassified, unknown 
PA3300 NHmuc_01265 
coaB 2.70384762 0.002586297 phage, transposon or 
plasmid 
PA0723 NHmuc_01270 
NHmuc_01284 -7.136382142 0.001110397 Cell 
Wall/LPS/Capsule 
PA0833 NHmuc_01284 
slyD -6.534345885 0.008156815 Protein and amino 
acid biosynthesis and 
metabolism 
PA0837 NHmuc_01289 
NHmuc_01290 -2.609395295 0.034375835 oxidative stress PA0838 NHmuc_01290 
NHmuc_01300 35.58361869 3.74161E-15 oxidative stress PA0848 NHmuc_01300 
trxB2 54.81523674 3.98306E-16 oxidative stress PA0849 NHmuc_01301 
cbpD 6.610567731 4.11705E-06 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA0852 NHmuc_01304 
rsmA -14.93915724 0.000746199 transcription regulator PA0905 NHmuc_01359 
NHmuc_01360 -4.900166645 0.000183243 hypothetical, unclassified, unknown NHmuc_01360 
NHmuc_01361 -4.609022852 0.000637352 hypothetical, unclassified, unknown NHmuc_01361 
NHmuc_01364 -3.64401698 0.001392162 hypothetical, 
unclassified, unknown 
PA0907 NHmuc_01364 
mgtE -7.863457474 0.000433862 transport, Secretion, 
export 
PA0913 NHmuc_01370 
NHmuc_01379 -4.521229961 0.001204117 transcription regulator PA0922 NHmuc_01379 
cysM -3.800231505 0.027112295 protein and amino 
acid biosynthesis and 
metabolism 
PA0932 NHmuc_01390 
NHmuc_01396 2.605107146 0.029013593 transcription regulator PA0938 NHmuc_01396 
NHmuc_01401 -5.784237538 0.002938608 transcription regulator PA0942 NHmuc_01401 
NHmuc_01402 -3.65809684 0.029709357 energy metabolism PA0943 NHmuc_01402 
wrbA -3.183162038 0.004118766 energy metabolism PA0949 NHmuc_01408 
NHmuc_01409 -3.335953213 0.016510761 arsenic metabolism PA0950 NHmuc_01409 
NHmuc_01422 6.184556714 0.000406335 oxidative stress PA0962 NHmuc_01422 
NHmuc_01434 -3.597560136 0.021356826 Cell 
Wall/LPS/Capsule 
PA0974 NHmuc_01434 
phnB -2.578358098 0.025076641 protein and amino 
acid biosynthesis and 
metabolism 
PA1002 NHmuc_01452 
mvfR -3.570357336 0.02503635 transcription regulator PA1003 NHmuc_01453 
NHmuc_01495 4.535217414 3.646E-07 Cell 
Wall/LPS/Capsule 
PA1041 NHmuc_01495 
NHmuc_01508 -8.160000738 0.002909878 Cell 
Wall/LPS/Capsule 
PA1053 NHmuc_01508 
NHmuc_01523 -2.959928862 0.023952779 Heat Shock and 
chaperones 
PA1068 NHmuc_01523 
NHmuc_01571 -5.497764274 5.12623E-05 Cell 
Wall/LPS/Capsule 
PA1114 NHmuc_01571 
NHmuc_01572 -3.797682932 0.029988851 Protein and amino 
acid biosynthesis and 
metabolism 
PA1115 NHmuc_01572 
NHmuc_01584 -4.362185577 0.001456352 energy metabolism PA1127 NHmuc_01584 
NHmuc_01586 2.046359001 0.032080301 antibiotic resistance PA1129 NHmuc_01586 
rhlC 2.490172951 0.001465559 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA1130 NHmuc_01587 
NHmuc_01593 -7.672642989 2.47166E-05 transcription regulator PA1136 NHmuc_01593 
NHmuc_01594 -13.29593162 2.08823E-05 energy metabolism PA1137 NHmuc_01594 
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NHmuc_01596 -3.37854828 0.001144294 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA1139 NHmuc_01596 
NHmuc_01628 6.776299037 1.29335E-08 hypothetical, 
unclassified, unknown 
PA1168 NHmuc_01628 
napB 2.59548182 0.000738088 Energy metabolism PA1173 NHmuc_01633 
napD 2.241452819 0.013677427 protein and amino 
acid biosynthesis and 
metabolism 
PA1175 NHmuc_01635 
napF 2.280340144 0.025427029 iron 
acquisition/virulence 
PA1176 NHmuc_01636 
NHmuc_01717 2.251167363 0.005877206 hypothetical, 
unclassified, unknown 
PA1245 NHmuc_01717 
aprE 2.180551102 0.012481039 transport, Secretion, 
export 
PA1247 NHmuc_01719 
aprF 3.471657702 2.60049E-05 Cell 
Wall/LPS/Capsule 
PA1248 NHmuc_01720 
aprA 11.71633006 5.10912E-08 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA1249 NHmuc_01721 
NHmuc_01736 -2.518645973 0.018900082 transcription regulator PA1264 NHmuc_01736 
NHmuc_01739 2.656807799 0.02677326 iron 
acquisition/virulence 
PA2193 NHmuc_01739 
cobU 2.141040954 0.036481054 Energy metabolism PA1278 NHmuc_01752 
cobS -3.206297988 0.002752124 energy metabolism PA1281 NHmuc_01755 
NHmuc_01757 -6.807554907 0.000270892 transcription regulator PA1283 NHmuc_01757 
NHmuc_01783 -2.902006306 0.018900082 transcription regulator PA1309 NHmuc_01783 
NHmuc_01843 5.51137458 0.005265267 hypothetical, 
unclassified, unknown 
PA2500 NHmuc_01843 
rsaL 6.047906396 0.011907376 Regulatory protein 
(cell cycle, immune 
response) 
PA1431 NHmuc_01889 
NHmuc_01929 -8.730001291 1.70018E-08 Cell 
Wall/LPS/Capsule 
PA1471 NHmuc_01929 
ccmH 2.125556767 0.024299075 iron 
acquisition/virulence 
PA1482 NHmuc_01940 
cycH 2.828875063 0.000562129 iron 
acquisition/virulence 
PA1483 NHmuc_01941 
hcpC_2 2.055387573 0.017628142 Type IV secretion 
system 
PA1511 NHmuc_01971 
NHmuc_02000 -3.170950536 0.004216376 transcription regulator PA1539 NHmuc_02000 
NHmuc_02001 -3.348894816 0.018561762 antibiotic resistance PA1540 NHmuc_02001 
NHmuc_02002 -3.996697211 0.000301358 antibiotic resistance PA1541 NHmuc_02002 
NHmuc_02052 -2.993159578 0.013173308 hypothetical, unclassified, unknown NHmuc_02052 
sucC -3.81566461 0.035295519 energy metabolism PA1588 NHmuc_02053 
NHmuc_02057 -7.115936005 0.000178199 Cell 
Wall/LPS/Capsule 
PA1592 NHmuc_02057 
htpG -23.28094446 3.58411E-07 Heat Shock and 
chaperones 
PA1596 NHmuc_02061 
NHmuc_02062 -2.621308324 0.015282819 energy metabolism PA1597 NHmuc_02062 
NHmuc_02074 -5.865210601 0.00251593 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA1609 NHmuc_02074 
fabA -9.712881246 1.20881E-05 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA1610 NHmuc_02075 
gpsA -3.787295825 0.028046734 energy metabolism PA1614 NHmuc_02079 
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NHmuc_02119 -2.927687842 0.013970729 transcription regulator PA1653 NHmuc_02119 
NHmuc_02122 3.559520708 0.003329986 DNA replication, 
recombination, 
modification and 
repair 
PA1656 NHmuc_02122 
impB3 3.222670815 1.49419E-05 DNA replication, 
recombination, 
modification and 
repair 
PA1657 NHmuc_02123 
NHmuc_02197 -2.494485198 0.036332027 protein and amino 
acid biosynthesis and 
metabolism 
PA1729 NHmuc_02197 
NHmuc_02204 2.882381314 0.000467782 hypothetical, 
unclassified, unknown 
PA2108 NHmuc_02204 
NHmuc_02208 -2.919519093 0.003414642 energy metabolism PA1739 NHmuc_02208 
NHmuc_02217 -3.492152455 0.02503635 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA1748 NHmuc_02217 
cysB -3.959456548 0.030317032 transcription regulator PA1754 NHmuc_02223 
NHmuc_02224 -3.595810992 0.006792633 hypothetical, 
unclassified, unknown 
PA1755 NHmuc_02224 
NHmuc_02238 -4.619928432 0.01250702 energy metabolism PA1769 NHmuc_02238 
ppsA -4.392060187 0.019900789 energy metabolism PA1770 NHmuc_02239 
NHmuc_02271 -6.641639409 1.70096E-05 hypothetical, 
unclassified, unknown 
PA3678 NHmuc_02271 
NHmuc_02272 -2.878996229 0.012156795 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA3319 NHmuc_02272 
clpP -3.948610443 0.029013593 Protein and amino 
acid biosynthesis and 
metabolism 
PA1801 NHmuc_02277 
clpX -10.93022828 0.000449626 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA1802 NHmuc_02278 
lon -9.404774021 0.000577797 DNA replication, 
recombination, 
modification and 
repair 
PA1803 NHmuc_02279 
hupB -4.05696024 0.039633641 DNA replication, 
recombination, 
modification and 
repair 
PA1804 NHmuc_02280 
ppiD -4.836174321 0.005722003 Heat Shock and 
chaperones 
PA1805 NHmuc_02282 
NHmuc_02316 2.458266941 0.01982077 hypothetical, 
unclassified, unknown 
PA2847 NHmuc_02316 
NHmuc_02317 2.039027757 0.023708185 hypothetical, 
unclassified, unknown 
PA0072 NHmuc_02317 
NHmuc_02326 -5.607963032 0.00415351 oxidative stress/iron 
acquisition 
PA1847 NHmuc_02326 
NHmuc_02350 28.53120916 1.3634E-26 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA1869 NHmuc_02350 
lasA 4.301121418 0.000350216 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA1871 NHmuc_02352 
NHmuc_02370 -4.161076002 0.002572734 hypothetical, 
unclassified, unknown 
PA1889 NHmuc_02370 
phzB1_1 4.582647863 0.002122241 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
PA1900 NHmuc_02381 
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enzymes, alginate) 
phzC1_1 5.810319852 6.24453E-06 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA4212 NHmuc_02382 
phzD1_1 3.80043932 0.000763431 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA4213 NHmuc_02383 
phzE1_1 7.015658355 3.15044E-06 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA4214 NHmuc_02384 
NHmuc_02465 2.348114795 0.028169864 protein and amino 
acid biosynthesis and 
metabolism 
PA1985 NHmuc_02465 
NHmuc_02479 3.356269444 7.34043E-05 protein and amino 
acid biosynthesis and 
metabolism 
PA1999 NHmuc_02479 
maiA 2.312535177 0.039710924 Energy metabolism PA2007 NHmuc_02487 
fahA 2.042346251 0.014870066 Protein and amino 
acid biosynthesis and 
metabolism 
PA2008 NHmuc_02488 
galU -4.492685043 0.011797459 energy metabolism PA2023 NHmuc_02503 
NHmuc_02511 2.139675735 0.011686936 hypothetical, 
unclassified, unknown 
PA2031 NHmuc_02511 
cynR -3.109134891 0.013103741 transcription regulator PA2054 NHmuc_02533 
NHmuc_02545 3.494192334 9.04805E-06 hypothetical, 
unclassified, unknown 
PA2066 NHmuc_02545 
NHmuc_02546 4.231453845 1.4957E-05 protein and amino 
acid biosynthesis and 
metabolism 
PA2067 NHmuc_02546 
NHmuc_02547 2.591372267 0.006680858 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA2068 NHmuc_02547 
NHmuc_02548 5.870527406 2.17334E-06 nucleotide 
biosynthesis 
PA2069 NHmuc_02548 
NHmuc_02589 2.030340731 0.01982077 hypothetical, 
unclassified, unknown 
PA2116 NHmuc_02589 
cupA1 -3.012679093 0.008823471 motility and 
attachement 
PA2128 NHmuc_02602 
NHmuc_02622 -3.126282845 0.019010709 hypothetical, 
unclassified, unknown 
PA0845 NHmuc_02622 
NHmuc_02623 3.577050193 0.001866626 oxidative stress PA2146 NHmuc_02623 
NHmuc_02636 -4.304387204 0.004229683 Signal transduction PA2159 NHmuc_02636 
NHmuc_02643 4.192987849 6.05419E-07 hypothetical, 
unclassified, unknown 
PA2166 NHmuc_02643 
NHmuc_02644 -2.991739486 0.017628142 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA2167 NHmuc_02644 
hcnA 3.396840965 9.87829E-05 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA2193 NHmuc_02673 
hcnB 2.978577379 0.000551741 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA2194 NHmuc_02674 
hcnC 2.589282848 0.018900082 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA2195 NHmuc_02675 
bkdR -2.87474868 0.036168641 transcription regulator PA2246 NHmuc_02721 
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bkdA1 -4.854043842 0.010701216 energy metabolism PA2247 NHmuc_02723 
bkdA2 -7.544732073 0.001329842 protein and amino 
acid biosynthesis and 
metabolism 
PA2248 NHmuc_02724 
bkdB -9.207888483 0.000332406 energy metabolism PA2249 NHmuc_02725 
lpdV -10.49827825 5.76107E-05 energy metabolism PA2250 NHmuc_02726 
chiC 16.87708596 1.45256E-09 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA2300 NHmuc_02776 
NHmuc_02777 2.74763445 0.000837484 transcription, RNA 
processing 
PA2301 NHmuc_02777 
NHmuc_02778 3.658376992 0.007289717 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA2302 NHmuc_02778 
NHmuc_02779 4.058868107 7.66919E-06 Regulatory protein 
(cell cycle, 
transcription, immune 
response) 
PA2303 NHmuc_02779 
NHmuc_02780 2.2227256 0.018142306 transcription regulator PA2304 NHmuc_02780 
NHmuc_02781 3.536534985 0.001247642 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA2305 NHmuc_02781 
NHmuc_02803 2.135429429 0.033385201 transport, Secretion, 
export 
PA2327 NHmuc_02803 
NHmuc_02806 2.356392155 0.002540432 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA2330 NHmuc_02806 
NHmuc_02807 2.331557238 0.013287939 oxidative stress PA2331 NHmuc_02807 
impJ 2.208912982 0.027112295 Type IV secretion 
system 
PA2363 NHmuc_02839 
impB 2.175508851 0.029709357 DNA replication, 
recombination, 
modification and 
repair 
PA2365 NHmuc_02841 
NHmuc_02856 -3.07709124 0.016419271 energy metabolism PA2379 NHmuc_02856 
NHmuc_02858 2.64977315 0.001456352 Energy metabolism PA2381 NHmuc_02858 
NHmuc_02881 -2.548744985 0.020430505 hypothetical, 
unclassified, unknown 
PA2405 NHmuc_02881 
NHmuc_02882 -6.119914005 0.000178199 Cell 
Wall/LPS/Capsule 
PA2406 NHmuc_02882 
NHmuc_02883 -5.580165379 0.008588433 Cell 
Wall/LPS/Capsule 
PA2407 NHmuc_02883 
NHmuc_02922 5.271546147 0.000355611 hypothetical, 
unclassified, unknown 
PA4734 NHmuc_02922 
NHmuc_02957 -2.621738075 0.025885357 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA2463 NHmuc_02957 
NHmuc_02976 -2.969068298 0.005026094 energy metabolism PA2482 NHmuc_02976 
NHmuc_02978 -3.684561603 0.023916663 transcription regulator PA2484 NHmuc_02978 
NHmuc_02980 -2.740258634 0.004950684 hypothetical, 
unclassified, unknown 
PA2486 NHmuc_02980 
NHmuc_02991 -2.659018459 0.015223029 transcription regulator PA2497 NHmuc_02991 
NHmuc_02998 2.976340437 4.908E-05 hypothetical, 
unclassified, unknown 
PA2504 NHmuc_02998 
antA 4.238259049 0.002714362 Energy metabolism PA2512 NHmuc_03006 
antB 2.442460011 0.034998279 Energy metabolism PA2513 NHmuc_03007 
antC 4.064440595 4.86797E-07 Energy metabolism PA2514 NHmuc_03008 
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cigR -9.542501423 0.00043664 Cell 
Wall/LPS/Capsule 
PA2562 NHmuc_03060 
tam 5.426198486 7.9258E-06 nucleotide 
biosynthesis 
PA2564 NHmuc_03062 
NHmuc_03063 3.54922096 6.02961E-06 hypothetical, 
unclassified, unknown 
PA2565 NHmuc_03063 
NHmuc_03064 4.348191152 2.08823E-05 nucleotide 
biosynthesis 
PA2566 NHmuc_03064 
NHmuc_03068 -2.986636015 0.008097799 hypothetical, 
unclassified, unknown 
PA2569 NHmuc_03068 
lecA 2.852771271 0.004612404 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA2570 NHmuc_03069 
NHmuc_03090 3.262625173 0.000507241 transcription regulator PA2588 NHmuc_03090 
infA -5.155983482 0.001631867 Transcription/translati
on  
PA2619 NHmuc_03122 
mnmA -3.622328348 0.038795247 Transcription/translati
on  
PA2626 NHmuc_03129 
NHmuc_03170 -3.612671473 0.033836706 energy metabolism PA2666 NHmuc_03170 
NHmuc_03171 -4.039889721 0.000799893 transcription regulator PA2667 NHmuc_03171 
infC -4.475492554 0.023536876 Transcription/translati
on  
PA2743 NHmuc_03257 
NHmuc_03262 -12.46367915 2.4886E-09 hypothetical, 
unclassified, unknown 
PA3505 NHmuc_03262 
NHmuc_03267 -3.35657899 0.018387567 hypothetical, 
unclassified, unknown 
PA1644 NHmuc_03267 
NHmuc_03272 -4.426147087 0.005930671 RNA Processing and 
degradation 
PA2751 NHmuc_03272 
NHmuc_03273 -8.101736164 3.86682E-07 hypothetical, 
unclassified, unknown 
PA2701 NHmuc_03273 
eco -5.560186916 0.005219523 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA2755 NHmuc_03279 
NHmuc_03311 2.586515523 0.010729427 hypothetical, 
unclassified, unknown 
PA2781 NHmuc_03311 
NHmuc_03316 2.277060446 0.005834829 Energy metabolism PA2786 NHmuc_03316 
NHmuc_03337 2.15962559 0.021690603 cell division PA2805 NHmuc_03337 
NHmuc_03353 3.482275145 8.7395E-05 hypothetical, unclassified, unknown NHmuc_03353 
NHmuc_03356 3.790543246 0.000162736 hypothetical, 
unclassified, unknown 
PA2633 NHmuc_03356 
NHmuc_03358 7.141090705 2.02246E-08 Inclusion bodies PA2188 NHmuc_03358 
NHmuc_03359 4.881351634 7.49282E-07 Inclusion bodies PA3779 NHmuc_03359 
NHmuc_03369 -2.561010762 0.025427029 oxidative stress PA2826 NHmuc_03369 
htpX -7.736662523 0.000359382 Heat Shock and 
chaperones 
PA2830 NHmuc_03373 
NHmuc_03383 -8.069092737 3.23529E-05 Transcription/translati
on  
PA2840 NHmuc_03383 
NHmuc_03386 3.116362519 0.007299763 protein and amino 
acid biosynthesis and 
metabolism 
PA2843 NHmuc_03386 
NHmuc_03389 -3.862659651 0.002325968 transcription regulator PA2846 NHmuc_03389 
efp -4.362809676 0.030156143 Transcription/translati
on  
PA2851 NHmuc_03394 
NHmuc_03398 -4.588589233 0.021339705 Protein and amino 
acid biosynthesis and 
metabolism 
PA2854 NHmuc_03398 
NHmuc_03409 -3.827955873 0.013287939 DNA replication, 
recombination, 
modification and 
repair 
PA2865 NHmuc_03409 
NHmuc_03410 -2.922739761 0.009303747 hypothetical, PA5141 NHmuc_03410 
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unclassified, unknown 
NHmuc_03413 8.169395697 9.13076E-15 phage, transposon or 
plasmid 
PA2868 NHmuc_03413 
NHmuc_03422 -5.320059031 0.000236161 transcription regulator PA2877 NHmuc_03422 
NHmuc_03441 -3.558989295 0.030156143 transcription regulator PA2896 NHmuc_03441 
NHmuc_03446 -4.726218374 0.003783375 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA2901 NHmuc_03446 
NHmuc_03466 2.422396137 0.008189319 hypothetical, 
unclassified, unknown 
PA2919 NHmuc_03466 
NHmuc_03478 -4.390146886 0.000233627 transcription regulator PA2931 NHmuc_03478 
NHmuc_03491 2.548459126 0.033842846 hypothetical, unclassified, unknown NHmuc_03491 
fabD -5.28912888 0.003034677 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA2968 NHmuc_03521 
NHmuc_03524 -4.053484541 0.015546538 iron 
acquisition/virulence 
PA2971 NHmuc_03524 
rluC -4.79376696 0.013075478 Ribosome 
structure/function 
PA2975 NHmuc_03528 
NHmuc_03537 -3.871514371 0.02311624 transport, Secretion, 
export 
PA2983 NHmuc_03537 
NHmuc_03539 -4.127793724 0.003089575 hypothetical, 
unclassified, unknown 
PA2985 NHmuc_03539 
NHmuc_03556 -6.366718441 0.003762449 energy metabolism PA3001 NHmuc_03556 
NHmuc_03560 -4.017712562 0.006598764 protein and amino 
acid biosynthesis and 
metabolism 
PA3005 NHmuc_03560 
lexA -2.49110919 0.021339705 DNA replication, 
recombination, 
modification and 
repair 
PA3007 NHmuc_03562 
NHmuc_03563 -7.362109338 4.97353E-06 cell division PA3008 NHmuc_03563 
NHmuc_03577 2.094805313 0.013287939 zinc/nitrogen 
metabolism 
PA3022 NHmuc_03577 
NHmuc_03586 -4.027562386 0.020368376 Cell 
Wall/LPS/Capsule 
PA3031 NHmuc_03586 
snr1 9.892182014 4.84724E-07 oxidative stress PA3032 NHmuc_03588 
NHmuc_03605 4.962311898 4.26321E-05 Hypothetical, unclassified, 
Unknown 
NHmuc_03605 
NHmuc_03611 -4.613794522 0.005165378 hypothetical, 
unclassified, unknown 
PA3055 NHmuc_03611 
NHmuc_03612 -5.216960425 0.003414642 DNA replication, 
recombination, 
modification and 
repair 
PA3056 NHmuc_03612 
NHmuc_03649 -2.799117393 0.010701216 cyanide metabolism PA3093 NHmuc_03649 
NHmuc_03671 -4.468931496 0.008296333 energy metabolism PA3112 NHmuc_03671 
NHmuc_03683 -6.063303937 0.000746199 transcription regulator PA3124 NHmuc_03683 
ibpA -30.86511182 1.09581E-07 Heat Shock and 
chaperones 
PA3126 NHmuc_03685 
NHmuc_03712 -3.843031509 0.027360342 vitamin/heavy metal 
metabolism 
PA4097 NHmuc_03712 
NHmuc_03713 -4.997319328 0.011907376 hypothetical, 
unclassified, unknown 
PA5449 NHmuc_03713 
NHmuc_03714 -5.959215244 0.016834283 energy metabolism PA1091 NHmuc_03714 
NHmuc_03719 -2.648229505 0.017715584 hypothetical, 
unclassified, unknown 
PA3538 NHmuc_03719 
wzz -5.384355659 0.008231901 Cell 
Wall/LPS/Capsule 
PA3160 NHmuc_03721 
NHmuc_03731 -3.092982635 0.018561762 hypothetical, unclassified, unknown NHmuc_03731 
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NHmuc_03744 -2.448786365 0.022137328 protein and amino 
acid biosynthesis and 
metabolism 
PA3181 NHmuc_03744 
pgl -5.12505861 3.03066E-06 energy metabolism PA3182 NHmuc_03745 
zwf -9.541037984 7.08974E-05 energy metabolism PA3183 NHmuc_03746 
NHmuc_03753 2.683365054 0.023384293 Energy metabolism PA3190 NHmuc_03753 
edd -5.657261045 0.00147933 energy metabolism PA3194 NHmuc_03757 
NHmuc_03778 2.286167248 0.011493221 motility and 
attachement 
PA3214 NHmuc_03778 
NHmuc_03801 3.898905706 0.007525246 Cell 
Wall/LPS/Capsule 
PA3237 NHmuc_03801 
NHmuc_03806 -2.713849794 0.026289545 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA3242 NHmuc_03806 
NHmuc_03832 -5.237851201 0.007233958 Protein and amino 
acid biosynthesis and 
metabolism 
PA3262 NHmuc_03832 
NHmuc_03834 -3.347983813 0.025725564 hypothetical, unclassified, unknown NHmuc_03834 
NHmuc_03843 -5.371565336 3.29044E-05 energy metabolism PA3270 NHmuc_03843 
NHmuc_03862 19.73740243 6.8494E-21 oxidative stress PA3287 NHmuc_03862 
NHmuc_03863 19.56925506 1.80626E-18 Cell 
Wall/LPS/Capsule 
PA3288 NHmuc_03863 
NHmuc_03896 5.800672948 4.80787E-06 hypothetical, 
unclassified, unknown 
PA3318 NHmuc_03896 
lecB 9.59332893 5.9344E-08 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA3361 NHmuc_03939 
NHmuc_03948 2.027326745 0.025766114 hypothetical, 
unclassified, unknown 
PA3369 NHmuc_03948 
amrZ -12.34248743 3.0104E-05 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA3385 NHmuc_03964 
NHmuc_03993 -4.511721246 0.009065186 DNA replication, 
recombination, 
modification and 
repair 
PA3413 NHmuc_03993 
NHmuc_03994 -2.570923693 0.02503635 hypothetical, 
unclassified, unknown 
PA3414 NHmuc_03994 
NHmuc_03995 -2.869435014 0.011897811 hypothetical, 
unclassified, unknown 
PA4700 NHmuc_03995 
NHmuc_04041 -4.020975863 0.018047309 energy metabolism PA3460 NHmuc_04041 
NHmuc_04042 -4.96172051 0.004642075 Protein and amino 
acid biosynthesis and 
metabolism 
PA3461 NHmuc_04042 
NHmuc_04053 -6.078803146 0.002338068 Cell 
Wall/LPS/Capsule 
PA3472 NHmuc_04053 
NHmuc_04054 -2.63177412 0.006267371 antibiotic resistance PA3473 NHmuc_04054 
rhlL 4.27426147 7.6398E-08 transcription regulator PA3476 NHmuc_04057 
rhlR 6.304817418 0.000121182 transcription regulator PA3477 NHmuc_04058 
rhlB 2.948971743 0.025300743 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA3478 NHmuc_04059 
rhlA 3.541824596 0.01439246 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA3479 NHmuc_04060 
NHmuc_04074 7.744181754 2.23045E-12 protein and amino 
acid biosynthesis and 
metabolism 
PA3496 NHmuc_04074 
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NHmuc_04079 -2.262660414 0.020516325 vitamin/heavy metal 
metabolism 
PA3519 NHmuc_04079 
bfrB -8.323042492 0.006845427 iron 
acquisition/virulence 
PA3531 NHmuc_04091 
NHmuc_04092 -8.099816012 0.00123197 transport, Secretion, 
export 
PA3532 NHmuc_04092 
NHmuc_04093 -4.612712281 0.029895396 oxidative stress PA3533 NHmuc_04093 
algD -30.44578348 1.01598E-09 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA3540 NHmuc_04100 
NHmuc_04101 -4.214291274 0.003052935 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA3541 NHmuc_04101 
algE -3.207155053 0.023536876 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA3544 NHmuc_04104 
algX -3.473695945 0.007697403 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA3546 NHmuc_04106 
algL -2.671378868 0.016628566 energy metabolism PA3547 NHmuc_04107 
algF -5.424078423 2.08823E-05 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA3550 NHmuc_04110 
algA -5.34709863 0.001961357 protein and amino 
acid biosynthesis and 
metabolism 
PA3551 NHmuc_04111 
NHmuc_04118 2.324453559 0.017829678 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA3558 NHmuc_04118 
NHmuc_04129 -5.795427756 0.001933383 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA3566 NHmuc_04129 
NHmuc_04130 -5.999199792 6.38087E-05 energy metabolism PA3567 NHmuc_04130 
NHmuc_04137 -4.552348941 0.00020543 transcription regulator PA3574 NHmuc_04137 
NHmuc_04138 -28.84538749 1.2516E-10 transport, Secretion, 
export 
PA3520 NHmuc_04138 
NHmuc_04143 -3.787913066 0.002586297 protein and amino 
acid biosynthesis and 
metabolism 
PA3580 NHmuc_04143 
glpD -3.944052639 0.028525891 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA3584 NHmuc_04147 
recX -4.466619396 3.10711E-05 DNA replication, 
recombination, 
modification and 
repair 
PA3616 NHmuc_04179 
NHmuc_04180 -16.07969736 3.3064E-06 DNA replication, 
recombination, 
modification and 
repair 
PA3617 NHmuc_04180 
NHmuc_04181 -2.526983646 0.039118729 DNA replication, 
recombination, 
modification and 
repair 
PA3618 NHmuc_04181 
NHmuc_04185 16.68827501 6.6701E-06 transcription regulator NHmuc_04185 
NHmuc_04201 -6.537941929 0.001524962 nucleotide 
biosynthesis 
PA3637 NHmuc_04201 
tsf -3.592454364 0.029845438 Transcription/translati PA3655 NHmuc_04219 
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on  
rpsB -4.289274841 0.018801312 Ribosome 
structure/function 
PA3656 NHmuc_04220 
NHmuc_04221 -3.279946179 0.01982077 hypothetical, unclassified, unknown NHmuc_04221 
map -4.233866306 0.028839065 Protein and amino 
acid biosynthesis and 
metabolism 
PA3657 NHmuc_04222 
NHmuc_04228 -3.038842109 0.024687056 motility and 
attachement 
PA3663 NHmuc_04228 
NHmuc_04250 -3.361544302 0.005026094 Protein and amino 
acid biosynthesis and 
metabolism 
PA3685 NHmuc_04250 
adk -4.825103304 0.003101391 nucleotide 
biosynthesis 
PA3686 NHmuc_04251 
cadA2 -5.765438836 0.00184906 transcription regulator PA3690 NHmuc_04255 
prfB -3.74772747 0.029513801 Protein and amino 
acid biosynthesis and 
metabolism 
PA3701 NHmuc_04266 
NHmuc_04287 2.101946485 0.03625249 Energy metabolism PA3723 NHmuc_04287 
lasB 5.4083324 0.000143769 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA3724 NHmuc_04288 
NHmuc_04295 -5.044114205 0.000551741 Heat Shock and 
chaperones 
PA3731 NHmuc_04295 
NHmuc_04296 -10.30190036 0.000638522 hypothetical, 
unclassified, unknown 
PA3732 NHmuc_04296 
NHmuc_04298 -7.21675114 4.49396E-05 hypothetical, 
unclassified, unknown 
PA2747 NHmuc_04298 
dsbC -6.357639387 0.002212046 Protein and amino 
acid biosynthesis and 
metabolism 
PA3737 NHmuc_04302 
ffh -4.249819748 0.019245838 Signal transduction PA3746 NHmuc_04311 
NHmuc_04327 -2.260437248 0.026302118 hypothetical, 
unclassified, unknown 
PA3762 NHmuc_04327 
NHmuc_04330 -2.124043799 0.035010105 hypothetical, 
unclassified, unknown 
PA3765 NHmuc_04330 
NHmuc_04351 2.450457945 0.003171616 hypothetical, 
unclassified, unknown 
PA3784 NHmuc_04351 
NHmuc_04352 5.43842799 1.89208E-07 Cell 
Wall/LPS/Capsule 
PA3785 NHmuc_04352 
NHmuc_04353 2.55202055 0.002055513 hypothetical, 
unclassified, unknown 
PA3786 NHmuc_04353 
NHmuc_04355 2.870284038 0.000181839 hypothetical, 
unclassified, unknown 
PA3788 NHmuc_04355 
oprC 2.507869567 0.010310287 transport, Secretion, 
export 
PA3790 NHmuc_04357 
NHmuc_04358 3.960203547 1.09581E-07 iron 
acquisition/virulence 
PA3791 NHmuc_04358 
ndk -4.854242673 0.00705587 nucleotide 
biosynthesis 
PA3807 NHmuc_04374 
NHmuc_04375 2.838575954 0.000616273 iron 
acquisition/virulence 
PA3808 NHmuc_04375 
NHmuc_04385 -5.149851173 0.004991789 transcription regulator PA3818 NHmuc_04385 
NHmuc_04386 -12.45456645 6.83353E-05 transport, Secretion, 
export 
PA3819 NHmuc_04386 
yajC -2.771058156 0.020688736 transport, Secretion, 
export 
PA3822 NHmuc_04389 
NHmuc_04396 -3.917395951 0.028544519 transport, Secretion, 
export 
PA3828 NHmuc_04396 
NHmuc_04413 2.55408797 0.001067257 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA3844 NHmuc_04413 
NHmuc_04470 -5.912053209 8.18586E-05 Secreted Factors PA3902 NHmuc_04470 
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(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
NHmuc_04472 3.165634912 0.000120594 Type IV Secretion 
system 
PA3904 NHmuc_04472 
NHmuc_04489 -9.730187002 3.13656E-05 energy metabolism PA3920 NHmuc_04489 
NHmuc_04520 -3.798234732 0.001144294 Transcription/translati
on  
PA3951 NHmuc_04520 
NHmuc_04521 -10.77256168 1.92605E-06 transport, Secretion, 
export 
PA3952 NHmuc_04521 
NHmuc_04533 -4.637766106 0.01439246 hypothetical, 
unclassified, unknown 
PA1846 NHmuc_04533 
NHmuc_04557 -2.706306551 0.036264195 hypothetical, 
unclassified, unknown 
PA3979 NHmuc_04557 
NHmuc_04564 3.833921619 2.63289E-06 hypothetical, 
unclassified, unknown 
PA3986 NHmuc_04564 
ppa -4.540826459 0.013075478 energy metabolism PA4031 NHmuc_04607 
nusB -2.868580009 0.024687056 transcription regulator PA4052 NHmuc_04628 
ribH -3.174719819 0.022137328 energy metabolism PA4053 NHmuc_04629 
ribB -2.414616216 0.029895396 energy metabolism PA4054 NHmuc_04630 
ribC -4.728478409 0.000363344 vitamin/heavy metal 
metabolism 
PA4055 NHmuc_04631 
NHmuc_04637 -9.242285213 0.000153815 oxidative stress PA4061 NHmuc_04637 
ampC 4.287109347 0.001646686 antibiotic resistance PA4110 NHmuc_04689 
NHmuc_04690 2.685363352 0.010118755 hypothetical, 
unclassified, unknown 
PA4111 NHmuc_04690 
NHmuc_04707 3.119692004 9.87829E-05 protein and amino 
acid biosynthesis and 
metabolism 
PA4128 NHmuc_04707 
NHmuc_04708 6.09181152 1.5135E-10 Energy metabolism PA4129 NHmuc_04708 
NHmuc_04711 2.73821285 0.004122396 transcription regulator PA4132 NHmuc_04711 
NHmuc_04712 3.454751116 0.008706714 Energy metabolism PA4133 NHmuc_04712 
NHmuc_04713 5.659064105 2.50923E-09 hypothetical, 
unclassified, unknown 
PA4134 NHmuc_04713 
NHmuc_04718 10.92503714 1.4704E-11 hypothetical, 
unclassified, unknown 
PA4139 NHmuc_04718 
NHmuc_04720 62.47174884 3.24397E-16 hypothetical, 
unclassified, unknown 
PA4141 NHmuc_04720 
NHmuc_04733 -4.000671454 8.18586E-05 transport, Secretion, 
export 
PA4154 NHmuc_04733 
NHmuc_04745 -2.301747237 0.025300743 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA4166 NHmuc_04745 
NHmuc_04760 -2.701592985 0.00187657 DNA replication, 
recombination, 
modification and 
repair 
PA4181 NHmuc_04760 
NHmuc_04761 -9.451508195 7.45465E-05 transcription regulator PA4182 NHmuc_04761 
NHmuc_04762 -4.066699062 8.18586E-05 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA4183 NHmuc_04762 
NHmuc_04775 -6.977326226 7.118E-07 two-component 
regulatory system 
PA4196 NHmuc_04775 
NHmuc_04776 -15.15225768 6.0636E-06 Signal transduction PA4197 NHmuc_04776 
NHmuc_04781 -4.649806111 0.000264072 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA4202 NHmuc_04781 
NHmuc_04782 -4.619689968 0.000133509 transcription regulator PA4203 NHmuc_04782 
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mexH 4.073102208 2.17334E-06 antibiotic resistance PA4206 NHmuc_04785 
mexI 3.039168715 0.025427029 antibiotic resistance PA4207 NHmuc_04786 
opmD 4.614094841 1.8488E-07 Cell 
Wall/LPS/Capsule 
PA4208 NHmuc_04787 
phzE1_2 2.530379352 0.027047635 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA4214 NHmuc_04793 
phzF1_2 3.81485457 0.001524962 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA4215 NHmuc_04794 
phzG2_2 7.397533527 3.34419E-06 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA1905 NHmuc_04795 
ssb -3.854195764 0.002794904 DNA replication, 
recombination, 
modification and 
repair 
PA4232 NHmuc_04811 
katA 22.80862551 7.12639E-10 oxidative stress PA4236 NHmuc_04815 
rpmJ_2 3.987906644 0.00200701 Ribosome 
structure/function 
PA4242 NHmuc_04821 
rpsN 2.314606081 0.018665522 Ribosome 
structure/function 
PA4250 NHmuc_04829 
tuf2_2 -7.716427272 0.000505605 transcription regulator PA4277 NHmuc_04860 
NHmuc_04863 -4.631211615 0.00705587 hypothetical, unclassified, unknown NHmuc_04863 
NHmuc_04886 3.33655998 0.006786276 Hypothetical, unclassified, 
Unknown 
NHmuc_04886 
NHmuc_04912 5.067236288 0.028169864 transcription regulator NHmuc_04912 
NHmuc_04924 11.35638131 3.24397E-16 hypothetical, 
unclassified, unknown 
PA4738 NHmuc_04924 
NHmuc_04925 10.74361491 2.20628E-08 transport, Secretion, 
export 
PA4739 NHmuc_04925 
NHmuc_04933 -6.640887399 0.00408448 Ribosome 
structure/function 
PA4746 NHmuc_04933 
NHmuc_04935 -2.725651884 0.025319825 hypothetical, unclassified, unknown NHmuc_04935 
tpiA -4.117484338 0.018665522 energy metabolism PA4748 NHmuc_04936 
NHmuc_04940 -4.556690059 0.011907376 Ribosome 
structure/function 
PA4752 NHmuc_04940 
NHmuc_04941 -3.600301931 0.028046734 RNA Processing and 
degradation 
PA4753 NHmuc_04941 
NHmuc_04942 -3.255479377 0.003271859 transport, Secretion, 
export 
PA4754 NHmuc_04942 
NHmuc_04945 -2.95852575 0.025731279 protein and amino 
acid biosynthesis and 
metabolism 
PA4757 NHmuc_04945 
NHmuc_04946 -9.042416191 0.000270892 nucleotide 
biosynthesis 
PA4758 NHmuc_04946 
NHmuc_04947 -6.762360152 0.000318762 hypothetical, unclassified, unknown NHmuc_04947 
dapB -17.0356775 2.75982E-06 energy metabolism PA4759 NHmuc_04948 
dnaJ -11.95228098 7.45465E-05 Heat Shock and 
chaperones 
PA4760 NHmuc_04949 
NHmuc_04950 -17.59238009 3.34419E-06 Heat Shock and 
chaperones 
PA4761 NHmuc_04950 
grpE -25.1319909 1.22598E-07 Heat Shock and 
chaperones 
PA4762 NHmuc_04951 
NHmuc_04967 2.161522462 0.019655562 transcription regulator PA4778 NHmuc_04967 
fdnH 2.938079851 0.000917438 protein and amino 
acid biosynthesis and 
metabolism 
PA4811 NHmuc_05001 
NHmuc_05019 -3.206480443 0.001329842 hypothetical, 
unclassified, unknown 
PA4826 NHmuc_05019 
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NHmuc_05036 -4.479050782 0.008220392 hypothetical, 
unclassified, unknown 
PA4842 NHmuc_05036 
NHmuc_05037 -7.992546431 0.000433862 hypothetical, 
unclassified, unknown 
PA1387 NHmuc_05037 
accB -3.111667039 0.001832216 energy metabolism PA4847 NHmuc_05042 
NHmuc_05046 -3.11209978 0.016834283 transcription regulator PA4851 NHmuc_05046 
NHmuc_05065 -3.215499207 0.015393726 transcription regulator PA4870 NHmuc_05065 
NHmuc_05073 -9.214901049 0.000376385 transcription regulator PA4878 NHmuc_05073 
NHmuc_05135 -4.095672986 0.01420864 nucleotide 
biosynthesis 
PA4938 NHmuc_05135 
hisZ -5.575182461 0.001150362 energy metabolism PA4939 NHmuc_05136 
NHmuc_05137 -6.162445331 0.000551741 transport, Secretion, 
export 
PA4940 NHmuc_05137 
NHmuc_05140 -6.883278059 0.001204117 energy metabolism PA4943 NHmuc_05140 
NHmuc_05141 -7.21776827 0.002586297 transcription regulator PA4944 NHmuc_05141 
NHmuc_05167 -2.387492012 0.025805715 energy metabolism PA4970 NHmuc_05167 
aspP -3.577195257 0.005616748 energy metabolism PA4971 NHmuc_05168 
NHmuc_05205 -2.19076535 0.038818698 energy metabolism PA5007 NHmuc_05205 
NHmuc_05206 -2.804926636 0.010676471 Cell 
Wall/LPS/Capsule 
PA5008 NHmuc_05206 
waaP -3.847140006 0.012156795 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA5009 NHmuc_05207 
waaG -5.274565797 0.004102209 Protein and amino 
acid biosynthesis and 
metabolism 
PA5010 NHmuc_05208 
NHmuc_05225 2.717887425 0.007375163 oxidative stress PA5027 NHmuc_05225 
gltB -3.86550244 0.019570838 protein and amino 
acid biosynthesis and 
metabolism 
PA5036 NHmuc_05234 
hslV -16.88301086 4.13225E-07 Heat Shock and 
chaperones 
PA5053 NHmuc_05252 
hslU -9.188294167 6.72388E-05 Heat Shock and 
chaperones 
PA5054 NHmuc_05253 
NHmuc_05272 -3.767009273 0.035008372 hypothetical, 
unclassified, unknown 
PA5073 NHmuc_05272 
NHmuc_05275 -3.257805589 0.027988263 transport, Secretion, 
export 
PA5076 NHmuc_05275 
mdoD -3.719137484 0.024655919 energy metabolism PA5078 NHmuc_05277 
blc -3.766031801 0.004723299 Cell 
Wall/LPS/Capsule 
PA5107 NHmuc_05306 
NHmuc_05307 -2.292737845 0.019208813 Cell 
Wall/LPS/Capsule 
PA5108 NHmuc_05307 
fbp -3.898648784 0.031413472 energy metabolism PA5110 NHmuc_05309 
glnA -12.30100677 5.84838E-06 protein and amino 
acid biosynthesis and 
metabolism 
PA5119 NHmuc_05318 
ntrB -3.186654488 0.01653863 two-component 
regulatory system 
PA5124 NHmuc_05323 
NHmuc_05324 -2.768129412 0.030434916 Protein and amino 
acid biosynthesis and 
metabolism 
PA5125 NHmuc_05324 
grx -3.909947953 0.005838259 energy metabolism PA5129 NHmuc_05328 
rmlD 2.477580729 0.017085558 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA5162 NHmuc_05365 
rmlA 2.548992766 0.012156795 Energy metabolism PA5163 NHmuc_05366 
rmlC 3.173655128 0.000153815 nucleotide 
biosynthesis 
PA5164 NHmuc_05367 
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arcA 2.738312052 0.027360342 protein and amino 
acid biosynthesis and 
metabolism 
PA5171 NHmuc_05374 
NHmuc_05385 -29.31646515 8.47921E-08 transport, Secretion, 
export 
PA5182 NHmuc_05385 
NHmuc_05386 -9.142058711 1.58886E-08 DNA replication, 
recombination, 
modification and 
repair 
PA5183 NHmuc_05386 
pckA -5.870222012 0.005265267 energy metabolism PA5192 NHmuc_05396 
gcvH1 -2.561356603 0.030434916 Protein and amino 
acid biosynthesis and 
metabolism 
PA5214 NHmuc_05418 
NHmuc_05424 2.904126995 0.000363344 hypothetical, 
unclassified, unknown 
PA5220 NHmuc_05424 
NHmuc_05425 2.128565137 0.012857887 oxidative stress PA5221 NHmuc_05425 
NHmuc_05426 2.090050077 0.014157681 transcription regulator PA5426 NHmuc_05426 
NHmuc_05431 -5.029373784 0.000703254 cell division PA5227 NHmuc_05431 
NHmuc_05433 -3.162367856 0.034847811 energy metabolism PA5228 NHmuc_05433 
rho -5.725244627 0.003749137 transcription regulator PA5239 NHmuc_05445 
NHmuc_05446 -8.250197002 0.000317519 hypothetical, unclassified, unknown NHmuc_05446 
hemC -3.886425859 0.03383863 iron 
acquisition/virulence 
PA5260 NHmuc_05468 
lppL -8.136777734 0.000908998 Cell 
Wall/LPS/Capsule 
PA5276 NHmuc_05485 
NHmuc_05512 2.848091794 0.000700034 nucleotide 
biosynthesis 
PA5222 NHmuc_05512 
NHmuc_05515 -2.896954142 0.027047635 Cell 
Wall/LPS/Capsule 
PA5306 NHmuc_05515 
pyrE -3.669096132 0.022137328 nucleotide 
biosynthesis 
PA5331 NHmuc_05540 
rph -4.694549778 0.006764943 RNA Processing and 
degradation 
PA5334 NHmuc_05543 
yicC -2.775364896 0.010484845 hypothetical, 
unclassified, unknown 
PA5335 NHmuc_05544 
gmk -2.295010127 0.025427029 nucleotide 
biosynthesis 
PA5336 NHmuc_05545 
NHmuc_05568 2.20696566 0.013287939 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA5359 NHmuc_05568 
betA -5.346222992 0.003089575 protein and amino 
acid biosynthesis and 
metabolism 
PA5372 NHmuc_05586 
betB -4.328697101 0.017085558 energy metabolism PA5373 NHmuc_05587 
NHmuc_05650 -7.984398594 0.001173191 energy metabolism PA5435 NHmuc_05650 
NHmuc_05652 -4.525188909 0.010701216 transcription regulator PA5437 NHmuc_05652 
NHmuc_05654 -8.261639183 0.000820513 transcription regulator PA5438 NHmuc_05654 
NHmuc_05663 4.728439825 7.08974E-05 hypothetical, 
unclassified, unknown 
PA5446 NHmuc_05663 
NHmuc_05677 3.497446692 2.18019E-05 hypothetical, 
unclassified, unknown 
PA5460 NHmuc_05677 
NHmuc_05697 2.089840528 0.038166819 Secreted Factors 
(Virulence factors, 
toxins, biofilm 
enzymes, alginate) 
PA5481 NHmuc_05697 
cc4 -3.725494621 0.038264587 energy metabolism PA5490 NHmuc_05706 
NHmuc_05707 -4.712631469 0.002212046 energy metabolism PA5491 NHmuc_05707 
engB -5.496461139 0.001860987 Ribosome 
structure/function 
PA5492 NHmuc_05708 
NHmuc_05719 -4.160315895 0.004018062 Cell 
Wall/LPS/Capsule 
PA5502 NHmuc_05719 
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NHmuc_05743 -4.087740302 0.000687276 transcription regulator PA5525 NHmuc_05743 
NHmuc_05744 -17.30352723 5.76107E-05 Cell 
Wall/LPS/Capsule 
PA5526 NHmuc_05744 
NHmuc_05746 -3.985684245 0.037072056 transport, Secretion, 
export 
PA5528 NHmuc_05746 
NHmuc_05751 -3.770535747 0.012085973 energy metabolism PA5533 NHmuc_05751 
NHmuc_05764 3.764297241 0.011948526 fatty acid, 
phospholipid and 
rhamnolipid 
metabolism 
PA5546 NHmuc_05764 
glmR -2.253629907 0.035035864 transcription regulator PA5550 NHmuc_05768 
atpH -3.592367501 0.03625249 energy metabolism PA5557 NHmuc_05775 
atpF -3.914812343 0.017223443 energy metabolism PA5558 NHmuc_05776 
atpB -3.836825345 0.023536876 energy metabolism PA5560 NHmuc_05778 
 
 
